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ABSTRACT	  
B	  virus	  (Macacine	  herpesvirus	  1,	  Cercopithecine	  herpesvirus	  1,	  herpes	  B	  virus)	  is	  an	  Old	  World	  
monkey	  simplex	  virus	  endemic	  in	  macaques.	  B	  virus	  infection	  in	  its	  natural	  host,	  macaque,	  is	  
very	  similar	  to	  HSV-­‐1	  infection	  in	  humans	  causing	  mild	  or	  asymptomatic	  infection.	  On	  the	  other	  
hand,	  zoonotic	  infection	  in	  humans	  results	  in	  death	  in	  the	  absence	  of	  early	  initiation	  of	  antiviral	  
drugs.	  Viruses	  evade	  host	  immune	  responses	  in	  order	  to	  survive	  and	  propagate.	  Most	  herpes	  
viruses	  including	  HSV-­‐1	  down-­‐regulate	  major	  histocompatibility	  complex	  class	  I	  (MHC	  class	  I)	  
surface	  expression	  on	  infected	  cells	  in	  order	  to	  prevent	  CD8+	  T-­‐cell	  recognition	  and	  subsequent	  
cell	  lysis.	  MHC	  class	  I	  molecules	  bind	  to	  the	  inhibitory	  receptors	  of	  NK	  cells	  and	  prevent	  NK	  cell	  
activity.	  Thus,	  this	  mechanism	  protects	  HSV-­‐1	  infected	  cells	  from	  CD8+	  T-­‐cell	  lysis,	  making	  them	  
sensitive	  to	  natural	  killer	  (NK)	  cell	  cytotoxicity.	  	  To	  investigate	  if	  B	  virus	  pathogenicity	  is	  a	  result	  
of	  novel	  immune	  evasion	  mechanisms	  employed	  by	  B	  virus,	  we	  determined	  NK	  cell	  regulation	  
during	  B	  virus	  infection.	  To	  this	  end,	  our	  experiments	  demonstrate	  that	  B	  virus	  does	  not	  down-­‐
regulate	  MHC	  I	  expression	  as	  effectively	  as	  HSV-­‐1,	  leading	  us	  to	  hypothesize	  that	  B	  virus	  in-­‐
fected	  cells	  are	  resistant	  to	  NK	  cell	  activity.	  We	  examined	  the	  expression	  of	  MHC	  I	  chain	  related	  
genes	  (MICA/	  MICB),	  which	  are	  activation	  ligands	  to	  NKG2D	  receptors	  on	  NK	  cells.	  Our	  results	  
 
 
show	  that	  there	  is	  no	  significant	  difference	  in	  MICA	  and	  MICB	  expression	  between	  HSV-­‐1	  and	  B	  
virus	  infected	  cells.	  Furthermore,	  we	  tested	  for	  the	  up-­‐regulation	  of	  cytokines	  and	  chemokines	  
responsible	  for	  NK	  cell	  activation	  and	  migration.	  Our	  results	  indicate	  a	  significant	  up-­‐regulation	  
of	  IFN-­‐α	  from	  PBMCs	  co-­‐cultured	  with	  HSV-­‐1	  infected	  cells,	  which	  plays	  an	  important	  role	  in	  
activating	  NK	  cells.	  NK	  cells	  within	  these	  PBMCs	  up-­‐regulate	  perforin	  release	  indicative	  of	  NK	  
cell	  activity.	  	  PBMCs	  co-­‐cultured	  with	  B	  virus	  infected	  cells	  do	  not	  up-­‐regulate	  any	  cytokines	  or	  
chemokines	  responsible	  for	  NK	  cell	  activity.	  As	  a	  result	  the	  NK	  cells	  within	  these	  PBMCs	  do	  not	  
significantly	  up-­‐regulate	  perforin	  release.	  These	  results	  demonstrate	  that	  B	  virus	  employs	  a	  
novel	  immune	  evasion	  mechanism	  to	  subvert	  NK	  cell	  activity.	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1.1 Part	  I.	  Literature	  Review	  
1.1.1 B	  Virus	  
1.1.1.1 Clinical	  Significance	  	  
	  Macacine	  herpesvirus	  1	  (Cercopithecine	  herpesvirus	  1,	  Herpes	  B	  virus,	  B	  virus)	  is	  a	  sim-­‐
plex	  virus	  endemic	  to	  macaques.	  B	  virus	  belongs	  to	  the	  subfamily	  alphaherpesvirinae	  of	  the	  
family	  Herpesviridae.	  Approximately	  72%	  to	  92%	  of	  the	  wild-­‐caught	  monkeys	  of	  adult	  age	  were	  
found	  to	  be	  B	  virus	  sero-­‐positive	  in	  early	  field	  studies	  (49,	  79,	  86,	  127,	  177,	  186).	  B	  virus	  in	  ma-­‐
caques	  causes	  mild	  or	  asymptomatic	  infection,	  unless	  the	  animal	  is	  immunocompromised.	  In	  
most	  cases	  B	  virus	  mode	  of	  transmission	  between	  macaques	  is	  venereal	  (189).	  The	  manifesta-­‐
tions	  of	  infection	  are	  similar	  to	  herpes	  simplex	  virus	  infection	  in	  humans	  resulting	  in	  life	  long	  
infection	  with	  occasional	  oral	  (9,	  84,	  85,	  130,	  176)	  and	  genital	  lesions	  (177,	  187).	  Stressors	  in-­‐
cluding	  immunosupression	  drugs	  (32),	  gang-­‐caging	  (178,	  189),	  transport,	  and	  climatic	  condi-­‐
tions	  (84)	  are	  associated	  with	  increased	  B	  virus	  shedding	  by	  macaques.	  	  
	  B	  virus	  infection	  in	  humans	  results	  in	  encephalitis,	  encephalomyelitis,	  and	  death	  in	  un-­‐
treated	  patients.	  Approximately	  30,	  000	  macaques	  are	  imported	  each	  year	  in	  to	  the	  United	  
States	  for	  biomedical	  research.	  B	  virus	  is	  a	  zoonotic	  virus,	  the	  only	  simplex	  virus	  that	  crosses	  
species	  in	  nature,	  and	  as	  such,	  personnel	  working	  with	  macaques	  are	  at	  the	  highest	  risk	  of	  B	  
virus	  infection.	  Approximately	  50	  B	  virus	  human	  cases	  are	  known	  in	  the	  U.S.	  biomedical	  com-­‐




humans	  once	  the	  virus	  has	  reached	  the	  central	  nervous	  system	  (CNS).	  Early	  anti-­‐viral	  interven-­‐
tion	  can	  help	  in	  preventing	  virus	  spread	  to	  central	  nervous	  system	  and	  reduce	  death	  rate	  to	  less	  
than	  20%	  as	  reported	  by	  the	  CDC	  B	  Virus	  Working	  Group	  (35).	  	  
B	  virus	  infection	  of	  non-­‐macaque	  monkeys	  is	  usually	  fatal	  (38,	  60,	  77,	  107,	  179)	  and	  
mostly	  observed	  when	  macaques	  have	  been	  co-­‐housed	  with	  other	  monkey	  species.	  Virus	  can	  
be	  transmitted	  from	  infected	  animals,	  from	  infected	  tissue	  (2,	  13,	  17,	  69,	  72),	  or	  in	  one	  case	  
from	  human-­‐to-­‐human	  contact	  (31).	  Because	  B	  virus	  is	  fatal	  in	  foreign	  hosts	  such	  as,	  humans,	  it	  
is	  important	  to	  understand	  the	  pathogenesis	  of	  zoonotic	  infection.	  Interestingly,	  B	  virus	  infec-­‐
tion	  in	  most	  monkeys	  induces	  a	  strong,	  high-­‐titered	  IgG	  response	  within	  2-­‐4	  weeks	  of	  infection,	  
however	  in	  humans	  B	  virus	  infection	  usually	  results	  in	  low	  levels	  of	  IgG,	  if	  any	  at	  all.	  	  Survivors	  
of	  B	  virus	  infection	  generally	  show	  detectable	  levels	  of	  B	  virus	  specific	  IgG,	  and	  in	  some	  of	  these	  
individuals	  these	  antibodies	  persist	  for	  decades,	  fluctuating	  significantly,	  suggesting	  periodic	  
reactivation	  of	  latent	  B	  virus	  (unpublished	  results,	  National	  B	  Virus	  Resource	  Center,	  Atlanta,	  
GA)	  
1.1.1.2 History	  of	  Herpes	  B	  virus	  
	   Dr.	  William	  Bartlet	  Brebner,	  a	  physician	  and	  research	  scientist,	  working	  on	  poliovirus	  
was	  bitten	  by	  an	  apparently	  normal	  monkey	  on	  his	  fourth	  and	  fifth	  fingers.	  He	  developed	  as-­‐
cending	  transverse	  myelitis	  and	  finally	  succumbing	  to	  infection	  following	  respiratory	  arrest.	  
Autopsy	  results	  did	  not	  show	  any	  significant	  pathology.	  Gay	  and	  Holden	  examined	  some	  of	  the	  
patient’s	  brain	  and	  cord	  tissue	  and	  prepared	  suspensions	  from	  these	  tissues	  for	  transmission	  
experiments.	  They	  named	  this	  new	  virus	  “W”	  virus.	  Rabbits	  were	  inoculated	  intradermally	  with	  




rhesus	  macaques	  were	  inoculated	  with	  virus	  passaged	  in	  rabbits,	  they	  did	  not	  exhibit	  a	  severe	  
disease.	  Thus,	  Gay	  and	  Holden	  concluded	  that	  this	  herpes-­‐like	  virus	  is	  innocuous	  to	  rhesus	  ma-­‐
caques.	  Virus	  passaged	  in	  the	  rabbits	  was	  also	  used	  to	  infect	  cebus	  monkeys	  and	  the	  infection	  
was	  fatal	  and	  characteristic	  of	  herpes	  infection	  in	  cebus	  monkeys.	  Finally,	  Gay	  and	  Holden	  con-­‐
ducted	  cross-­‐immunity	  tests	  by	  using	  human	  and	  rhesus	  serum	  samples	  to	  neutralize	  a	  known	  
herpes	  virus	  and	  also	  “W”	  virus.	  In	  their	  experiments	  both	  the	  known	  herpes	  virus	  and	  “W”	  vi-­‐
rus	  behaved	  similarly.	  Thus,	  Gay	  and	  Holden	  concluded	  this	  “W”	  virus	  to	  be	  similar	  to	  other	  
herpes	  viruses	  capable	  of	  causing	  encephalitis	  (60).	  	  	  
Subsequently,	  Sabin	  and	  Wright	  examined	  brain,	  spinal	  cord,	  spleen,	  and	  regional	  lymph	  
nodes	  from	  the	  autopsy	  specimens	  and	  prepared	  emulsions	  of	  these	  tissues.	  	  They	  conducted	  
transmission	  experiments	  using	  macaque	  monkeys.	  The	  first	  monkey	  that	  was	  infected	  by	  the	  
tissue	  emulsions	  died	  without	  any	  apparent	  pathology.	  The	  tissue	  derived	  from	  this	  monkey	  
was	  used	  to	  infect	  other	  monkeys,	  and	  these	  monkeys	  survived.	  The	  original	  brain	  and	  cord	  tis-­‐
sue	  from	  the	  human	  was	  then	  used	  to	  inoculate	  rabbits	  via	  intracerebral,	  and	  intracutaneous	  
routes.	  The	  animals	  became	  infected	  and	  showed	  symptoms	  similar	  to	  humans	  and	  eventually	  
died.	  From	  their	  experiments,	  Sabin	  and	  Wright	  reported	  the	  causative	  organism	  to	  be	  a	  filter-­‐
able	  agent,	  as	  did	  Gay	  and	  Holden.	  They	  noted	  that	  this	  filterable	  agent	  was	  similar	  to	  human	  
herpes	  simplex	  virus,	  but	  noted	  further	  that	  this	  agent	  had	  properties	  that	  would	  allow	  classifi-­‐
cation	  of	  it	  as	  a	  new	  and	  a	  different	  virus	  from	  human	  herpes	  simplex	  virus.	  This	  virus	  was	  
named	  “B	  virus”	  by	  Sabin	  and	  Wright	  to	  honor	  the	  first	  known	  victim	  who	  was	  an	  accomplished	  
scientist	  and	  who	  has	  contributed	  much	  to	  science	  (39)	  (6).	  That	  name	  has	  subsequently	  been	  




1.1.1.3 B	  virus	  growth	  and	  replication	   	  
B	  virus	  is	  currently	  regulated	  as	  a	  Select	  Agent	  by	  the	  U.S.	  Department	  of	  Homeland	  Se-­‐
curity	  and	  in	  accordance	  with	  the	  5th	  Edition	  of	  the	  bio-­‐safety	  in	  microbiological	  and	  biomedical	  
laboratories	  (BMBL)	  (166)	  and	  the	  propagation	  of	  B	  virus	  can	  only	  be	  done	  in	  a	  bio-­‐safety	  level-­‐
4	  (BSL-­‐4)	  laboratory.	  B	  virus	  propagation	  in	  a	  tissue	  culture	  based	  system	  was	  first	  demon-­‐
strated	  by	  Burnet	  et	  al.,	  using	  chorioallantoic	  membrane	  of	  the	  developing	  chick	  embryo	  (28).	  
Reissig	  et	  al.,	  infected	  adult	  rhesus	  kidney	  epithelial	  cells	  with	  B	  virus	  at	  multiplicity	  of	  infection	  
(MOI)	  2	  from	  virus	  stock	  prepared	  and	  titered	  in	  monkey	  renal	  tissue	  culture.	  After	  2	  hours	  
post-­‐infection	  (hpi),	  infected	  cells	  contained	  vacuoles	  and	  more	  significant	  changes	  started	  to	  
appear	  at	  4-­‐6	  hpi.	  Between	  4	  and	  6	  hpi,	  irregular	  and	  larger	  nucleoli	  were	  observed.	  Clear	  
changes	  in	  chromatin	  occurred	  by	  10	  hpi	  and	  by	  this	  time	  new	  virus	  particles	  started	  appearing.	  
Both	  intracellular	  progeny	  virus	  and	  extracellular	  virus	  titers	  start	  increasing	  at	  6	  hpi	  and	  keep	  
increasing	  until	  24	  hpi,	  after	  which	  the	  virus	  titers	  plateau.	  At	  18	  hpi,	  polynucleated	  cells	  were	  
observed	  and	  these	  cells	  were	  formed	  due	  to	  cell	  fusion,	  called	  syncytia	  (148).	  Around	  the	  same	  
time,	  Krech	  and	  Lewis	  passaged	  B	  virus	  obtained	  from	  an	  infected	  monkey	  in	  rabbits.	  The	  tissue	  
fluid	  obtained	  was	  used	  to	  infect	  the	  chick	  embryos	  and	  monkey	  kidney	  cells	  (derived	  from	  
rhesus	  or	  cynomolgus	  macaques)	  (89).	  Their	  stability	  studies	  show	  that	  B	  virus	  is	  stable	  for	  8	  
weeks	  when	  stored	  at	  4ºC,	  however,	  B	  virus	  loses	  its	  infectivity	  by	  2	  logs	  when	  stored	  at	  −20ºC	  
and	  −72ºC	  (89).	  Subsequently,	  the	  kinetics	  of	  virus	  replication	  and	  the	  identification	  of	  infected	  
cell	  polypeptides	  was	  published	  (70).	  B	  virus	  replication	  kinetics	  in	  cell	  culture	  was	  similar	  to	  




In	  the	  natural	  host	  B	  virus	  replicates	  at	  the	  site	  of	  infection	  and	  travels	  by	  retrograde	  
transmission	  and	  establishes	  latency	  in	  the	  dorsal	  root	  of	  the	  sensory	  ganglia.	  B	  virus	  
reactivation	  is	  thought	  to	  be	  stimulated	  upon	  exposure	  to	  stress	  factors	  such	  as	  UV	  exposure,	  
hormonal	  stress,	  infection	  and	  other	  unknown	  factors.	  Virus	  travels	  anterograde,	  returning	  to	  
the	  epithelial	  site	  where	  it	  was	  initially	  introduced	  (78)	  (50),	  (24),	  (64).	  Thus,	  B	  virus	  life	  cycle	  in	  
a	  natural	  host,	  macaques,	  is	  similar	  to	  HSV-­‐1	  life	  cycle	  in	  natural	  host,	  humans.	  In	  humans,	  
however,	  B	  virus	  spreads	  to	  the	  CNS	  ultimately	  affecting	  the	  integrity	  of	  the	  brain	  stem	  (75).	  
Respiratory	  arrest	  results,	  although	  it	  remains	  unknown	  whether	  this	  is	  due	  to	  virus	  or	  immune	  
response.	  
1.1.1.4 B	  virus	  structure	  and	  genome	   	  
B	  virus	  size	  and	  structure	  is	  similar	  to	  that	  of	  other	  herpes	  simplex	  viruses,	  such	  as,	  HSV-­‐
1	  and	  herpes	  simplex	  virus	  type	  2	  (HSV-­‐2)	  (111).	  It	  has	  a	  glycoprotein	  studded	  envelope	  within	  
which	  is	  the	  tegument	  surrounding	  a	  nucleocapsid	  that	  contains	  the	  circular	  double	  stranded	  
genome	  of	  approximately	  156K	  base	  pairs	  rich	  in	  G	  +	  C	  content.	  Electron	  microscopy	  studies	  of	  
B	  virus	  have	  revealed	  that	  the	  virus	  is	  transported	  from	  cytoplasm	  to	  nucleus	  at	  relative	  earlier	  
time	  points	  than	  HSV	  virions.	  The	  enveloped	  virus	  within	  the	  cell	  was	  found	  to	  be	  located	  near	  
the	  perinuclear	  spaces,	  endoplasmic	  reticulum	  (ER),	  and	  Golgi	  complex.	  B	  virus	  was	  described	  
by	  Ruebner	  et	  al.	  to	  exit	  through	  the	  cytocavitary	  network	  rather	  than	  through	  microfilaments	  
as	  suggested	  in	  the	  case	  of	  HSV-­‐1	  (154).	  These	  studies	  have	  never	  been	  expanded	  upon	  to	  date.	  
	   Previous	  data	  from	  Harrington	  et	  al.,	  predicted	  the	  size	  of	  B	  virus	  genome	  to	  be	  165.2	  
Kbp	  (92).	  Complete	  genome	  sequence	  analysis	  of	  B	  virus	  lab	  strain	  E2490	  by	  Perelygina	  et	  al.,	  




G+C	  content.	  The	  G+C	  content	  in	  B	  virus	  was	  found	  to	  be	  significantly	  greater	  than	  HSV-­‐1	  and	  
HSV-­‐2	  (137),	  and	  perhaps	  the	  highest	  of	  any	  simplex	  virus.	  The	  B	  virus	  genome	  when	  compared	  
to	  that	  of	  HSV-­‐1	  has	  	  >80%	  DNA	  sequence	  homology	  (92,	  137).	  	  Also,	  a	  high	  DNA	  sequence	  ho-­‐
mology	  is	  observed	  between	  HSV-­‐1,	  HSV-­‐2	  (human	  herpes	  simplexviruses),	  B	  virus,	  HVP-­‐2,	  and	  
SA8	  (non-­‐human	  primate	  herpes	  simplexviruses)	  (81).	  
1.1.1.5 Animal	  model	  systems	  for	  B	  virus	  
	   The	  first	  successful	  animal	  model	  for	  B	  virus	  studies	  was	  a	  rabbit	  model,	  used	  by	  Gay	  
and	  Holden	  and	  later	  by	  Sabin	  and	  Wright	  to	  investigate	  the	  first	  documented	  zoonotic	  infec-­‐
tion.	  Rabbits	  were	  injected	  with	  tissue-­‐collected	  post-­‐mortem	  with	  B	  virus	  infection.	  The	  tissue	  
was	  used	  to	  inoculate	  the	  rabbits	  via	  intracerebral,	  intracutaneous,	  intratesticular,	  and	  intrape-­‐
ritoneal	  routes.	  Infection	  through	  intracerebral	  route	  resulted	  in	  convulsions,	  salivation,	  and	  
death	  within	  24	  hpi.	  While	  intracutaneous	  routes	  resulted	  in	  flaccid	  paralysis	  and	  respiratory	  
failure	  followed	  by	  death	  6	  days	  post	  inoculation	  with	  onset	  of	  symptoms	  appearing	  by	  24	  post	  
inoculation	  with	  cutaneous	  lesions.	  Intratesticular	  infection	  resulted	  in	  paralysis	  and	  ascending	  
myelitis	  7	  dpi.	  Complete	  posterior	  paralysis	  followed	  by	  death	  on	  11	  day	  was	  observed	  after	  the	  
animal	  was	  infected	  through	  intraperitoneal	  route.	  Therefore,	  Acute	  B	  virus	  infection	  in	  rabbits	  
was	  very	  similar	  to	  that	  observed	  in	  humans	  (6)	  (60).	  
	   Later	  in	  1954,	  Melnick	  et	  al.,	  published	  their	  results	  from	  experiments	  in	  which	  various	  
animals	  such	  as,	  cotton	  rats,	  albino	  mice,	  guinea	  pigs,	  rabbits,	  and	  hamsters	  were	  inoculated	  
with	  rhesus	  macaque	  poliomyelitis	  infected	  tissue.	  None	  of	  their	  experimental	  animal	  models	  
showed	  any	  signs	  of	  poliomyelitis	  as	  per	  the	  observations	  from	  pathological	  and	  histological	  




lated	  into	  cotton	  rats	  and	  the	  infected	  CNS	  tissue	  from	  cotton	  rats	  was	  passaged	  several	  times.	  
The	  infected	  tissue	  obtained	  from	  the	  final	  passage	  in	  cotton	  rats	  was	  used	  to	  inoculate	  differ-­‐
ent	  animals	  in	  order	  to	  study	  the	  B	  virus	  host	  range.	  When	  they	  infected	  four-­‐week	  old	  cotton	  
rats	  via	  intracerebral	  and	  intraperitoneal	  routes	  of	  inoculation,	  they	  observed	  myelitis,	  perivas-­‐
cular	  infiltration,	  neurodegenration,	  and	  encephalitis	  in	  examined	  spinal	  cord	  sections.	  They	  
observed	  no	  apparent	  damage	  to	  the	  meninges.	  Intracerebral	  inoculation	  of	  infected	  tissue	  into	  
newborn	  mice	  resulted	  in	  ataxia,	  failure	  to	  grow,	  abnormal	  movements	  and	  ultimately	  leading	  
to	  death.	  Intracerebral	  inoculation	  of	  4-­‐week-­‐old	  mice	  resulted	  in	  meningoenecphalitis	  and	  in-­‐
filtration	  of	  lymphocytes	  into	  the	  brain.	  Intracerebral	  routes	  of	  inoculation	  of	  infected	  tissue	  
into	  guinea	  pigs	  resulted	  in	  development	  of	  meningitis,	  however,	  subcutaneous	  inoculations	  
caused	  necrosis	  around	  the	  site	  of	  inoculation.	  Inoculation	  tissues	  into	  rabbits	  yielded	  similar	  
results	  to	  those	  observed	  by	  Sabin	  and	  Wright.	  Intracerebral	  route	  of	  inoculation	  of	  tissue	  into	  
hamsters	  resulted	  in	  ataxia,	  irregular	  movements,	  and	  prostration	  followed	  by	  death.	  Each	  of	  
these	  symptoms	  was	  consistent	  with	  the	  symptoms	  noted	  by	  Sabin	  and	  Wright	  in	  their	  trans-­‐
mission	  experiments	  of	  rabbits	  that	  were	  injected	  with	  B	  virus	  infected	  tissue	  (115).	  Thus,	  these	  
animals	  were	  infected	  with	  a	  virus	  that	  was	  innocuous	  to	  macaques	  and	  later	  classified	  and	  
named	  B	  virus.	  
Many	  decades	  later,	  Richey	  et	  al.,	  infected	  mice	  with	  B	  virus	  and	  reported	  that	  sympto-­‐
mology	  was	  similar	  to	  that	  observed	  in	  humans	  with	  some	  B	  virus	  isolates,	  but	  that	  each	  isolate	  
differed	  in	  terms	  of	  ability	  to	  cause	  symptoms	  and	  doses	  at	  which	  significant	  numbers	  of	  ani-­‐
mals	  showed	  apparent	  signs	  of	  infection.	  Severity	  of	  infection	  was	  clearly	  B	  virus	  strain-­‐	  and	  




muscularly	  with	  virus	  preparation	  of	  different	  serial	  dilutions.	  Similar	  experiments	  in	  a	  different	  
strain	  of	  mice	  (C57BL/6)	  did	  not	  result	  in	  a	  different	  outcome	  from	  that	  observed	  in	  BLAB/	  c	  
mice	  once	  disease	  in	  CNS	  is	  observed	  (149).	  This	  study	  emphasizes	  on	  the	  fact	  that	  B	  virus	  viru-­‐
lence	  in	  a	  foreign	  host	  is	  a	  result	  of	  many	  factors	  such	  as,	  virus	  strain,	  viral	  dose,	  and	  host	  im-­‐
mune	  responses	  against	  the	  invading	  virus.	  
1.1.1.6 B	  virus	  diagnosis	  and	  treatment	  
	   B	  virus	  can	  be	  diagnosed	  by	  isolation	  of	  virus	  or	  identification	  of	  antibodies.	  	  In	  some	  
cases	  virus	  isolation	  is	  difficult	  if	  not	  impossible	  and	  reliance	  on	  clinical	  symptoms	  and/or	  the	  
presence	  of	  increasing	  antibodies	  is	  the	  basis	  of	  diagnosis	  and	  treatment.	  B	  virus-­‐specific	  PCR	  
can	  be	  used	  additionally,	  but	  this	  technique	  does	  not	  confirm	  the	  presence	  of	  replication	  com-­‐
petent	  virus.	  (110,	  112).	  	  Because	  there	  can	  be	  antibody	  cross	  reactivity	  if	  the	  person	  has	  anti-­‐
bodies	  against	  herpes	  simplex	  viruses	  (1,	  40,	  83),	  competition	  ELISA	  and	  western	  blot	  assays	  
must	  be	  used	  for	  serodiagnosis.	  
	   Nucleoside	  analogs	  such	  as	  acyclovir	  (ACV),	  ganciclovir	  (GCV),	  and	  adenine	  arabinoside	  
(ara-­‐A)	  are	  used	  against	  HSV-­‐1	  and	  HSV-­‐2	  infections	  in	  humans.	  ACV	  was	  also	  found	  to	  be	  effec-­‐
tive	  against	  other	  human	  herpes	  virus	  infections	  such	  as	  varicella	  zoster-­‐virus	  (VZV),	  human	  cy-­‐
tomegalovirus	  (HCMV),	  and	  Epstein	  barr	  virus	  (EBV)	  (36,	  52).	  ACV	  is	  phosphorylated	  to	  tri-­‐
phosphates	  by	  viral	  thymidine	  kinase	  (TK).	  Once	  phosphorylated,	  ACV	  inhibits	  viral	  DNA	  polym-­‐
erase	  and	  ultimately	  viral	  replication	  (146).	  2`-­‐	  fluoro-­‐5-­‐substituted	  arabinosyl	  pyrimidine	  nu-­‐
cleosides	  such	  as	  2`-­‐fluoro-­‐5-­‐methyl-­‐Ara-­‐U	  (FMAU)	  and	  2`-­‐	  fluoro-­‐5-­‐ethyl-­‐Ara-­‐U	  (FEAU)	  were	  
found	  to	  be	  effective	  against	  human	  herpes	  simplex	  virus	  at	  the	  same	  time	  were	  less	  toxic	  to	  




virus	  in	  rabbits.	  They	  found	  that	  GCV	  was	  more	  effective	  than	  ACV	  even	  at	  lower	  doses,	  how-­‐
ever,	  GCV	  was	  not	  found	  to	  be	  as	  effective	  if	  administered	  later	  during	  infection	  (188).	  	  There-­‐
fore,	  ACV	  (10	  mg/kg)	  is	  an	  effective	  anti-­‐viral	  used	  in	  the	  treatment	  of	  B	  virus	  infection	  in	  the	  
absence	  of	  symptoms	  in	  humans.	  Prophylactic	  treatment	  with	  acyclovir	  can	  also	  be	  effective,	  
since	  it	  may	  inhibit	  replication	  of	  B	  virus	  at	  peripheral	  sites,	  reducing	  the	  virus	  load	  available	  for	  
establishing	  latency	  in	  subserving	  sensory	  ganglia.	  This	  may	  in	  turn	  reduce	  the	  probability	  of	  
reactivation	  of	  B	  virus	  in	  individuals	  who	  survive	  infection	  (25,	  75).	  Recent	  studies	  by	  Krug	  et	  al,	  
have	  shown	  that	  FEAU	  and	  FMAU	  nucleoside	  analogs	  were	  100	  times	  more	  potent	  than	  con-­‐
ventional	  nucleoside	  analogs	  such	  as	  ACV	  and	  GCV	  (90).	  Therefore,	  FEAU	  and	  FMAU	  could	  po-­‐
tentially	  be	  used	  as	  “compassionate	  use”	  drugs	  for	  the	  treatment	  of	  advanced	  zoonotic	  infec-­‐
tion.	  
Attempts	  to	  develop	  vaccines	  to	  prevent	  B	  virus	  have	  not	  been	  successful	  in	  macaques	  
(16,	  108).	  In	  order	  to	  produce	  vaccines	  to	  induce	  good	  immune	  response,	  it	  is	  important	  to	  un-­‐
derstand	  how	  B	  virus	  interacts	  with	  host	  immune	  responses	  and	  what	  the	  immune	  correlates	  of	  
infection	  are.	  Interestingly,	  although	  HSV-­‐1	  infection	  in	  humans	  induces	  specific	  and	  detectable	  
adaptive	  immune	  response,	  zoonotic	  B	  virus	  infection	  fails	  to	  induce	  a	  detectable	  adaptive	  im-­‐
mune	  response	  comparable	  to	  that	  seen	  with	  HSV	  infection.	  In	  each	  of	  the	  B	  virus	  fatal	  cases,	  at	  
least	  since	  1987,	  infected	  individuals	  failed	  to	  show	  robust	  antibody	  production	  against	  B	  virus.	  	  
HSV-­‐1,	  which	  is	  also	  a	  herpes	  simplex	  virus	  evades	  specific	  immune	  responses	  in	  order	  
to	  survive	  in	  a	  natural	  host.	  B	  virus	  is	  very	  similar	  to	  HSV-­‐1	  in	  its	  life	  cycle	  in	  a	  natural	  host	  (60)	  
sharing	  extensive	  homology	  with	  HSV	  proteins	  (137),	  a	  point	  which	  suggests	  that	  B	  virus	  may	  




immune	  correlates	  of	  B	  virus	  infection	  in	  the	  natural	  versus	  the	  foreign	  host	  may	  illuminate	  
how	  to	  redirect	  the	  immune	  response	  in	  infected	  humans	  such	  that	  morbidities	  and	  mortalities	  
may	  be	  avoided	  in	  cases	  of	  zoonotic	  B	  virus	  infections.	  	  
1.1.2 Immune	  evasion	  mechanisms	  by	  herpesviruses	   	  
Within	  natural	  hosts,	  viruses	  successfully	  replicate	  and	  spread	  without	  adversely	  affect-­‐
ing	  the	  host.	  This	  guarantees	  the	  availability	  of	  the	  host	  for	  virus.	  	  A	  host,	  in	  turn,	  will	  elicit	  
strong	  immune	  responses	  to	  stop	  or	  minimize	  the	  effects	  of	  the	  virus	  invasion,	  however,	  viruses	  
select	  traits	  that	  facilitate	  bypassing	  restrictive	  host	  immune	  responses.	  As	  long	  as	  a	  balance	  is	  
maintained	  between	  virus	  propagation	  and	  host	  immune	  responses,	  virus	  will	  be	  able	  to	  propa-­‐
gate	  in	  successfully	  and	  immune	  responses	  will	  protect	  the	  host	  against	  morbidity	  and	  mortal-­‐
ity.	  
	   Of	  the	  many	  evasion	  mechanisms,	  down-­‐regulation	  of	  surface	  expression	  of	  major	  his-­‐
tocompatibility	  complex	  (MHC	  class	  I)	  is	  hallmark	  of	  all	  herpes	  viruses.	  Cellular	  immune	  re-­‐
sponses	  involve	  the	  activities	  of	  CD8+	  T-­‐cells,	  cytotoxic	  lymphocytes	  (CTL)	  that	  recognize	  for-­‐
eign	  antigen	  presented	  by	  the	  MHC	  class	  I	  molecules	  on	  the	  infected	  cell	  surface.	  Antigens	  pre-­‐
sented	  are	  the	  result	  of	  proteosomal	  degradation	  of	  foreign	  proteins	  to	  8-­‐10	  amino	  acid	  long	  
peptides.	  The	  US12	  gene	  of	  HSV-­‐1	  and	  2	  encode	  for	  Infected	  cell	  protein	  47	  (ICP47),	  an	  immedi-­‐
ate	  early	  (IE)	  protein,	  which	  binds	  to	  the	  cytosolic	  transport	  associated	  protein	  (TAP)	  involved	  in	  
the	  transport	  of	  peptides	  to	  the	  MHC	  class	  I	  molecule	  in	  the	  endoplasmic	  reticulum	  (ER)	  (57,	  68,	  
184).	  This	  blockade	  of	  peptide	  translocation	  by	  HSV	  ICP47	  results	  in	  the	  sequestration	  of	  MHC	  
class	  I	  in	  the	  ER.	  The	  unloaded	  MHC	  class	  I	  is	  degraded	  via	  ER	  degradation	  pathway,	  which	  will	  




the	  cytoplasm	  inhibits	  the	  HSV	  specific	  CTLs	  from	  recognizing	  the	  infected	  cell	  and	  killing	  them	  
(59,	  61,	  80,	  93,	  123,	  124,	  164,	  165).	  Although	  HSV	  specific	  CTLs	  are	  generated	  due	  to	  antigen	  
presentation	  by	  antigen	  presenting	  cells	  (APC),	  these	  CTLs	  are	  unable	  to	  lyse	  HSV-­‐1	  infected	  
cells	  due	  to	  lack	  of	  MHC	  class	  I	  on	  the	  cell	  surface.	  Thus,	  the	  presence	  of	  HSV	  antigen	  specific	  to	  
CD8+	  T-­‐cells	  is	  important	  for	  limiting	  the	  spread	  and	  reactivation	  of	  the	  virus	  and	  not	  so	  much	  
during	  primary	  infection	  (129,	  171).	  	  	  	  
The	  critical	  3-­‐35	  amino	  acid	  sequence	  of	  ICP47,	  which	  binds	  to	  the	  peptide-­‐binding	  re-­‐
gion	  of	  TAP	  and	  inhibits	  peptide	  loading,	  is	  conserved	  in	  both	  HSV-­‐1	  and	  HSV-­‐2	  (63,	  122,	  140,	  
153,	  164).	  This	  TAP	  binding	  domain	  is	  absent	  in	  each	  of	  the	  other	  alphaherpesviruses	  studied	  to	  
date,	  although	  most	  of	  the	  known	  alphaherpesviruses,	  such	  as,	  pseudorabies	  virus	  (PrV),	  
varicella	  zoster	  virus	  (VZV),	  equine	  herpesvirus-­‐1,	  and	  bovine	  herpesvirus-­‐1	  down	  regulate	  MHC	  
1	  (180).	  PrV	  is	  similar	  to	  HSV-­‐1	  in	  down-­‐regulating	  MHC	  class	  I,	  in	  that,	  peptide	  transport	  is	  
blocked	  and	  the	  MHC	  class	  I	  remains	  unloaded	  (8).	  During	  VZV	  infection,	  MHC	  class	  I	  is	  accumu-­‐
lated	  in	  the	  Golgi	  complex	  and	  prevented	  from	  surface	  expression	  (4).	  Equine	  herpesvirus-­‐1	  
down	  regulates	  MHC	  class	  I	  surface	  expression	  by	  blocking	  peptide	  translocation	  via	  TAP	  (7,	  
143).	  Bovine	  herpesvirus	  1	  UL49.5	  blocks	  TAP	  dependent	  peptide	  translocation,	  thus	  down	  
regulating	  surface	  MHC	  class	  I	  (88).	  Non-­‐human	  primate	  simplex	  viruses,	  such	  as	  B	  virus,	  herpes	  
virus	  papio-­‐2	  (HVP-­‐2),	  and	  simian	  herpes	  virus	  (SA8)	  contain	  US12	  gene	  encoding	  ICP47,	  how-­‐
ever,	  the	  TAP	  binding	  sequence	  present	  in	  HSV-­‐1	  and	  2	  ICP47	  is	  absent	  (19).	  The	  down-­‐
regulation	  of	  MHC	  class	  I	  on	  the	  cell	  surface	  of	  an	  infected	  cell	  results	  in	  sensitivity	  to	  natural	  
killer	  (NK)	  cells	  lysis.	  NK	  cells	  are	  also	  cytotoxic	  lymphocytes,	  but	  are	  not	  specific	  in	  the	  sense	  




presenting	  MHC	  class	  I	  and	  are	  thus	  inhibited	  from	  killing	  the	  cell.	  When	  present	  on	  the	  cell	  sur-­‐
face,	  MHC	  class	  I	  molecules	  bind	  to	  the	  cell	  surface	  inhibitory	  receptors	  on	  NK	  cells,	  thus	  acting	  
as	  inhibitory	  ligands.	  In	  case	  of	  certain	  virus	  infections,	  such	  as	  herpesviruses	  where	  MHC	  class	  I	  
is	  down	  regulated,	  these	  cells	  become	  sensitive	  to	  NK	  cell	  lysis.	  Certain	  herpes	  viruses	  like	  CMV	  
employ	  mechanisms	  to	  down	  regulate	  NK	  cell	  recognition	  of	  infected	  cells.	  This	  mechanism	  is	  
not	  observed	  in	  the	  case	  of	  HSV-­‐1	  and	  HSV-­‐2	  thus	  resulting	  in	  lysis	  by	  NK	  cells.	  The	  mechanism	  
of	  regulation	  of	  MHC	  class	  I	  and	  the	  subsequent	  modulation	  of	  NK	  cell	  activity	  during	  B	  virus	  
infection	  is	  the	  major	  focus	  of	  this	  thesis.	  Later	  in	  this	  section,	  details	  of	  MHC	  class	  I	  presenta-­‐
tion	  and	  NK	  cell	  regulation	  will	  be	  discussed.	  
Another	  sub-­‐type	  of	  CTL,	  which	  is	  far	  less	  studied	  but	  as	  important	  as	  CD8+	  T-­‐cells	  are	  
natural	  killer	  T-­‐cells	  (NKT).	  NKT	  cells	  are	  a	  subtype	  of	  CTLs	  that	  recognize	  glycolipid	  antigens	  
presented	  by	  CD1d	  molecules	  on	  the	  cell	  surface.	  Viruses	  can	  block	  lipid	  presentation	  to	  evade	  
NKT	  cell	  activity	  (170).	  NKT	  cells	  express	  both	  CD8+	  T-­‐cell	  and	  NK	  cell	  markers	  and	  thus	  the	  
name	  NKT.	  During	  HSV-­‐1	  infection,	  presentation	  of	  CD1d	  molecules	  on	  the	  cell	  surface	  is	  
blocked	  by	  displacing	  CD1d	  through	  endocytosis	  (185).	  The	  virus	  protein	  responsible	  for	  this	  
mechanism	  is	  not	  known	  currently.	  Thus,	  this	  is	  another	  example	  of	  how	  HSV-­‐1	  and	  HSV-­‐2	  em-­‐
ploy	  different	  mechanisms	  to	  delay	  or	  prevent	  immune	  responses	  that	  can	  block	  successful	  rep-­‐
lication	  and	  spread	  of	  the	  virus.	  	  
1.1.3 Major	  Histocompatibility	  Complex	  Class	  I	  (MHC	  class	  I)	  
	   MHC	  class	  I	  molecules	  are	  constitutively	  expressed	  on	  the	  cell	  surface	  in	  all	  cells	  except	  
red	  blood	  cells,	  and	  these	  are	  tightly	  regulated	  in	  neurons.	  MHC	  class	  I	  expression	  is	  enhanced	  




interferon-­‐gamma	  (IFN-­‐γ),	  and	  interferon-­‐alpha	  (IFN-­‐α).	  Genes	  encoding	  MHC	  1	  are	  regulated	  
by	  transcription	  factors	  belonging	  to	  Rel	  family	  members	  including	  nuclear	  factor	  kappa-­‐light-­‐
chain-­‐enhancer	  or	  activated	  B	  cells	  (NF-­‐κB).	  These	  factors	  bind	  to	  the	  enhancer	  region	  of	  the	  
genes	  upstream	  of	  initiation	  region	  at	  the	  κB	  binding	  site.	  H2TF1,	  which	  was	  found	  to	  share	  se-­‐
quence	  homology	  with	  many	  members	  of	  Rel	  family	  members,	  is	  implicated	  as	  the	  major	  tran-­‐
scription	  regulator	  of	  MHC	  class	  I	  (141).	  Thus,	  H2TF1	  is	  an	  ideal	  target	  for	  many	  pathogens	  and	  
tumor	  cells	  to	  down	  regulate	  surface	  expression	  of	  MHC	  class	  I	  (102).	  	  	  
	   MHC	  class	  I	  molecules	  are	  composed	  of	  a	  transmembrane	  heavy	  chain	  that	  has	  three	  
domains:	  α1,	  α	  2,	  and	  α3.	  Domains	  α1	  and	  α	  2	  are	  the	  peptide	  binding	  domains	  (125,	  128)	  and	  
α3	  domain	  serves	  to	  anchor	  the	  molecules	  into	  the	  membrane	  of	  ER	  (131).	  MHC	  class	  I	  mole-­‐
cules	  must	  be	  folded	  properly	  for	  stability	  in	  order	  to	  be	  expressed	  on	  the	  cell	  surface.	  The	  
proper	  folding	  of	  MHC	  class	  I	  in	  the	  ER	  is	  achieved	  by	  the	  association	  of	  calnexin,	  a	  transmem-­‐
brane	  protein,	  to	  MHC	  class	  I	  molecule	  (65).	  Once	  MHC	  class	  I	  molecules	  bind	  to	  β-­‐
microglobulin	  (β2m),	  calnexin	  disassociates	  from	  the	  MHC	  class	  I	  protein	  (125,	  128,	  160).	  	  The	  
MHC	  class	  I	  heavy	  chain	  with	  β2m	  is	  further	  stabilized	  by	  another	  transmembrane	  protein	  cal-­‐
reticulin,	  which	  recruits	  endoplasmic	  reticulum	  protein	  57	  (ERp57)	  (48,	  56,	  100).	  	  Residue	  Cys-­‐
57	  of	  the	  a	  domain	  of	  ERp57	  forms	  a	  disulfide	  bond	  with	  Cys-­‐95	  of	  tapasin	  (12,	  43),	  thus	  form-­‐
ing	  a	  calreticulin/ERp57/	  MHC-­‐1/	  β2m/	  tapasin	  complex	  on	  the	  ER	  membrane.	  This	  complex	  is	  
important	  for	  peptide	  loading	  and	  is	  called	  MHC	  class	  I	  peptide	  loading	  complex	  (PLC)	  (136).	  
Interaction	  of	  TAP1	  and	  TAP2	  with	  MHC	  class	  I	  PLC	  is	  mediated	  by	  tapasin.	  The	  TAP	  protein	  be-­‐
longs	  to	  ATP	  binding	  cassette	  (ABC)	  family	  of	  transporters.	  Approximately	  8-­‐10	  amino	  acid	  pep-­‐




binding	  domain.	  This	  process	  of	  peptide	  loading	  by	  TAP	  to	  the	  PLC	  is	  an	  energy	  consuming	  
process	  involving	  hydrolysis	  and	  translocation	  of	  ATP	  (3,	  136).	  Another	  protein	  ER	  aminopepti-­‐
dase	  associated	  with	  antigen	  processing	  (ERAAP)	  trims	  the	  peptide	  to	  an	  appropriate	  length	  to	  
be	  loaded	  onto	  MHC	  class	  I	  complex	  (155,	  158,	  183).	  
	   The	  20S	  subunit	  of	  the	  proteosome	  is	  involved	  in	  degradation	  of	  proteins	  to	  peptides	  
that	  can	  be	  loaded	  on	  MHC	  class	  I	  peptide-­‐binding	  domain	  via	  TAP.	  20S	  subunit	  together	  with	  
19S	  (PA700)	  forms	  the	  26S	  proteosome	  involved	  in	  the	  degradation	  of	  large	  polyubiquitinated	  
and	  mis-­‐folded	  proteins	  (42).	  The	  base	  of	  19S	  has	  6	  ATPases	  that	  are	  required	  for	  the	  unfolding	  
of	  proteins,	  however	  the	  degradation	  of	  proteins	  by	  20S	  proteosome	  itself	  is	  an	  ATP-­‐
independent	  process	  mediated	  by	  11S	  regulatory	  complex	  (PA28)(32,	  47,	  131,	  147).	  Peptides	  
that	  bind	  to	  MHC	  class	  I	  are	  8-­‐10	  amino	  acids	  long	  and	  contain	  a	  hydrophobic	  C-­‐terminus.	  The	  
peptide-­‐binding	  site	  present	  on	  TAP1/TAP2	  hetero-­‐dimer	  suggests	  an	  equal	  role	  for	  both	  pro-­‐
teins	  in	  peptide	  binding.	  In	  uninfected	  cells,	  self-­‐proteins	  are	  degraded	  to	  MHC	  class	  I	  specific	  
peptides	  by	  the	  proteosome	  and	  loaded	  onto	  the	  MHC	  class	  I	  complex.	  Once	  the	  MHC	  class	  I	  
molecule	  is	  loaded	  with	  peptide,	  it	  disassociates	  from	  the	  chaperone	  complex	  and	  is	  trans-­‐
ported	  to	  the	  cell	  surface	  through	  the	  secretory	  pathway	  where	  the	  MHC	  class	  I	  is	  further	  gly-­‐
cosylated	  and	  modified	  in	  Golgi	  complex	  and	  secretory	  vesicles.	  These	  modifications	  are	  neces-­‐
sary	  for	  MHC	  class	  I	  protein	  stability	  and	  proper	  antigen	  expression	  on	  the	  cell	  surface.	  MHC	  
class	  I	  proteins	  that	  are	  not	  properly	  folded	  or	  stabilized	  will	  undergo	  degradation	  in	  the	  ER	  
through	  ER-­‐aminopeptidate	  associated	  antigen	  degradation	  pathway	  (ERAAP)	  (136).	  The	  above	  




During	  infection,	  virus	  proteins	  are	  degraded	  by	  proteosome,	  loaded	  onto	  the	  cell	  sur-­‐
face	  to	  be	  recognized	  by	  specific	  CD8+	  T-­‐cells.	  Because	  self-­‐reactive	  T	  cells	  are	  destroyed	  during	  
thymic	  selection	  processes,	  normal	  cells	  presenting	  self-­‐antigen	  are	  not	  destroyed	  by	  CD8+	  T-­‐
cells.	  To	  minimize	  presentation	  of	  foreign	  antigen	  and	  thus	  cytolysis,	  many	  viruses	  down	  regu-­‐
late	  MHC	  class	  I	  expression	  on	  the	  cell	  surface	  by	  disrupting	  MHC	  class	  I	  peptide	  loading	  and/or	  










Figure	  1:	  MHC	  class	  I	  antigen	  presentation	  on	  the	  cell	  surface.	  	  Proteins	  are	  degraded	  by	  pro-­‐
teosome	  into	  8-­‐10	  aa	  peptides,	  which	  are	  loaded	  on	  MHC	  class	  I	  molecule	  via	  TAP.	  The	  MHC	  
class	  I	  molecule	  disassociates	  from	  the	  chaperone	  complex	  and	  translocates	  to	  surface	  through	  

















Figure	  2:	  Viral	  down-­‐regulation	  of	  MHC	  class	  I	  on	  cell	  surface.	  Different	  viruses	  block	  MHC	  










There	  are	  6	  isoforms	  of	  MHC	  class	  I	  of	  which	  HLA-­‐A,	  -­‐B,	  and	  -­‐C	  are	  categorized	  as	  MHC	  
class	  Ia	  and	  HLA-­‐E,	  -­‐F,	  and	  -­‐G	  are	  categorized	  as	  MHC	  class	  Ib.	  MHC	  class	  Ia	  molecules	  are	  gen-­‐
erally	  involved	  in	  antigen	  presentation	  to	  CD8+	  T-­‐cells,	  however	  they	  also	  function	  as	  inhibitory	  
ligands	  to	  NK	  cell	  receptors	  and	  inhibit	  NK	  cell	  activation.	  HLA-­‐E	  and	  HLA-­‐G	  predominantly	  func-­‐
tion	  as	  NK	  cell	  inhibitory	  ligands,	  but	  the	  function	  of	  HLA-­‐F	  is	  not	  known	  currently.	  HLA-­‐E	  is	  pre-­‐
sent	  in	  as	  much	  abundance	  as	  HLA-­‐A,	  -­‐B,	  and	  –C.	  There	  are	  two	  transcripts	  of	  HLA-­‐E,	  short	  and	  
long	  transcripts,	  regulated	  by	  alternative	  polyadenylation.	  Short	  transcript	  is	  found	  slightly	  
more	  in	  cancer	  cells	  than	  long	  transcript,	  otherwise	  there	  are	  found	  in	  same	  amounts	  with	  the	  
long	  transcript	  probably	  being	  the	  functional	  one	  (167).	  HLA-­‐E	  expression	  is	  regulated	  by	  CIITA	  
transcription	  factor	  and	  is	  responsive	  to	  IFN-­‐γ	  (30).	  HLA-­‐E	  associates	  with	  β2m	  and	  binds	  to	  
nonamers	  of	  HLA-­‐1a	  signal	  sequence-­‐derived	  peptides	  obtained	  by	  proteosomal	  degradation	  
(22).	  TAP	  hetero-­‐dimer	  is	  required	  for	  stability	  and	  peptide	  binding	  to	  HLA-­‐E.	  Thus,	  a	  non-­‐
functional	  TAP	  hetero-­‐dimer	  will	  lead	  to	  down-­‐regulation	  of	  HLA-­‐E	  surface	  expression	  (101).	  	  In	  
contrast,	  recent	  studies	  on	  HLA-­‐E	  have	  shown	  that	  in	  the	  absence	  of	  signal	  sequence-­‐derived	  
peptides,	  a	  functional	  TAP	  or	  tapasin	  results	  in	  surface	  expression	  of	  an	  immature	  HLA-­‐E	  glyco-­‐
forms.	  (104).	  Stable	  HLA-­‐E	  molecules	  on	  the	  cell	  surface	  are	  available	  to	  bind	  to	  NK	  inhibitory	  
receptor	  CD94/NKG2A	  (23,	  101).	  CD94/NKG2A	  complex	  binds	  at	  the	  peptide-­‐binding	  domain	  α1	  
and	  α2	  heavy	  chain	  of	  HLA-­‐E	  (82).	  Not	  all	  HLA-­‐E	  molecules	  that	  bind	  to	  signal	  sequence-­‐derived	  
peptides	  bind	  to	  CD94/NKG2A	  inhibitory	  receptors.	  HLA-­‐E	  that	  bind	  to	  only	  specific	  peptides	  
derived	  from	  some	  isoforms	  of	  HLA-­‐1a	  are	  capable	  of	  binding	  to	  NK	  cell	  inhibitory	  ligand	  and	  




	   HLA-­‐G	  protein	  is	  selectively	  expressed	  on	  placenta	  and	  thymus	  (76).	  The	  transcription	  of	  
HLA-­‐G	  is	  not	  dependent	  on	  NF-­‐κB,	  CIITA,	  or	  IRF-­‐1,	  but	  is	  regulated	  by	  RFX	  and	  SP1	  transcription	  
factors,	  which	  differs	  from	  HLA-­‐1a	  or	  HLA-­‐E	  transcription	  regulation	  (30).	  Also,	  IL-­‐10	  cytokine	  
induces	  HLA-­‐G	  cell	  surface	  expression	  especially	  in	  cancer	  cells	  (157,	  168).	  HLA-­‐G	  exists	  in	  7	  iso-­‐
forms,	  HLA-­‐G1,	  -­‐G2,	  -­‐G3,	  -­‐G4,	  -­‐G5,	  -­‐G6,	  and	  -­‐G7,	  as	  a	  result	  of	  alternative	  splicing.	  HLA-­‐G1,	  -­‐G2,	  -­‐
G3,	  and	  -­‐G4	  are	  membrane	  bound	  while	  HLA-­‐G5,	  -­‐G6,	  and	  -­‐G7are	  soluble	  forms.	  HLA-­‐G	  is	  dif-­‐
ferentially	  expressed	  in	  different	  cells	  (30,	  169),	  (29),	  (116).	  The	  structure	  of	  HLA-­‐G	  is	  very	  simi-­‐
lar	  to	  each	  of	  the	  other	  HLA	  molecules	  consisting	  of	  a	  heavy	  chain	  with	  3α	  domains,	  and	  with	  
α1	  and	  α2	  forming	  the	  peptide-­‐binding	  groove.	  The	  third	  domain	  binds	  non-­‐covalently	  to	  β2m.	  
HLA-­‐G	  can	  present	  peptides	  in	  a	  TAP	  dependent	  or	  TAP	  independent	  manner	  (34).	  HLA-­‐G	  iso-­‐
forms	  expressed	  on	  the	  cell	  surface	  bind	  to	  variety	  of	  NK	  cell	  inhibitory	  receptors	  such	  as,	  leu-­‐
kocyte	  Ig-­‐like	  receptor	  (LIR-­‐1)	  (62)	  and	  KIR2DL4	  (NK	  cell	  killer	  inhibitory	  receptor).	  HLA-­‐G2,	  -­‐G3,	  
and	  -­‐G4	  isoforms	  not	  only	  block	  NK	  cell	  lytic	  activity	  (135,	  150,	  151),	  but	  also	  block	  CD8+	  T-­‐cell	  
lytic	  activity	  (152).	  HLA-­‐G	  dimerization	  can	  occur	  in	  some	  instances	  on	  the	  cell	  surface.	  The	  cell	  
surface	  dimerization	  occurs	  due	  to	  the	  disulfide	  bonds	  of	  Cys-­‐42	  of	  the	  heavy	  chain	  (26).	  	  
1.1.4 Natural	  killer	  cells	  
	   Natural	  Killer	  cells	  (NK	  cells)	  are	  lymphoid	  origin	  cells	  that	  play	  an	  important	  role	  in	  both	  
innate	  and	  adaptive	  immunity.	  NK	  cells	  are	  mainly	  known	  to	  be	  part	  of	  innate	  immune	  re-­‐
sponses,	  however,	  recent	  studies	  have	  shown	  data	  that	  suggest	  NK	  cells	  share	  not	  only	  similar	  
phenotypic	  features	  with	  T-­‐cells	  but	  also,	  certain	  functional	  features	  such	  as,	  cytotoxicity,	  
memory,	  proliferation,	  and	  contraction	  (41,	  161,	  182).	  There	  are	  two	  subsets	  of	  NK	  cells:	  




IL-­‐2	  playing	  an	  important	  role	  in	  cytotoxicity	  including	  antibody	  dependent	  cell	  cytotoxicity	  
(ADCC).	  The	  other	  10%	  of	  NK	  cells,	  which	  form	  the	  CD16bright	  population,	  upon	  activation	  pro-­‐
duce	  IFN-­‐γ,	  TNF-­‐α,	  and	  granulocyte	  macrophage	  colony-­‐stimulating	  factor	  (GM-­‐CSF)	  as	  well	  as	  
other	  cytokines	  (IL-­‐10	  and	  IL-­‐13)	  that	  drive	  a	  Th2	  immune	  response.	  	  Each	  subset	  is	  capable	  of	  
similar	  cytolytic	  activity	  (51).	  
NK	  cells	  can	  lyse	  infected	  or	  cancerous	  cells	  in	  the	  absence	  of	  antigen	  presentation,	  
however,	  presence	  of	  proper	  activation	  ligands	  on	  the	  surface	  of	  target	  cells	  is	  important	  for	  
activation	  of	  NK	  cells.	  	  As	  discussed	  previously,	  under	  normal	  conditions,	  cells	  present	  self-­‐
antigen	  via	  MHC	  class	  I	  pathway.	  These	  are	  recognized	  as	  “self”	  by	  NK	  cells	  as	  they	  bind	  to	  the	  
MHC	  class	  I	  molecules	  and	  are	  inhibited	  from	  lysis.	  When	  cells	  are	  infected	  with	  viruses	  that	  
down	  regulate	  MHC	  class	  I,	  NK	  cells	  are	  not	  inhibited	  due	  to	  “missing	  self”	  or	  inhibitory	  ligands.	  	  
The	  presence	  of	  activation	  ligands	  will	  activate	  the	  NK	  cell	  to	  kill	  the	  infected	  cell	  lacking	  MHC	  
class	  I.	  Thus,	  MHC	  class	  I	  molecules	  act	  as	  inhibitory	  ligands	  that	  bind	  to	  inhibitory	  receptors	  
present	  on	  the	  NK	  cells	  (95,	  96,	  98,	  117,	  181).	  	  
There	  are	  various	  activation	  receptors	  on	  NK	  cells	  and	  they	  fall	  in	  three	  main	  catagories:	  
ITAM	  (immunoreceptor	  tyrosine	  based-­‐	  acvtivation	  motif),	  non-­‐ITAM,	  and	  integrins	  (27,	  97,	  
175).	  While	  most	  inhibitory	  receptors	  bind	  to	  MHC	  class	  I	  molecules,	  activation	  receptors	  of	  NK	  
cells	  are	  more	  diverse,	  facilitating	  activation	  of	  NK	  cells	  in	  different	  situations,	  e.g.,	  when	  cells	  
are	  infected	  with	  either	  a	  pathogen	  that	  regulates	  specific	  ligands	  or	  when	  cells	  are	  trans-­‐
formed.	  FcgIIIR	  receptor	  belongs	  to	  ITAM	  activation	  receptors	  where	  the	  FcgIIIR	  (CD16)	  binds	  to	  
IgG	  and	  results	  in	  ADCC	  (174).	  Certain	  activation	  receptors	  also	  bind	  MHC	  class	  I	  molecules.	  For	  




KIR2DS1-­‐2	  to	  activate	  NK	  cells	  it	  dimerizes	  (98).	  Another	  ITAM	  activation	  receptor	  NKG2C	  binds	  
to	  HLA-­‐E	  ligands,	  because	  of	  its	  homology	  to	  NKG2A	  inhibitory	  receptor	  that	  also	  binds	  to	  HLA-­‐
E.	  	  Receptors	  KIR2DL4	  and	  BY55,	  non-­‐ITAM	  activation	  receptors,	  bind	  soluble	  HLA-­‐G	  and	  HLA-­‐C,	  
respectively.	  How	  and	  when	  the	  HLA-­‐A	  molecules	  selectively	  bind	  to	  activation	  or	  inhibitory	  re-­‐
ceptors	  is	  not	  well	  defined.	  Number	  of	  these	  activation	  and	  inhibitory	  receptors	  are	  also	  pre-­‐
sent	  on	  CTLs.	  	  	  
Certain	  activation	  ligands	  are	  expressed	  at	  basal	  levels	  on	  specific	  cell	  surfaces,	  how-­‐
ever,	  these	  activation	  ligands	  in	  the	  presence	  of	  MHC	  class	  I	  molecules	  are	  insufficient	  to	  acti-­‐
vate	  NK	  cells,	  thus,	  preventing	  cytolysis.	  During	  stress	  such	  as,	  infection	  or	  tumorogenesis,	  cells	  
over-­‐express	  specific	  activation	  ligands,	  thus	  activating	  NK	  cells	  even	  in	  the	  presence	  of	  MHC	  
class	  I	  molecules.	  The	  molecule	  NKG2D	  is	  a	  non-­‐ITAM	  activation	  receptor	  on	  NK	  cells	  that	  binds	  
to	  MICA,	  MICB,	  or	  ULBP	  (1-­‐4)	  ligands	  expressed	  on	  the	  target	  cell	  surface.	  NKG2D	  is	  also	  ex-­‐
pressed	  on	  T-­‐cells.	  These	  NKG2D	  ligands	  belong	  to	  MHC	  class	  I	  family	  where	  the	  protein	  folding	  
is	  very	  similar	  to	  MHC	  class	  I.	  	  The	  binding	  of	  ligands	  to	  NKG2D	  receptor	  can	  override	  the	  inhibi-­‐
tory	  effect	  of	  MHC	  class	  I	  when	  present	  (15,	  37,	  44,	  45,	  106).	  	  
Certain	  viruses,	  e.g.,	  many	  herpesviruses,	  down	  regulate	  surface	  MHC	  class	  I	  thus	  mak-­‐
ing	  infected	  cells	  sensitive	  to	  NK	  cell–mediated	  cytolysis.	  The	  beta-­‐herpesvirus,	  HCMV	  (cy-­‐
tomegalovirus)	  down	  regulates	  MHC	  1,	  however,	  peptide	  from	  the	  leader-­‐sequence	  of	  HCMV	  
UL40	  glycoprotein	  binds	  to	  HLA-­‐E	  and	  up-­‐regulates	  HLA-­‐E	  expression	  independently	  of	  TAP	  
(163).	  This	  HLA-­‐E	  presenting	  UL40	  peptide	  binds	  to	  the	  NKG2A/CD94,	  protecting	  the	  infected	  
cell	  from	  NK	  mediated	  cytolysis.	  Additionally,	  CMV	  UL16	  binds	  to	  ULBP	  stress	  proteins	  and	  




cell	  activation	  ligands	  and	  disrupt	  NK	  cell	  activity.	  	  With	  these	  mechanisms	  in	  place,	  CMV	  can	  
down	  regulate	  both	  MHC	  class	  I	  expression	  for	  CD8+	  T-­‐cell	  presentation	  (133)	  and	  also	  NK	  cell	  
activity	  (activation	  and	  inhibition	  of	  NK	  cells	  is	  illustrated	  in	  figure	  3),	  sparing	  the	  infected	  cells	  

























Figure	  3:	  NK	  cell	  activation	  and	  inhibition.	  A	  normal	  cell,	  which	  expresses	  MHC	  class	  I	  and	  basal	  
levels	  of	  activation	  ligands,	  is	  resistant	  to	  NK	  cell	  lysis.	  In	  cases	  of	  over	  expression	  of	  activation	  








Within	  the	  NK	  cell,	  ligation	  of	  ITAM	  receptors	  recruits	  DAP12	  adaptor	  molecules,	  an	  
event	  which	  is	  followed	  by	  phosphorylation	  of	  Syk/	  ZAP70	  tyrosine	  kinases.	  This	  phosphoryla-­‐
tion	  event	  leads	  to	  further	  downstream	  signaling	  events	  that	  induce	  mitogen	  activated	  protein	  
kinase	  (MAPK)	  and	  extracellular	  signal	  regulated	  kinase	  (ERK),	  a	  pathway	  resulting	  in	  release	  of	  
cytotoxic	  granules	  and/	  or	  expression	  of	  cytokines	  IFN-­‐γ	  and	  TNF-­‐α,	  GM-­‐CSF,	  IL-­‐2,	  and	  other	  
Th2	  associated	  cytokines.	  When	  ligation	  of	  non-­‐ITAM	  receptors	  e.g.,	  NKG2D	  occurs,	  DAP10	  
adaptor	  molecules	  are	  also	  recruited,	  but	  the	  signaling	  pathway	  is	  independent	  of	  Syk	  phos-­‐
phorylation.	  In	  these	  cases,	  the	  signaling	  pathway	  involves	  phosphorylation	  of	  phosphatidyli-­‐
nositol	  3	  kinase	  (PI3K)	  and	  phospholipase	  C-­‐γ1	  (PLCγ1)	  (20,	  97,	  99,	  138,	  175).	  Upon	  ligation	  of	  
inhibitory	  receptors	  by	  MHC	  class	  I	  molecules,	  SHP1/2	  protein	  is	  phosphorylated,	  preventing	  
phosphorylation	  of	  SLP-­‐76	  and	  Vav	  proteins,	  each	  of	  which	  is	  involved	  in	  ITAM	  and	  non-­‐ITAM	  
induced	  activation	  (172,	  173,	  175)	  (Figure	  4).	  For	  NK	  cells	  to	  properly	  function,	  they	  purportedly	  
adhere	  to	  the	  target	  cells.	  The	  adherence	  is	  mediated	  by	  the	  integrin	  receptors	  on	  the	  NK	  cells	  
when	  these	  bind	  to	  ligands,	  e.g.,	  ICAM,	  VCAM,	  and	  fibronectin.	  This	  ligation	  facilitates	  lysis	  of	  
target	  cells	  (27).	  Alternatively,	  NK	  cell	  killing	  may	  be	  facilitated	  by	  exocytic	  release	  of	  lysosomes	  










Figure	  4:	  NK	  cell	  inhibitory	  and	  activation	  signaling.	  Inhibitory	  ligation	  results	  in	  the	  phos-­‐
phorylation	  and	  activation	  of	  SHP,	  which	  leads	  to	  dephosphorylation	  of	  SLP76	  and	  Vav	  inhibit-­‐
ing	  NK	  cell	  activity.	  Activation	  ligation	  through	  ITAM	  recruits	  DAP12	  and	  phosphorylation	  of	  Syk	  
and	  Zap70	  leading	  to	  NK	  cell	  activity.	  Activation	  ligation	  through	  non-­‐ITAM	  recruits	  DAP10	  and	  








	   In	  order	  for	  NK	  cells	  to	  bind	  to	  respective	  ligands,	  NK	  cells	  need	  to	  be	  primed	  and	  re-­‐
cruited	  to	  the	  site	  of	  infection	  or	  cancer	  growth	  (localized	  tissue).	  This	  activation	  and	  migration	  
is	  induced	  by	  certain	  cytokines,	  which	  are	  produced	  by	  the	  infected	  cell.	  Type	  II	  cytokines,	  e.g.,	  
IFN	  I	  are	  involved	  in	  NK	  cell	  migration	  and	  cytotoxicity	  activity.	  Likewise,	  IL-­‐2,	  IL-­‐12,	  TNFα,	  IL-­‐
1α/β,	  IL-­‐15,	  and	  IL-­‐10	  are	  all	  important	  for	  production	  of	  IFN-­‐γ	  production	  by	  NK	  cells	  upon	  ac-­‐
tivation.	  Beside	  these	  cytokines,	  chemokines	  such	  as,	  MIP-­‐1α,	  MIP-­‐1β,	  IP-­‐10,	  and	  MCP-­‐1,	  2,	  3	  
are	  involved	  in	  the	  chemoattraction,	  migration,	  and	  activation	  of	  NK	  cells	  (21,	  162).	  
NK	  cells	  upon	  activation	  exert	  effects	  on	  target	  cells	  in	  two	  ways:	  cytotoxicity	  and/or	  cy-­‐
tokine	  production.	  Cytotoxicity	  is	  mediated	  by	  release	  of	  perforin	  granules	  and	  granzyme	  pro-­‐
tease	  molecules	  from	  the	  NK	  cells	  via	  exocytosis	  after	  engaging	  the	  target	  cells	  or	  by	  ligation	  of	  
TRAIL	  and	  FAS	  receptors.	  Cytokines	  such	  as,	  TNF-­‐α	  and	  IFN-­‐γ	  produced	  by	  activated	  NK	  cells	  re-­‐
sult	  in	  apoptosis	  of	  target	  cells.	  IFN-­‐γ,	  a	  Th1	  cytokine,	  produced	  by	  NK	  cells	  can	  result	  in	  activa-­‐
tion	  of	  CD8+	  T-­‐cell	  cytotoxicity	  (121).	  NK	  cells	  also	  produce,	  although	  in	  smaller	  amounts,	  Th2	  
cytokines	  (66,	  67,	  91)	  and	  play	  a	  role	  in	  regulating	  hematopoiesis	  and	  B-­‐cell	  differentiation	  (10,	  
139).	  NK	  cells	  can	  interact	  with	  DCs	  to	  activate	  them	  and	  help	  antigen	  presentation.	  This	  is	  a	  
bidirectional	  interaction,	  where	  dendritic	  cells	  can	  activate	  NK	  cells	  by	  production	  of	  IFN-­‐α.	  
Thus,	  NK	  cells	  and	  dendritic	  cells	  exert	  influence	  upon	  each	  other	  either	  by	  the	  production	  of	  
cytokines	  or	  by	  receptor-­‐ligand	  binding	  (145).	  Thus,	  NK	  cells	  upon	  activation	  can	  modulate	  not	  
only	  innate	  immune	  responses,	  but	  also	  the	  adaptive	  immune	  responses	  and	  act	  as	  a	  bridge	  






1.1.5 Natural	  Killer	  cells	  and	  encephalitis	   	  
	   Natural	  killer	  cells	  are	  associated	  with	  the	  innate	  immune	  responses,	  but	  also	  play	  a	  ma-­‐
jor	  role	  in	  adaptive	  immune	  responses.	  Because	  of	  these	  important	  roles,	  NK	  cells	  are	  impli-­‐
cated	  in	  infections	  leading	  to	  encephalitis.	  Aforementioned,	  NK	  cells	  can	  induce	  the	  production	  
of	  Th1	  and	  Th2	  cytokines	  that	  affect	  the	  T	  cells	  to	  produce	  cellular	  and/or	  humoral	  immune	  re-­‐
sponses.	  NK	  cells	  play	  a	  major	  role	  in	  providing	  protective	  immunity	  against	  various	  encephali-­‐
tis-­‐causing	  viral	  infections,	  such	  as,	  HSV-­‐1,	  rabies	  and	  Theiler’s	  virus	  (5,	  132,	  134).	  These	  cells	  
compensate	  for	  the	  lack	  of	  T-­‐cells	  during	  HSV-­‐1	  infection	  and	  prevent	  mortality	  due	  to	  en-­‐
cephalitis	  (5).	  Recent	  studies	  by	  Nandakumar	  et	  al.,	  have	  shown	  that	  NK	  cells	  play	  an	  important	  
role	  in	  limiting	  encephalitis	  as	  shown	  in	  in	  vivo	  experiments	  in	  mice	  (121).	  Results	  from	  this	  
group	  suggest	  that	  NK	  cells	  can	  compensate	  for	  the	  loss	  of	  CD4	  T	  helper	  cell	  function.	  Fatal	  B	  
virus	  infection	  in	  humans	  is	  very	  similar	  to	  HSV-­‐1	  encephalitis	  in	  humans.	  Therefore,	  taking	  into	  
consideration	  all	  the	  important	  aspects	  of	  NK	  cells,	  it	  is	  important	  to	  study	  the	  roles	  played	  by	  




1.2 Part	  II:	  RESEARCH	  GOALS	  
	   In	  humans	  B	  virus	  reaches	  the	  CNS	  quickly,	  often	  in	  a	  matter	  of	  days	  following	  virus	  in-­‐
fection	  resulting	  in	  severe	  neuropathological	  disease	  leading	  to	  death.	  Zoonotic	  infection	  of	  B	  
virus	  is	  of	  prime	  concern	  for	  the	  personnel	  working	  with	  macaques.	  B	  virus	  infection	  in	  ma-­‐
caques	  results	  in	  a	  robust	  adaptive	  immune	  response,	  however,	  the	  same	  is	  not	  true	  in	  case	  of	  
humans.	  Therefore,	  it	  is	  important	  to	  understand	  how	  the	  virus	  behaves	  in	  a	  foreign	  host	  and	  
how	  it	  suppresses	  immune	  responses	  required	  for	  maintaining	  a	  balance	  between	  virus	  replica-­‐
tion	  and	  immune	  response.	  Previous	  results	  from	  our	  lab	  suggested	  that	  B	  virus	  has	  some	  eva-­‐
sion	  mechanisms	  that	  result	  in	  rendering	  innate	  immune	  responses	  insufficient,	  which	  might	  
ultimately	  affect	  the	  adaptive	  immune	  response.	  Although,	  NK	  cells	  belong	  to	  innate	  immunity,	  
they	  are	  capable	  of	  producing	  both	  Th1	  and	  Th2	  cytokines.	  They	  can	  also	  activate	  DCs	  to	  effi-­‐
ciently	  present	  antigen	  to	  T-­‐cells.	  Because	  NK	  cells	  play	  an	  important	  role	  in	  forming	  this	  bridge	  
between	  innate	  and	  adaptive	  immunity,	  it	  is	  critical	  to	  understand	  how	  B	  virus	  may	  impede	  or	  
subvert	  the	  innate	  immune	  responses	  during	  zoonotic	  infection.	  Therefore,	  we	  hypothesize	  
that	  B	  virus	  evades	  host	  innate	  immune	  responses	  by	  down	  regulating	  signals	  for	  activation	  
and	  migration	  of	  natural	  killer	  cells	  in	  a	  foreign	  host.	  To	  test	  this	  hypothesis,	  we	  focused	  on	  
the	  regulation	  of	  MHC	  class	  I,	  which	  plays	  an	  important	  role	  in	  regulating	  CD8+	  T-­‐cell	  activity	  
(adaptive	  immune	  response)	  and	  NK	  cell	  activity	  (innate	  immune	  response).	  Because	  these	  re-­‐
sponses	  are	  responsible	  for	  lysing	  the	  infected	  cell,	  the	  virus	  is	  prevented	  from	  spreading	  to	  
other	  cells	  by	  cell	  fusion.	  These	  studies	  were	  designed	  to	  identify	  and	  understand	  specific	  eva-­‐




spread	  of	  virus	  and	  suppression	  of	  immune	  response.	  Basing	  on	  the	  previous	  research	  on	  HSV-­‐1	  
in	  other	  labs,	  we	  designed	  our	  experiments	  to	  test	  our	  hypothesis	  using	  a	  cell	  culture	  based	  sys-­‐
tem	  that	  will	  allow	  us	  to	  examine	  the	  factors	  that	  determine	  NK	  cell	  activity	  or	  inhibition	  of	  NK	  
cell	  activity	  during	  B	  virus	  infection	  at	  a	  cellular	  level.	  To	  achieve	  this,	  we	  proposed	  the	  follow-­‐
ing	  specific	  aims:	  
	  
1. Identify	  how	  regulation	  of	  MHC	  class	  I	  in	  B	  virus	  infected	  HFF	  cells	  proceeds.	  
2. Identify	  how	  B	  virus	  infection	  down	  regulates	  factors	  necessary	  for	  NK	  cell	  activation	  







2 MATERIALS	  AND	  METHODS	  
	  
2.1 Cells	  and	  viruses	  
Human	  foreskin	  fibroblast	  cells	  (HFF,	  ATCC	  #	  CRL-­‐2097)	  obtained	  from	  ATCC	  	  (Manassas,	  
VA)	  were	  maintained	  as	  a	  monolayer	  in	  minimal	  essential	  media	  (MEM),	  purchased	  from	  Medi-­‐
atech,	  Inc.	  (Manassas,	  VA)	  supplemented	  with	  10%	  fetal	  bovine	  serum	  (FBS)	  purchased	  from	  
Atlanta	  Biologicals,	  Norcross,	  GA,	  1%	  non-­‐essential	  amino	  acids,	  and	  1%	  sodium	  pyruvate.	  Pas-­‐
sages	  between	  6	  and	  13	  were	  used	  for	  all	  experiments	  with	  HFF	  cells.	  Macaque	  kidney	  epithe-­‐
lial	  cells	  (MK2,	  ATTC#	  CCL-­‐7)	  were	  obtained	  from	  ATCC	  and	  were	  maintained	  as	  a	  monolayer	  in	  
Dulbecco’s	  Modified	  Eagle’s	  Media	  (DMEM,	  Mediatech,	  Inc.)	  with	  10%	  FBS.	  B	  virus	  lab	  strain	  
E2490,	  passages	  71-­‐73,	  originally	  from	  Dr.	  E.	  Hull,	  HSV-­‐1	  strain	  MacIntyre	  (Lot	  VR-­‐539)	  pur-­‐
chased	  from	  ATCC,	  and	  HVP-­‐2	  lab	  strain	  X2980	  from	  Southwest	  Foundation	  for	  Biomedical	  Re-­‐
search,	  San	  Antonio,	  TX	  were	  used	  in	  the	  experiments	  presented.	  All	  virus	  stocks	  were	  prepared	  
using	  Vero	  cells	  (Lot	  #	  CCL-­‐81)	  obtained	  from	  ATCC.	  B	  virus	  lab	  strain	  E2490,	  HSV-­‐1	  strain	  Mac-­‐
Intyre	  (Lot	  #	  VR-­‐539	  from	  ATCC),	  and	  HVP-­‐2	  lab	  strain	  X2980	  were	  used	  in	  our	  experiments.	  All	  
experiments	  with	  B	  virus	  were	  done	  in	  the	  CDC	  approved	  Bio-­‐safety	  Level-­‐4	  (BSL-­‐4)	  laboratory	  
in	  compliance	  with	  the	  Biosafety	  in	  Microbiological	  and	  Biomedical	  Laboratories	  manual	  	  
(BMBL,	  5th	  edition)	  and	  the	  U.S.	  Department	  of	  Justice’s	  Homeland	  Security	  directives	  on	  Select	  




2.2 Virus	  stocks	  and	  plaque	  assay	  
Vero	  cells	  were	  grown	  to	  sub-­‐confluency	  in	  roller	  bottles	  after	  which	  cells	  were	  infected	  
with	  0.01	  multiplicity	  of	  infection	  (MOI)	  for	  48	  hpi	  (hours	  post-­‐infection).	  Infected	  cells	  were	  
then	  collected,	  centrifuged	  at	  1000	  rpm	  for	  10	  minutes	  at	  room	  temperature,	  and	  the	  subse-­‐
quent	  pellet	  re-­‐suspended	  in	  fresh	  MEM	  with	  2%	  FBS.	  The	  virus	  cell	  lysate	  was	  rapidly	  frozen–
thawed	  three	  times	  to	  disrupt	  cells	  for	  release	  of	  virus.	  Virus	  infectivity	  in	  different	  cell	  lines	  
was	  determined	  using	  standard	  plaque	  assays	  in	  order	  to	  quantify	  the	  efficiency	  of	  plating	  or	  
the	  amount	  of	  virus	  needed	  for	  infection	  to	  achieve	  equivalent	  results	  regardless	  of	  the	  cell	  line	  
used.	  For	  the	  plaque	  assay,	  Vero	  or	  HFF	  cells	  were	  grown	  to	  sub-­‐confluency	  in	  6-­‐well	  plates.	  
Media	  were	  removed	  and	  serially	  diluted	  virus	  1:10	  to	  a	  final	  dilution	  of	  1	  x	  1010	  with	  each	  dilu-­‐
tion	  added	  to	  two	  wells.	  Virus	  was	  adsorbed	  in	  400	  µl	  for	  1	  hr	  at	  37ºC	  in	  a	  5%	  CO2	  incubator.	  At	  
1	  hpi	  media	  was	  removed	  and	  fresh	  MEM	  media	  with	  1%	  methylcellulose	  was	  added	  to	  each	  
well.	  The	  plates	  were	  incubated	  for	  48	  hpi.	  After	  48	  hrs	  media	  was	  removed	  and	  the	  wells	  were	  
washed	  twice	  with	  PBS	  (Phosphate	  buffer	  saline)	  and	  fixed	  with	  100%	  methanol.	  Fixed	  cells	  
were	  stained	  with	  crystal	  violet	  and	  the	  number	  of	  plaques	  was	  counted.	  HSV-­‐1	  infection	  in	  
MK2	  cells	  is	  abortive,	  however,	  immediate-­‐early	  protein	  expression	  was	  observed	  in	  independ-­‐
ent	  studies	  (I.Patrusheva,	  R.Farah.,	  personal	  communication).	  	  
2.3 Western	  Blot	  Analysis	  
HFF	  cells	  were	  infected	  with	  HSV-­‐1	  or	  B	  virus	  at	  a	  multiplicity	  of	  Infection	  (MOI)	  10	  to	  
uniformly	  infect	  all	  cells	  simultaneously	  to	  detect	  total	  antigen	  expression	  of	  HLA-­‐A,	  -­‐B,	  -­‐C,	  HLA-­‐




(MICA),	  HFF	  cells	  were	  infected	  with	  HSV-­‐1	  or	  B	  virus	  at	  a	  MOI	  5.	  Prepared	  infected	  cell	  lysates	  
were	  collected	  and	  re-­‐suspended	  in	  using	  Laemmili	  sample	  buffer	  containing	  5%	  2-­‐	  mercap-­‐
toethanol.	  The	  solution	  was	  boiled	  for	  3	  minutes	  and	  samples	  were	  fractionated	  on	  a	  10%	  SDS-­‐
PAGE	  polyacrylamide	  gel.	  Subsequently,	  proteins	  were	  transferred	  onto	  a	  nitrocellulose	  mem-­‐
brane	  (0.45	  µm	  membrane,	  GE	  Healthcare,	  Piscataway,	  NJ)	  by	  electroblotting	  for	  2	  hours.	  
Transferred	  proteins	  were	  probed	  with	  mouse	  anti-­‐human	  HLA-­‐A,	  -­‐B,	  -­‐C	  clone	  LY5.1	  antibody	  
(Santa	  Cruz	  Biotechnology,	  Inc.	  Santa	  Cruz,	  CA)	  at	  a	  dilution	  of	  1:100	  was	  used	  to	  detect	  total	  
HLA-­‐A,	  -­‐B,	  -­‐C	  antigen	  content	  in	  HFF	  cells.	  Mouse	  anti-­‐human	  HLA-­‐E	  clone	  MEM-­‐E/02	  (Santa	  
Cruz	  Biotechnology,	  Inc.)	  at	  a	  dilution	  of	  1:200	  was	  used	  to	  determine	  total	  HLA-­‐E	  expression	  in	  
HFF	  cells.	  Mouse	  anti-­‐human	  HLA-­‐G	  clone	  4H84	  (Santa	  Cruz	  Biotechnology,	  Inc.)	  at	  a	  dilution	  of	  
1:200	  was	  used	  to	  measure	  total	  HLA-­‐G	  protein.	  For	  detection	  of	  total	  MICA,	  mouse	  anti-­‐	  hu-­‐
man	  MICA	  purchased	  from	  Abcam	  was	  used	  at	  a	  dilution	  of	  1:1000.	  Rabbit	  anti-­‐human	  GAPDH	  
(purchased	  from	  Imgenex	  Corp.,	  CA)	  was	  used	  at	  a	  dilution	  of	  1:500	  to	  detect	  GAPDH	  expres-­‐
sion	  to	  evaluate	  consistency	  of	  loading	  volume	  of	  individual	  wells.	  Goat	  anti-­‐mouse	  antibody	  
conjugated	  to	  HRP	  and	  goat	  anti-­‐rabbit	  antibody	  conjugated	  to	  HRP	  (Pierce,	  Rockford,	  IL)	  were	  
used	  at	  dilutions	  of	  1:20,000	  to	  detect	  the	  mouse	  anti-­‐human	  and	  rabbit	  anti-­‐human	  primary	  
antibodies,	  respectively.	  Respective	  bands	  were	  detected	  using	  ECL	  plus	  western	  blotting	  de-­‐
tection	  reagent	  (GE	  Healthcare).	  
2.4 Flow	  Cytometry	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  HFF	  and	  MK2	  cells	  were	  infected	  at	  sub-­‐confluency	  (MOI	  10)	  or	  uninfected.	  At	  




were	  trypsinized	  and	  fixed	  with	  4%	  paraformaldehyde	  at	  room	  temperature	  for	  1	  hour.	  Fixed	  
cells	  were	  washed	  three	  times	  with	  1%	  Bovine	  Serum	  Albumin	  (BSA)	  in	  PBS.	  Cells	  were	  then	  la-­‐
beled	  with	  mouse	  monoclonal	  anti-­‐human	  HLA	  class	  I	  clone	  W6/32	  conjugated	  to	  FITC	  (Sigma-­‐
Aldrich,	  St.	  Louis,	  MO)	  according	  to	  manufacturer	  instructions	  (10µl/	  1	  million	  cells),	  and	  subse-­‐
quently	  incubated	  at	  room	  temperature	  for	  1	  hour	  in	  darkness.	  Labeled	  cells	  were	  washed	  two	  
times	  in	  cold	  PBS	  and	  the	  cells	  were	  analyzed	  using	  BD	  FACS	  Canto	  (BD	  Biosciences,	  San	  Jose,	  
CA).	  Protein	  expression	  of	  HLA-­‐A,	  -­‐B,	  -­‐C	  was	  measured	  in	  terms	  of	  the	  mean	  fluorescence	  inten-­‐
sity	  (mfi)	  emitted	  by	  the	  labeled	  cells.	  Uninfected,	  unlabeled	  cells	  were	  used	  as	  negative	  control	  
to	  assess	  auto-­‐fluorescence.	  Mean	  fluorescent	  intensity	  of	  labeled	  cells	  was	  normalized	  by	  sub-­‐
tracting	  the	  mean	  fluorescent	  intensity	  of	  unlabeled	  cells	  from	  mean	  fluorescent	  intensity	  of	  
labeled	  cell.	  Ratio	  of	  mean	  fluorescent	  intensity	  was	  measured	  using	  the	  formula:	  
Mean	  fluorescent	  intensity	  of	  infected	  cells	  
Mean	  fluorescent	  intensity	  of	  uninfected	  cells	  
For	  detection	  of	  MICA/MICB	  surface	  expression,	  HFF	  cells	  were	  infected	  at	  a	  MOI	  5,	  or	  
left	  uninfected.	  At	  12	  and	  24	  hours	  post	  infection	  (hpi),	  cells	  were	  washed	  with	  phosphate	  buff-­‐
ered	  saline	  (PBS).	  Cells	  were	  prepared	  for	  flow	  cytometry	  as	  explained	  before.	  Cells	  were	  la-­‐
beled	  with	  anti-­‐MICA/MICB	  antibody	  conjugated	  to	  PE	  	  (20	  µl/	  1	  million	  cells)	  purchased	  from	  
Biolegend,	  San	  Diego,	  CA.	  Uninfected	  cells	  that	  were	  unlabeled	  were	  used	  as	  negative	  control	  
to	  assess	  auto-­‐fluorescence.	  	  Data	  analyses	  were	  performed	  using	  BD	  FACS	  Canto	  (BD	  Bio-­‐





2.5 PBMC	  isolation	  
	   Whole	  blood	  was	  drawn	  from	  two	  healthy	  donors	  who	  were	  sero-­‐negative	  for	  B	  virus	  
and	  HSV-­‐1	  antibodies	  as	  determined	  by	  western	  blot.	  	  Whole	  blood	  (10	  ml)	  was	  layered	  onto	  
4ml	  Ficoll-­‐Paque	  PLUS	  purchased	  from	  GE	  Amersham	  (Piscataway,	  NJ)	  in	  15	  ml	  conical	  tubes.	  	  
PBMCs	  (peripheral	  blood	  mononuclear	  cells)	  were	  separated	  by	  density	  gradient	  by	  spinning	  at	  
2000	  rpm	  at	  room	  temperature	  for	  30	  minutes	  with	  the	  brake	  set	  to	  off.	  Three	  layers	  are	  
formed,	  with	  the	  top	  layer	  containing	  plasma	  and	  platelets	  and	  the	  bottom	  layer	  containing	  red	  
blood	  cells.	  A	  buffy	  coat,	  which	  contains	  all	  the	  PBMCs,	  was	  present	  between	  the	  top	  and	  bot-­‐
tom	  layer.	  The	  buffy	  coat	  was	  collected	  and	  washed	  in	  excess	  PBS	  to	  eliminate	  platelets	  and	  
plasma	  by	  spinning	  at	  800	  rpm	  at	  room	  temperature	  for	  10	  minutes.	  The	  resultant	  pellet	  was	  
washed	  again	  with	  RBC	  lysis	  buffer	  (room	  temperature)	  to	  remove	  red	  blood	  cells	  in	  the	  pellet.	  
The	  pellet	  containing	  PBMCs	  was	  washed	  again	  with	  PBS	  twice	  at	  room	  temperature.	  Super-­‐
natant	  was	  discarded	  and	  the	  pellet	  was	  re-­‐suspended	  in	  excess	  cold	  RPMI	  with	  10%	  FBS	  (25	  ml	  
media	  for	  every	  100ml	  whole	  blood),	  then	  stored	  at	  4ºC	  overnight	  for	  subsequent	  PBMC	  assays	  
and	  NK	  cell	  isolation.	  
2.6 NK	  cell	  isolation	  
	   Natural	  killer	  cells	  (NK	  cells)	  were	  isolated	  using	  MACS	  NK	  cell	  isolation	  kit	  on	  PBMCs	  	  
(described	  above)	  obtained	  from	  laboratory	  donors	  lacking	  antibodies	  against	  the	  specific	  vi-­‐
ruses	  described	  (Miltenyi	  Biotec,	  Auburn,	  CA).	  The	  NK	  cells	  were	  separated	  using	  indirect	  mag-­‐




of	  nearly	  pure	  populations	  of	  NK	  cells	  that	  remained	  un-­‐activated	  by	  the	  process.	  About	  5%	  NK	  
cells	  were	  isolated	  from	  donor	  PBMCs.	  
2.7 Cytokine/	  chemokine	  production	  in	  infected	  HFF	  cells	  
	   HFF	  cells	  were	  infected	  in	  a	  minimum	  volume	  containing	  B	  virus	  or	  HSV-­‐1	  at	  a	  MOI	  5,	  or	  
mock	  infected	  using	  vero	  cell	  lysates	  and	  incubated	  in	  37ºC,	  5%	  CO2	  incubator	  for	  1	  hour	  to	  fa-­‐
cilitate	  adsorption.	  At	  5	  and	  23	  hours	  post-­‐adsorption	  (6	  and	  24	  hours	  post	  infection,	  respec-­‐
tively),	  supernatants	  from	  the	  different	  wells	  were	  collected	  to	  quantify	  chemokines	  and	  cyto-­‐
kines	  released	  by	  infected	  cells	  for	  NK	  cell	  migration	  and	  activation.	  Cytokines	  and	  chemokines	  
were	  detected	  using	  Liquichip™	  assay	  and	  instrumentation	  from	  Qiagen,	  Valencia,	  CA.	  
2.8 PBMC	  assay	  
	   HFF	  cells	  were	  infected	  with	  B	  virus,	  HSV-­‐1,	  or	  mock	  infected	  with	  uninfected	  Vero	  cell	  
lysates.	  At	  6	  hours	  post-­‐infection	  (hpi),	  PBMCs	  isolated	  (as	  described	  above)	  from	  antibody-­‐
negative	  donors	  were	  added	  to	  each	  well	  at	  1:50	  target	  to	  effector	  ratio.	  The	  infected	  cells	  
overlaid	  with	  PBMCs	  were	  incubated	  for	  18	  hrs	  and	  the	  supernatants	  were	  then	  collected	  to	  
measure	  the	  cytokines	  and	  chemokines	  produced	  using	  Liquichip™	  assay.	  	  The	  presence	  of	  per-­‐
forin	  and	  granzyme	  B	  (indicative	  of	  activated	  NK	  cell	  killing)	  in	  the	  supernatants	  was	  detected	  
using	  an	  ELISA.	  	  Centrifuged	  pellets	  prepared	  from	  cell	  lysates	  were	  solubilized	  in	  Laemmili	  
sample	  buffer	  containing	  with	  5%	  2-­‐	  mercaptoethanol.	  These	  samples	  were	  fractionated	  on	  a	  
10%	  acrylamide	  gel	  and	  the	  proteins	  were	  transferred	  to	  nitrocellulose	  membrane	  by	  electrob-­‐




of	  1:1000	  and	  1:5000	  respectively	  to	  identify	  involvement	  of	  syk	  dependent	  activation	  recep-­‐
tors	  expressed	  by	  cells	  from	  the	  PBMC	  population.	  
2.9 NK	  cell	  activation	  assay	  
	   To	  measure	  NK	  cell	  activation,	  HFF	  cells	  were	  infected	  with	  B	  virus,	  HSV-­‐1,	  or	  uninfected	  
cell	  lysates.	  At	  6	  hours	  post-­‐infection	  (hpi),	  NK	  cells	  isolated	  (as	  described	  above)	  from	  anti-­‐
body-­‐negative	  donors	  were	  added	  to	  each	  well	  at	  1:5	  target	  to	  effector	  ratio.	  The	  infected	  cells	  
overlaid	  with	  NK	  cells	  were	  incubated	  with	  or	  without	  the	  media	  containing	  IL-­‐2	  (70	  U/ml)	  for	  
18	  hrs.	  The	  presence	  of	  Th1	  and	  Th2	  cytokines	  produced	  upon	  NK	  cell	  exposure	  to	  infected	  HFF	  
cells	  was	  quantified	  using	  LiquiChip	  ™	  technology.	  The	  presence	  of	  perforin	  and	  granzyme	  B	  in	  
the	  supernatants	  was	  detected	  using	  ELISA.	  In	  order	  to	  determine	  if	  NK	  cell	  activity	  is	  syk	  de-­‐
pendent	  the	  same	  protocol	  described	  above	  for	  PBMC’s	  was	  used	  for	  NK	  cell	  assays.	  
	  
2.10 Liquichip	  assay	  
	   A	  Liquichip™	  assay	  was	  performed	  using	  Luminex	  (xMAP	  technology)	  from	  Qiagen,	  Va-­‐
lencia,	  CA.	  The	  assay	  was	  performed	  as	  per	  the	  manufacturer’s	  instructions.	  Liquichip™	  human	  
cytokine	  detection	  kit	  was	  purchased	  from	  Millipore,	  Billerica,	  MA.	  The	  samples	  and	  controls	  
were	  mixed	  with	  beads	  coated	  with	  specific	  antibody	  so	  that	  each	  specific	  bead	  can	  capture	  a	  
specific	  analyte	  (cytokine)	  from	  the	  sample.	  The	  bead	  sample	  mixture	  was	  then	  incubated	  with	  




conjugate,	  sorted	  and	  interrogated	  by	  a	  laser	  which	  quantified	  each	  binding	  to	  each	  specifically	  
coated	  microbead	  population.	  	  Data	  analysis	  was	  performed	  using	  Milliplex™	  Analyst	  software.	  
2.11 Perforin	  and	  Granzyme	  B	  release	  assay	  
	   Supernatants	  from	  NK	  cells	  with	  or	  without	  treatment	  with	  IL-­‐2,	  as	  well	  as	  PBMC	  co-­‐
cultured	  cell	  supernatants	  were	  used	  to	  quantify	  released	  perforin	  and	  Granzyme	  B,	  which	  
were	  indicative	  of	  NK	  cell	  cytolytic	  activity.	  Perforin	  and	  Granzyme	  B	  were	  measured	  using	  a	  
perforin	  ELISA	  kit	  and	  Granzyme	  B	  ELISA	  kit	  purchased	  from	  Abcam,	  Cambridge,	  MA.	  These	  as-­‐
says	  were	  sandwich	  ELISAs	  and	  were	  performed	  according	  to	  manufacturer’s	  instructions.	  The	  
wells	  of	  the	  microtiter	  plates	  were	  coated	  with	  ant-­‐perforin	  or	  anti-­‐granzyme	  B	  antibody	  and	  
incubated	  with	  respective	  samples.	  After	  one-­‐hour	  incubation,	  wells	  were	  washed	  three	  times	  
with	  washing	  buffer.	  Each	  well	  is	  then	  incubated	  with	  biotinylated	  anti-­‐perforin	  or	  granzyme	  B.	  
After	  the	  incubation,	  the	  wells	  were	  washed	  again	  three	  times	  with	  the	  washing	  buffer.	  The	  an-­‐
tibody-­‐antigen-­‐antibody	  interaction	  was	  detected	  using	  streptavidin-­‐HRP.	  Tetramethyl-­‐
benzidine	  (TMB)	  substrate	  was	  used	  for	  the	  development	  of	  color	  in	  the	  wells	  with	  super-­‐
natants	  that	  have	  detectable	  amounts	  of	  perforin	  or	  granzyme	  B.	  The	  optical	  density	  (OD)	  val-­‐
ues	  were	  converted	  to	  pico	  grams/	  milliliter	  (pg/ml)	  using	  a	  standard	  curve.	  	  
2.12 Statistical	  Analysis	  
Data	  obtained	  by	  FACS	  for	  HLA-­‐A,	  -­‐B,	  -­‐C	  expression	  were	  repeated	  four	  times	  and	  stan-­‐
dard	  deviation	  was	  calculated.	  We	  used	  paired,	  two-­‐tailed	  Students	  t-­‐test	  to	  calculate	  the	  p-­‐




fected	  and	  B	  virus	  or	  uninfected	  and	  HSV-­‐1	  infected	  cells	  or	  HSV-­‐1	  and	  B	  virus	  infected	  cells	  if	  
the	  p-­‐values	  were	  found	  to	  be	  <	  0.05.	  	  
Data	  dealing	  with	  cytokines,	  chemokines,	  granzyme	  B,	  and	  perforin	  measurements	  were	  ana-­‐
lyzed	  using	  one-­‐way	  analysis	  of	  variance	  (one-­‐way	  ANOVA)	  to	  compare	  mock	  infected,	  HSV-­‐1,	  
and	  B	  virus	  infected	  samples.	  One-­‐way	  ANOVA,	  however,	  gives	  an	  overall	  difference	  between	  
different	  samples.	  	  For	  that	  reason,	  a	  multiple	  pair-­‐wise	  comparison	  test,	  such	  as	  Student	  
Newman-­‐Keuls	  test	  (SNK	  test)	  was	  used	  as	  a	  post-­‐hoc	  ANOVA.	  If	  q-­‐values	  obtained	  from	  SNK	  
test	  were	  found	  to	  be	  more	  than	  the	  critical	  value	  for	  αT=0.05,	  then	  the	  two	  samples	  were	  con-­‐
sidered	  to	  be	  significantly	  different	  from	  each	  other.	  




















3.1 Part	  I:	  	  MHC	  class	  I	  regulation	  in	  B	  virus	  infected	  cells.	  
	   Down-­‐regulation	  of	  surface	  expression	  of	  MHC	  class	  I	  is	  a	  hallmark	  of	  all	  herpes	  viruses.	  
HSV-­‐1	  and	  HSV-­‐2	  US12	  encodes	  for	  ICP47,	  which	  binds	  to	  host	  TAP	  and	  prevents	  peptide	  load-­‐
ing	  onto	  MHC	  class	  I.	  This	  block	  leads	  to	  sequestration	  of	  MHC	  class	  I	  in	  the	  ER	  and	  subsequent	  
down-­‐regulation	  of	  surface	  MHC	  class	  I.	  B	  virus,	  a	  non-­‐human	  simplex	  virus,	  very	  similar	  to	  HSV-­‐
1	  and	  2	  contains	  US12	  gene	  encoding	  ICP47.	  B	  virus	  ICP47	  does	  not	  have	  TAP	  binding	  domain	  
required	  for	  down	  regulating	  TAP.	  The	  absence	  of	  TAP	  binding	  domain	  in	  ICP47	  protein	  is	  also	  
observed	  in	  other	  non-­‐human	  primate	  simplex	  viruses	  such	  as	  HVP-­‐2	  and	  SA8.	  Therefore,	  we	  
hypothesize	  that	  B	  virus	  regulation	  of	  MHC	  class	  I	  is	  different	  from	  HSV	  in	  natural	  and	  foreign	  
hosts.	  The	  following	  experiments	  were	  conducted	  to	  test	  this	  hypothesis.	  
Virus	  infectivity.	  In	  order	  to	  determine	  the	  efficiency	  of	  B	  virus	  infection	  in	  HFF	  cells	  
(cells	  derived	  from	  a	  foreign	  host	  or	  one	  in	  which	  the	  virus	  had	  not	  co-­‐adapted	  to),	  virus	  infec-­‐
tivity	  in	  Vero	  cells	  was	  compared	  with	  virus	  infectivity	  in	  HFF	  cells	  using	  plaque	  assay.	  Similarly,	  
HSV-­‐1	  and	  HVP-­‐2	  virus	  infectivity	  was	  also	  determined	  in	  Vero	  cells	  and	  HFF	  cells.	  In	  contrast,	  
MK2	  cells	  are	  derived	  from	  a	  natural	  host,	  macaque	  monkeys,	  and	  serve	  as	  such	  for	  B	  virus	  in-­‐
fection	  while	  these	  serve	  as	  a	  foreign	  host	  cell	  line	  for	  HSV-­‐1	  infection.	  Therefore,	  virus	  infectiv-­‐
ity	  of	  HSV-­‐1	  and	  B	  virus	  was	  also	  determined	  in	  MK2	  cells.	  The	  results	  indicated	  that	  B	  virus	  in-­‐




the	  African	  green	  monkey.	  As	  a	  result	  of	  these	  findings,	  three	  times	  more	  B	  virus	  was	  required	  
to	  infect	  HFF	  cells	  compared	  to	  that	  required	  for	  Vero	  cells	  to	  obtain	  equivalent	  plaque	  forming	  
units	  (PFU).	  	  Results	  for	  HSV-­‐1	  indicated	  that	  there	  was	  no	  difference	  in	  efficiency	  of	  virus	  infec-­‐
tivity	  in	  Vero	  cells	  or	  HFF	  cells.	  Interestingly,	  10	  times	  more	  B	  virus	  was	  required	  to	  infect	  MK2	  
at	  equivalent	  levels	  to	  that	  in	  Vero	  cells.	  HSV-­‐1	  infection	  in	  MK2	  cells	  was	  abortive	  with	  only	  IE	  
(immediate	  early)	  and	  E	  (early)	  protein	  expression	  detected	  in	  independent	  studies	  
(I.Patrusheva	  and	  	  R.Farah	  ,	  personal	  communication).	  HVP-­‐2,	  a	  virus	  naturally	  found	  in	  ba-­‐
boons	  was	  10	  times	  less	  efficient	  replicating	  in	  HFF	  cells	  when	  compared	  to	  replication	  in	  Vero	  
cells	  (Table	  1).	  







Table	  1:	  Virus	  infectivity	  in	  different	  cell	  lines	  compared	  to	  Vero	  cells.	  Virus	  infectivity	  in	  dif-­‐
ferent	  cell	  lines	  was	  quantified	  by	  plaque	  assay.	  
	  
	   HFF	   MK2	  
B	  Virus	   3X	   10X	  
HSV-­‐1	   1X	   Abortive	  
HVP-­‐2	   10X	   ND	  





Total	  antigen	  expression	  of	  HLA-­‐A,	  -­‐B,	  -­‐C	  in	  B	  virus	  infected	  HFF	  cells.	  Once	  equivalent	  
virus	  loads	  were	  determined	  for	  each	  cell	  line,	  experiments	  proceeded	  to	  evaluate	  the	  effect	  of	  
each	  virus	  in	  each	  cell	  system	  with	  respect	  to	  virus:host	  cell	  interactions.	  HLA-­‐A,	  -­‐B,	  and	  -­‐C	  are	  
predominantly	  antigen	  presenting	  MHC	  1a	  molecules.	  It	  is	  well	  known	  that	  HSV-­‐1	  down	  regu-­‐
lates	  MHC	  Class	  1	  at	  a	  post-­‐translational	  level	  by	  sequestering	  MHC	  class	  I	  molecules	  in	  the	  en-­‐
doplasmic	  reticulum	  (68,	  184).	  This	  sequestration	  results	  in	  down-­‐regulation	  of	  surface	  MHC	  
class	  I	  expression.	  Western	  blot	  analysis	  of	  MHC	  Class	  1	  total	  protein	  in	  HSV-­‐1	  infected	  cells,	  
however,	  showed	  no	  reduction	  in	  levels.	  To	  determine	  if	  B	  virus	  regulates	  MHC	  class	  I	  at	  trans-­‐
lational	  level,	  we	  examined	  the	  effect	  of	  B	  virus	  infection	  on	  total	  antigen	  expression	  of	  HLA-­‐A,	  -­‐
B,	  -­‐C	  in	  HFF	  cells.	  Cells	  were	  infected	  with	  B	  virus	  or	  HSV-­‐1	  at	  10	  MOI,	  and	  for	  controls,	  cells	  
were	  either	  left	  uninfected	  or	  mock	  infected	  with	  uninfected	  cell	  lysates.	  At	  6	  and	  18	  hours	  post	  
infection	  (hpi),	  cells	  were	  lysed	  using	  Laemmli	  sample	  buffer	  containing	  with	  5%	  2-­‐
Mercaptoethanol.	  Following	  fractionation	  and	  western	  blotting,	  the	  presence	  of	  HLA-­‐A,	  -­‐B,	  -­‐C	  in	  
these	  samples	  was	  measured.	  Data	  indicated	  similar	  levels	  of	  HLA-­‐A,	  -­‐B,	  -­‐C	  in	  uninfected,	  mock,	  
B	  virus	  infected	  and	  HSV-­‐1	  infected	  HFF	  cells	  at	  6	  and	  18	  hpi.	  These	  data	  suggest	  that	  B	  virus	  














Figure	  5:	  	  Total	  HLA-­‐A,	  -­‐B,	  -­‐C	  antigen	  expression	  in	  B	  virus	  or	  HSV-­‐1	  infected	  HFF	  cells.	  	  There	  
was	  no	  significant	  difference	  in	  the	  total	  MHC	  class	  I	  protein	  expression	  between	  infected	  and	  













Regulation	  of	  MHC	  class	  I	  surface	  expression	  in	  B	  virus	  infected	  cells.	  Most	  herpes	  vi-­‐
ruses	  are	  known	  to	  down	  regulate	  cell	  surface	  MHC	  class	  I.	  From	  the	  western	  blot	  results,	  it	  was	  
apparent	  that	  MHC	  Class	  1	  gene	  expression	  was	  not	  down	  regulated	  in	  either.	  B	  virus,	  or	  the	  
closely	  related	  HSV-­‐1	  infected	  HFF	  cells.	  	  The	  next	  logical	  question	  posed	  as	  a	  result	  of	  these	  
data	  was	  whether	  reduced	  levels	  of	  cell	  surface	  in	  HLA-­‐A,	  -­‐B,	  -­‐C	  is	  observed	  in	  B	  virus	  infected	  
HFF	  cells.	  To	  address	  this	  question,	  experiments	  were	  designed	  to	  measure	  HLA-­‐A,	  -­‐B,	  -­‐C	  sur-­‐
face	  expression	  on	  B	  virus	  infected	  cells	  using	  flow	  cytometry	  at	  18	  hpi.	  As	  a	  control,	  HSV-­‐1	  in-­‐
fected	  cells	  were	  used,	  since	  this	  virus	  is	  known	  to	  down-­‐regulate	  HLA-­‐A,	  -­‐B,	  -­‐C	  surface	  expres-­‐
sion.	  Results	  of	  the	  experiments	  show	  that	  HSV-­‐1	  infected	  HFF	  cells	  showed	  ~65%	  HLA-­‐A,	  -­‐B,	  -­‐C	  
down-­‐regulation	  when	  compared	  to	  uninfected	  HFF	  cells.	  On	  the	  other	  hand,	  B	  virus	  infected	  
HFF	  cells	  showed	  only	  32%	  reduction	  compared	  to	  uninfected	  cells	  (Figure	  6A	  and	  6B).	  To-­‐
gether,	  these	  results	  suggest	  that	  B	  virus	  does	  not	  down-­‐regulate	  HLA-­‐A,	  -­‐B,	  -­‐C	  surface	  expres-­‐
sion	  as	  efficiently	  as	  HSV-­‐1	  in	  HFF	  infected	  cells	  (p<	  0.05),	  although	  there	  is	  significant	  decrease	  


















Figure	  6A:	  FACS	  analysis	  showing	  surface	  expression	  of	  HLA-­‐A,	  -­‐B,	  -­‐C	  on	  B	  virus	  or	  HSV-­‐1	  in-­‐
fected	  HFF	  cells	  at	  18	  hpi.	  Down-­‐regulation	  of	  HLA-­‐A,	  -­‐B,	  -­‐C	  on	  the	  cell	  surface	  is	  greater	  in	  HSV-­‐
1	  infected	  HFF	  cells	  as	  compared	  to	  B	  virus	  infected	  HFF	  cells	  at	  18	  hpi.	  This	  figure	  is	  a	  represen-­‐


















Figure	  6B:	  Ratio	  of	  mean	  FITC	  intensities	  of	  infected/uninfected.	  Mean	  FITC	  values	  were	  calcu-­‐
lated	  from	  four	  independent	  experiments.	  Mean	  FITC	  of	  uninfected	  HFF	  cells	  labeled	  with	  HLA-­‐
A,	  -­‐B,	  -­‐C	  was	  given	  an	  arbitrary	  value	  of	  1	  and	  mean	  intensities	  of	  infected	  HFF	  cells	  calculated	  
relative	  to	  uninfected	  HFFcells.	  The	  error	  bars	  represent	  standard	  deviation	  obtained	  from	  the	  
ratio	  of	  mean	  FITC	  intensities.	  p-­‐values	  were	  measured	  using	  Student	  t-­‐test.	  






Regulation	  of	  HLA-­‐A,	  -­‐B,	  -­‐C	  cell	  surface	  expression	  in	  B	  virus	  infected	  cells	  derived	  from	  
natural	  vs.	  foreign	  hosts.	  The	  previous	  data	  show	  that	  B	  virus	  does	  not	  down	  regulate	  HLA-­‐	  A,	  -­‐
B,	  -­‐C	  cell	  surface	  expression	  efficiently	  in	  HFF	  cells	  relative	  to	  HSV-­‐1.	  To	  determine	  if	  this	  obser-­‐
vation	  was	  consistent	  in	  cells	  derived	  from	  macaques	  (MK2),	  the	  natural	  host	  for	  B	  virus,	  we	  
infected	  MK2	  cells	  with	  B	  virus	  or	  HSV-­‐1	  (MOI	  10)	  as	  described	  in	  Materials	  and	  Methods.	  We	  
analyzed	  the	  infected	  cells	  at	  18	  hpi	  for	  HLA-­‐A,	  -­‐B,	  -­‐C	  surface	  expression	  using	  flow	  cytometry,	  
since	  at	  that	  point	  turnover	  of	  surface	  MHC	  Class	  1	  molecules	  occurs.	  Data	  showed	  that	  B	  virus	  
did	  not	  down-­‐regulate	  HLA-­‐A,	  -­‐B,	  -­‐C	  surface	  expression	  as	  efficiently	  as	  HSV-­‐1	  in	  macaque	  host	  
cells,	  in	  spite	  of	  the	  observations	  that	  HSV-­‐1	  underwent	  an	  abortive	  infection	  in	  these	  cells.	  B	  
virus	  infected	  cells	  showed	  ~24%	  reduction	  of	  HLA-­‐A,	  -­‐B,	  -­‐C	  as	  compared	  to	  uninfected	  cells,	  
while	  HSV-­‐1	  infected	  cells	  showed	  59%	  down-­‐regulation	  compared	  to	  uninfected	  cells	  (Figure	  
7A	  and	  7B).	  The	  p-­‐	  value	  for	  HSV-­‐1	  infected	  cells	  is	  <	  0.05,	  indicating	  a	  significant	  reduction	  in	  
cell	  surface	  expression	  of	  HLA-­‐A,	  -­‐B,	  and	  -­‐C	  between	  HSV-­‐1	  infected	  and	  uninfected	  cells.	  The	  p	  
value	  for	  B	  virus	  infected	  cells,	  however,	  is	  >	  0.05	  indicating	  that	  there	  is	  no	  difference	  in	  MHC	  
class	  I	  expression	  between	  uninfected	  and	  B	  virus	  infected	  MK2	  cells.	  These	  data	  suggest	  that	  B	  
virus	  does	  not	  block	  normal	  levels	  of	  surface	  MHC	  Class	  1	  molecules	  in	  cells	  derived	  from	  ma-­‐
caque	  hosts,	  nor	  does	  it	  interfere	  in	  cells	  derived	  from	  human	  hosts.	  As	  a	  result,	  it	  is	  likely	  that	  







	  	  	  




Figure	  7A:	  FACS	  analysis	  of	  HLA-­‐A,	  -­‐B,	  -­‐C	  expression	  on	  B	  virus	  and	  HSV-­‐1	  infected	  MK2	  cells	  at	  
18	  hpi.	  There	  was	  no	  difference	  in	  the	  HLA-­‐A,	  -­‐B,	  -­‐C	  surface	  expression	  in	  B	  virus	  or	  HSV-­‐1	  in-­‐
















Figure	  7B:	  Ratio	  of	  mean	  FITC	  intensities	  of	  infected/uninfected.	  Mean	  FITC	  values	  were	  calcu-­‐
lated	  from	  three	  independent	  experiments.	  Mean	  FITC	  values	  and	  p-­‐values	  were	  calculated	  in	  a	  
similar	  manner	  as	  explained	  in	  figure	  6B.	  The	  error	  bars	  represent	  standard	  deviation	  obtained	  










Effects	  of	  Viral	  Proteins	  regulating	  protein	  loading	  of	  the	  MHC	  Class	  1	  molecules.	  HSV-­‐
1	  and	  HSV-­‐2	  encode	  for	  a	  protein,	  ICP47	  containing	  a	  TAP	  binding	  domain	  responsible	  for	  se-­‐
questering	  HLA-­‐A,	  -­‐B,	  -­‐C	  molecules	  in	  the	  ER.	  Non-­‐human	  primate	  simplex	  viruses	  such	  as	  B	  vi-­‐
rus,	  Herpesvirus	  Papio-­‐2	  (HVP-­‐2,	  Cercopithecine	  Herpesvirus	  16),	  and	  Simian	  Herpesvirus	  (SA8)	  
encode	  for	  an	  ICP47	  protein	  that	  does	  not	  have	  a	  TAP	  binding	  domain	  similar	  to	  HSV-­‐1	  and	  HSV-­‐
2.	  We	  wanted	  to	  look	  at	  HLA-­‐A,	  -­‐B,	  -­‐C	  regulation	  in	  a	  similar	  virus	  that	  lacks	  TAP	  binding	  do-­‐
main.	  For	  this	  reason,	  we	  chose	  HVP-­‐2,	  which	  is	  very	  close	  to	  B	  virus.	  This	  would	  allow	  us	  to	  
predict	  if	  lack	  of	  TAP	  binding	  domain	  in	  ICP47	  protein	  plays	  a	  role	  in	  inefficient	  down-­‐regulation	  
of	  HLA-­‐A,	  -­‐B,	  -­‐C.	  HFF	  cells	  were	  infected	  with	  HVP-­‐2	  or	  HSV-­‐1	  and	  HLA-­‐A,	  -­‐B,	  -­‐C	  surface	  expres-­‐
sion	  was	  analyzed	  using	  flow	  cytometry.	  Our	  results	  showed	  that	  HVP-­‐2	  behaves	  in	  a	  similar	  
way	  to	  B	  virus	  in	  down	  regulating	  HLA-­‐A,	  -­‐B,	  -­‐C	  surface	  expression	  on	  infected	  cells	  (Figure	  8A	  
and	  8B).	  These	  results	  do	  not	  indicate	  direct	  correlation	  between	  the	  lack	  of	  TAP	  binding	  do-­‐
main	  and	  inefficient	  HLA-­‐A,	  -­‐B,	  -­‐C	  down-­‐regulation,	  however,	  these	  results	  do	  indicate	  that	  non-­‐




















Figure	  8A:	  FACS	  analysis	  of	  HLA-­‐A,	  -­‐B,	  -­‐C	  surface	  expression	  in	  HVP-­‐2	  or	  HSV-­‐1	  infected	  HFF	  
cells.	  HVP-­‐2	  is	  closely	  related	  to	  B	  virus	  and	  also	  lacks	  TAP	  binding	  domain	  in	  its	  ICP47	  protein	  
similar	  to	  B	  virus.	  HVP-­‐2	  down-­‐regulation	  of	  HLA-­‐A,	  -­‐B,	  -­‐C	  was	  significantly	  less	  than	  HSV-­‐1	  















Figure	  8B:	  Ratio	  of	  mean	  FITC	  intensities	  of	  infected/uninfected.	  Mean	  FITC	  values	  were	  calcu-­‐
lated	  from	  three	  independent	  experiments.	  Mean	  FITC	  values	  and	  p-­‐values	  were	  calculated	  in	  a	  
similar	  manner	  as	  explained	  in	  figure	  6B.	  The	  error	  bars	  represent	  standard	  deviation	  obtained	  








HLA-­‐E	  expression	  correlates	  with	  HLA-­‐A,	  -­‐B,	  -­‐C	  expression	  in	  B	  virus	  or	  HSV-­‐1	  infected	  
cells.	  HLA-­‐E	  cell	  surface	  expression	  is	  dependent	  on	  HLA-­‐A,	  -­‐B,	  -­‐C	  cell	  surface	  expression	  and	  
stability,	  because	  HLA-­‐E	  presents	  HLA-­‐A,	  -­‐B,	  -­‐C	  leader	  peptide	  via	  TAP.	  Our	  data	  suggested	  32%	  
down-­‐regulation	  of	  HLA-­‐A,	  -­‐B,	  -­‐C	  in	  B	  virus	  infected	  cells	  and	  65%	  down-­‐regulation	  in	  HSV-­‐1	  in-­‐
fected	  cells.	  Therefore,	  we	  analyzed	  HLA-­‐E	  expression	  in	  B	  virus	  or	  HSV-­‐1	  infected	  cells	  using	  
western	  blot	  analysis.	  At	  6	  hpi,	  data	  revealed	  reduced	  expression	  of	  HLA-­‐E	  in	  B	  virus	  infected	  
HFF	  cells.	  A	  significant	  reduction	  in	  HLA-­‐E	  expression	  is	  observed	  in	  HSV-­‐1	  infected	  cells	  com-­‐
pared	  to	  uninfected	  cells.	  At	  18	  hpi,	  there	  is	  total	  reduction	  in	  HLA-­‐E	  expression	  in	  virus	  infected	  
cells	  compared	  to	  the	  controls	  (Figure	  9).	  These	  data	  suggest	  that	  HLA-­‐E	  expression	  correlates	  





















Figure	  9.	  Western	  blot	  analysis	  of	  HLA-­‐E	  expression	  in	  B	  virus	  or	  HSV-­‐1	  infected	  HFF	  cells	  at	  6	  
and	  18	  hpi.	  HLA-­‐E	  expression	  correlates	  HLA-­‐A,	  -­‐B,	  -­‐C	  expression	  in	  HSV-­‐1	  or	  B	  virus	  infected	  
HFF	  cells.	  HLA-­‐E	  was	  reduced	  by	  6	  hpi	  more	  prominently	  in	  HSV-­‐1	  infected	  cells	  as	  compared	  to	  











Differential	  expression	  of	  HLA-­‐G	  in	  B	  virus	  infected	  and	  HSV-­‐1	  infected	  cells.	  HLA-­‐G	  is	  
not	  expressed	  in	  all	  cells	  and	  is	  mostly	  observed	  on	  placenta	  protecting	  the	  fetus	  from	  maternal	  
NK	  cell	  activity.	  The	  regulation	  of	  HLA-­‐G	  expression	  in	  HSV-­‐1	  infected	  HFF	  cells	  has	  not	  been	  
previously	  described.	  Total	  HLA-­‐G	  expression	  in	  B	  virus	  infected,	  HSV-­‐1,	  and	  uninfected	  HFF	  
cells	  was	  analyzed	  using	  western	  blot	  analysis.	  These	  data	  show	  that	  HSV-­‐1	  infected	  cells	  at	  6	  
hpi	  expressed	  proteins	  corresponding	  to	  21,	  34,	  and	  37	  KDa	  when	  western	  blots	  were	  probed	  
with	  anti-­‐HLA-­‐G	  antibody.	  These	  bands	  correspond	  to	  each	  different	  isoform	  of	  HLA-­‐G.	  B	  virus	  
infected	  HFF	  cells	  showed	  little	  expression	  of	  HLA-­‐G	  (34	  KDa	  isoform)	  while	  uninfected	  cells	  
showed	  no	  expression	  of	  any	  of	  the	  HLA-­‐G	  isoforms.	  By	  18	  hpi,	  only	  faint	  band	  was	  noted	  corre-­‐
sponding	  to	  34	  KDa	  in	  case	  of	  HSV-­‐1	  infected	  HFF	  cells	  with	  no	  HLA-­‐G	  observed	  in	  B	  virus	  and	  
uninfected	  cells	  (Figure	  10).	  Thus,	  HSV-­‐1	  and	  B	  virus	  appear	  to	  differentially	  regulate	  HLA-­‐G	  ex-­‐





















Figure	  10:	  Western	  blot	  analysis	  of	  HLA-­‐G	  expression	  in	  HSV-­‐1	  or	  B	  virus	  infected	  HFF	  cells	  at	  
6	  and	  18	  hpi.	  Differential	  expression	  of	  HLA-­‐G	  is	  observed	  in	  HSV-­‐1	  and	  B	  virus	  infected	  HFF	  
cells.	  Here,	  different	  isoforms	  of	  HLA-­‐G	  was	  observed	  in	  HSV-­‐1	  infection,	  however,	  only	  one	  iso-­‐













3.2 PART	  II:	  Natural	  Killer	  cell	  regulation	  during	  B	  virus	  infection	  in	  HFF	  cells.	  
Although	  HSV	  specific	  CTLs	  are	  generated	  by	  antigen	  presenting	  cells,	  these	  CTLs	  fail	  to	  
recognize	  HSV-­‐1	  infected	  cell	  due	  to	  lack	  of	  antigen	  presenting	  MHC	  class	  I	  on	  the	  cell	  surface.	  
The	  CTLs	  that	  are	  generated	  are	  important	  in	  limiting	  the	  spread	  of	  virus	  and	  in	  inhibiting	  
reactivation.	  Because	  of	  MHC	  class	  I	  down-­‐regulation	  on	  HSV	  infected	  cells,	  these	  cells	  are	  sus-­‐
ceptible	  to	  NK	  cell	  lysis.	  NK	  cell	  recognition	  limits	  the	  virus	  spread	  and	  replication	  during	  pri-­‐
mary	  infection.	  Thus,	  a	  balance	  between	  HSV	  infection	  and	  immune	  response	  is	  maintained	  
that	  helps	  HSV	  to	  co-­‐exist	  in	  a	  natural	  host.	  During	  fatal	  zoonotic	  B	  virus	  infection,	  this	  balance	  
might	  not	  be	  maintained.	  Strong	  innate	  immune	  responses	  are	  important	  during	  primary	  infec-­‐
tion	  and	  previous	  studies	  in	  our	  lab	  have	  shown	  that	  some	  of	  the	  innate	  immune	  responses	  are	  
impaired	  during	  B	  virus	  infection	  of	  human	  cells.	  One	  of	  the	  important	  components	  of	  innate	  
immunity	  is	  NK	  cell	  activity.	  From	  our	  results	  it	  is	  evident	  that	  B	  virus	  does	  not	  down	  regulate	  
MHC	  class	  I,	  therefore	  we	  hypothesize	  that	  B	  virus	  infected	  cells	  are	  resistant	  to	  NK	  cell	  lysis.	  
Consequently,	  we	  tested	  for	  different	  factors	  that	  effect	  NK	  cell	  activity	  during	  B	  virus	  infection	  
in	  the	  next	  series	  of	  experiments.	  
MICA/MICB	  expression	  in	  B	  virus	  infected	  HFF	  cells.	  	  MICA	  and	  MICB	  belong	  to	  the	  
family	  of	  MHC	  class	  I,	  however,	  they	  bind	  to	  NKG2D,	  activation	  receptor	  of	  NK	  cells.	  The	  other	  
family	  members	  that	  bind	  to	  NKG2D	  are	  ULBP1-­‐4.	  Therefore,	  MICA,	  MICB,	  and	  ULBP	  proteins	  
are	  involved	  in	  the	  activation	  of	  NK	  cells	  while	  MHC	  class	  I	  proteins	  are	  involved	  in	  the	  inhibi-­‐
tion	  of	  NK	  cells.	  The	  NKG2D	  activation	  ligands	  can	  overcome	  the	  inhibitory	  effect	  of	  MHC	  class	  I.	  




infected	  HFF	  cells	  at	  12	  and	  24	  hpi.	  HFFs	  do	  not	  express	  ULBP	  proteins	  under	  normal	  conditions,	  
however	  MICA/MICB	  are	  expressed	  at	  a	  basal	  level.	  Here	  we	  examined	  the	  total	  antigen	  ex-­‐
pression	  of	  MICA	  in	  infected	  cells	  at	  12	  and	  24	  hpi	  using	  western	  blot	  analysis.	  HFF	  cells	  were	  
infected	  with	  HSV-­‐1	  or	  B	  virus	  at	  5	  MOI	  or	  remained	  uninfected	  for	  12	  and	  24	  hpi.	  Western	  blot	  
analysis	  shows	  reduced	  expression	  of	  MICA	  in	  B	  virus	  and	  HSV-­‐1	  infected	  HFF	  cells	  by	  24	  hpi	  
(Figure	  11A).	  We	  then	  measured	  the	  surface	  expression	  of	  MICA/MICB	  using	  FACS	  analysis,	  as	  
we	  did	  not	  test	  for	  the	  total	  antigen	  expression	  of	  MICB	  in	  infected	  cells	  because	  of	  the	  lack	  of	  
commercially	  available	  antibody	  against	  MICB.	  MICA/MICB	  antibody	  detects	  the	  presence	  of	  
both	  MICA	  and	  MICB	  proteins	  on	  the	  cell	  surface.	  	  Our	  results	  showed	  an	  up-­‐regulation	  of	  
MICA/MICB	  on	  the	  cell	  surface	  of	  infected	  cells	  at	  12	  and	  24	  hpi,	  thus	  indicating	  that	  the	  up-­‐





















Figure	  11A:	  Western	  blot	  analysis	  of	  total	  antigen	  expression	  of	  MICA	  in	  B	  virus	  and	  HSV-­‐1	  
infected	  HFF	  cells	  at	  12	  and	  24	  hpi.	  There	  is	  no	  difference	  in	  MICA	  expression	  between	  unin-­‐
fected	  and	  infected	  cells	  at	  12	  hpi.	  By	  24	  hpi,	  B	  virus	  and	  HSV-­‐1	  down	  regulate	  MICA	  as	  com-­‐
















Figure	  11B:	  FACS	  analysis	  of	  MICA/MICB	  surface	  expression	  in	  B	  virus	  and	  HSV-­‐1	  infected	  cells	  
at	  12	  and	  24	  hpi.	  An	  up-­‐regulation	  of	  MICA/MICB	  is	  observed	  at	  12	  and	  24	  hpi	  in	  infected	  cells,	  
most	  probably	  contributed	  by	  MICB.	  This	  increase	  in	  surface	  expression	  could	  be	  a	  stress	  re-­‐






Expression	  of	  cytokines	  and	  chemokines	  involved	  in	  NK	  cell	  migration	  and	  activation	  in	  
B	  virus	  and	  HSV-­‐1	  infected	  HFF	  cells.	  During	  infection,	  a	  cell	  will	  produce	  certain	  chemoattrac-­‐
tants	  for	  the	  migration	  of	  NK	  cells	  and	  cytokines	  to	  prime	  them.	  Therefore,	  NK	  cells	  need	  both	  
activation	  ligands	  and	  cytokines	  that	  can	  help	  in	  activation	  ligand-­‐receptor	  binding	  in	  order	  for	  
their	  activation.	  IFN-­‐α	  and	  IL-­‐15	  are	  cytokines	  implicated	  in	  playing	  a	  role	  in	  activating	  NK	  cells.	  
Chemokines	  that	  are	  involved	  in	  NK	  cell	  migration	  and	  activation	  are	  IL-­‐8,	  IP-­‐10,	  MIP-­‐1a,	  MIP-­‐
1b,	  and	  MCP-­‐1.	  Therefore,	  in	  our	  experiment	  we	  quantified	  the	  expression	  of	  above	  cytokines/	  
chemokines	  produced	  by	  mock,	  HSV-­‐1,	  or	  B	  virus	  infected	  HFF	  cells	  at	  6	  and	  24	  hpi.	  	  B	  virus	  or	  
HSV-­‐1	  infected	  HFF	  cells	  do	  not	  induce	  the	  expression	  of	  any	  of	  the	  cytokines	  or	  chemokines	  
described	  above.	  In	  fact	  HSV-­‐1	  and	  B	  virus	  infection	  of	  HFF	  cells	  leads	  to	  down-­‐regulation	  of	  
INF-­‐α,	  IP-­‐10,	  IL-­‐8,	  and	  MCP-­‐1	  by	  24	  hpi	  (Figure	  12A-­‐	  12D	  respectively).	  Certain	  chemokines	  like	  
MIP-­‐1a	  and	  MIP-­‐1b	  are	  not	  induced	  in	  mock,	  HSV-­‐1,	  or	  B	  virus	  infected	  HFF	  cells	  at	  6	  and	  24	  
hpi.	  These	  combined	  results	  suggest	  that	  both	  B	  virus	  and	  HSV-­‐1	  do	  not	  induce	  cytokines	  and	  

















	  	  	  	  	   	  
Figure	  12A:	  IFN-­‐α 	  expression	  by	  mock,	  B	  virus,	  or	  HSV-­‐1	  infected	  HFF	  cells	  at	  6	  and	  24	  hpi.	  
One-­‐way	  ANOVA	  of	  mock,	  HSV-­‐1,	  and	  B	  virus	  infected	  samples	  at	  24	  hpi	  yields	  a	  p-­‐value	  of	  
0.018.	  Multiple	  comparisons	  between	  the	  samples	  using	  SNK	  test	  shows	  a	  significant	  difference	  
between	  mock	  and	  HSV-­‐1	  or	  mock	  and	  B	  virus	  infected	  cells	  with	  q	  values	  greater	  than	  the	  criti-­‐
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Figure	  12B:	  	  Liquichip	  analysis	  of	  IP-­‐10	  expression	  in	  mock,	  B	  virus	  or	  HSV-­‐1	  infected	  at	  6	  and	  
24	  hpi.	  One-­‐way	  ANOVA	  of	  mock,	  HSV-­‐1,	  and	  B	  virus	  infected	  samples	  at	  24	  hpi	  yields	  a	  p-­‐value	  
of	  0.03.	  Multiple	  comparisons	  between	  the	  samples	  using	  SNK	  test	  shows	  a	  significant	  differ-­‐
ence	  between	  mock	  and	  B	  virus	  infected	  cells	  with	  q	  values	  greater	  than	  the	  critical	  values.	  
However,	  there	  is	  no	  difference	  between	  mock	  and	  HSV-­‐1	  treated	  samples	  and	  that	  is	  because	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Figure	  12C:	  Detection	  of	  expression	  of	  IL-­‐8	  at	  6	  and	  24	  hpi	  by	  mock,	  B	  virus,	  or	  HSV-­‐1	  infected	  
cells	  at	  6	  and	  24	  hpi	  using	  liquichip	  analysis.	  One-­‐way	  ANOVA	  of	  mock,	  HSV-­‐1,	  and	  B	  virus	  in-­‐
fected	  samples	  at	  6	  and	  24	  hpi	  yields	  a	  p-­‐value	  of	  <0.0001	  for	  both	  time	  points	  respectively.	  
Multiple	  comparisons	  between	  the	  samples	  using	  SNK	  test	  shows	  a	  significant	  difference	  be-­‐
tween	  mock	  and	  HSV-­‐1	  or	  mock	  and	  B	  virus	  infected	  cells	  with	  q	  values	  greater	  than	  the	  critical	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*Mock-­‐infected	  HFF	  cells	  induced	  >	  6000	  pg/ml,	  higher	  than	  the	  detection	  levels,	  but	  plotted	  
with	  the	  value	  for	  maximum	  detection	  level.	  
	  
Figure	  12D:	  MCP-­‐1	  expression	  in	  B	  virus	  and	  HSV-­‐1	  infected	  cells	  at	  6	  and	  24	  hpi	  using	  
liquichip	  assay.	  One-­‐way	  ANOVA	  of	  mock,	  HSV-­‐1,	  and	  B	  virus	  infected	  samples	  at	  6	  and	  24	  hpi	  
yields	  a	  p-­‐value	  of	  <0.0001	  and	  0.00048	  respectively.	  Multiple	  comparisons	  between	  the	  sam-­‐
ples	  using	  SNK	  test	  shows	  a	  significant	  difference	  between	  mock	  and	  HSV-­‐1	  or	  B	  virus	  infected	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Table	  2:	  Summary	  of	  expression	  of	  cytokines	  and	  chemokines	  responsible	  for	  NK	  cell	  migra-­‐
tion	  and	  activation	  by	  mock,	  HSV-­‐1,	  or	  B	  virus	  infected	  HFF	  cells	  at	  24	  hpi	  
	  
	   	  
Mock	  Infected	  HFF	  
	  
HSV-­‐1	  infected	  HFF	  
cells	  
	  
B	  virus	  infected	  HFF	  
cells	  
IFN-­‐α 	   ✔ 	  (30.27	  pg/ml)	   ⇓(10.59	  pg/ml)	   ✖ 	  	  (6.71	  pg/ml)	  
IL-­‐15	   ✖ 	  (<10	  pg/ml)	   ✖ 	  	  (<10	  pg/ml)	   ✖ 	  	  (<10	  pg/ml)	  
IP-­‐10	   ✔ 	  (21	  pg/ml)	   ✖ 	  	  (4	  pg/ml)	   ✖ 	  	  (5	  pg/ml)	  
IL-­‐8	   ✔ 	  (2539	  pg/ml)	   ⇓ 	  (43.75	  pg/ml)	   ⇓ 	  (22.79	  pg/ml)	  
MCP-­‐1	   ✔ 	  	  (5291	  pg/ml)	   ⇓ 	  (2364	  pg/ml)	   ⇓ 	  (239	  pg/ml)	  
MIP-­‐1α 	   ✖ 	  	  (<10	  pg/ml)	   ✖ 	  	  (<10	  pg/ml)	   ✖ 	  (<10	  pg/ml)	  






	   Cytokines/	  chemokines	  released	  by	  PBMC	  upon	  exposure	  to	  infected	  HFF	  cells.	  From	  
our	  results	  we	  observed	  that	  B	  virus	  as	  well	  as	  HSV-­‐1	  infected	  HFF	  cells	  do	  not	  induce	  cytokines	  
and	  chemokines	  involved	  in	  NK	  cell	  migration	  and	  activation.	  Resident	  tissue	  NK	  cells,	  however,	  
can	  mobilize	  and	  interact	  with	  infected	  target	  cells.	  For	  influx	  of	  additional	  NK	  cells	  during	  an	  
infection,	  other	  immune	  cells	  in	  circulation	  can	  be	  regulated	  to	  induce	  immune	  responses	  
against	  the	  infected	  cells.	  Therefore,	  we	  tested	  for	  cytokines	  and	  chemokines	  involved	  in	  migra-­‐
tion	  and	  activation	  of	  NK	  cells	  by	  immune	  cells	  in	  circulation	  upon	  exposure	  to	  infected	  cells.	  
For	  this	  purpose,	  we	  isolated	  PBMCs	  from	  sero-­‐negative	  individuals.	  By	  using	  PBMCs	  from	  sero-­‐
negative	  individuals	  we	  are	  eliminating	  the	  possible	  reaction	  by	  adaptive	  immune	  responses	  (T-­‐
cell	  and	  B	  cell	  activity)	  for	  HSV-­‐1	  specific	  antigen	  and	  at	  the	  same	  time	  determine	  the	  innate	  
immune	  responses	  induced	  during	  primary	  infection	  by	  cells	  in	  circulation.	  Also,	  these	  experi-­‐
ments	  reflect	  a	  primary	  infection	  where	  all	  cells	  are	  exposed	  to	  infection	  for	  the	  first	  time.	  In	  
our	  experiments,	  we	  infected	  cells	  with	  mock	  cell	  lysate,	  HSV-­‐1,	  or	  B	  virus	  at	  MOI	  of	  5.	  At	  6	  hpi,	  
PBMCs	  were	  added	  to	  the	  infected	  cells	  (overlay)	  and	  co-­‐cultured	  for	  18	  hrs.	  The	  supernatants	  
were	  collected	  to	  test	  for	  cytokines	  and	  chemokines	  mentioned	  in	  the	  above	  experiment.	  Our	  
results	  show	  that	  IFN-­‐α	  and	  IP-­‐10	  are	  up-­‐regulated	  when	  PBMCs	  were	  sub-­‐cultured	  with	  HSV-­‐1	  
infected	  HFF	  cells.	  The	  same	  is	  not	  observed	  in	  case	  of	  B	  virus	  infection,	  therefore,	  we	  conclude	  
that	  B	  virus	  does	  not	  induce	  responses	  for	  activation	  of	  NK	  cells	  either	  by	  infected	  cells	  or	  by	  













Figure	  13A:	  IFN-­‐α 	  expression	  during	  PBMC	  exposure	  to	  mock,	  HSV-­‐1,	  B	  virus	  infected	  HFF	  
cells	  for	  18	  hrs.	  One-­‐way	  ANOVA	  of	  mock,	  HSV-­‐1,	  and	  B	  virus	  infected	  samples	  yields	  a	  p-­‐value	  
of	  <0.0001.	  Multiple	  comparisons	  between	  the	  samples	  using	  SNK	  test	  shows	  a	  significant	  dif-­‐
































Figure	  13B:	  IP-­‐10	  expression	  during	  PBMC	  exposure	  of	  mock,	  HSV-­‐1,	  or	  B	  virus	  infected	  HFF	  
cells	  for	  18	  hrs.	  	  One-­‐way	  ANOVA	  of	  mock,	  HSV-­‐1,	  and	  B	  virus	  infected	  samples	  yields	  a	  p-­‐value	  
of	  0.038.	  Multiple	  comparisons	  between	  the	  samples	  using	  SNK	  test	  shows	  a	  significant	  differ-­‐
ence	  between	  HSV-­‐1	  and	  mock.	  B	  virus	  samples	  had	  values	  with	  high	  variance	  from	  the	  mean	  
and	  therefore	  did	  not	  show	  any	  significant	  difference	  as	  compared	  to	  mock	  or	  HSV-­‐1.	  The	  error	  































	  	  	  	  	   	  
Figure	  13C:	  IL-­‐8	  expression	  during	  PBMC	  exposure	  of	  mock,	  HSV-­‐1,	  or	  B	  virus	  infected	  HFF	  
cells	  for	  18	  hrs.	  One-­‐way	  ANOVA	  of	  mock,	  HSV-­‐1,	  and	  B	  virus	  infected	  samples	  yields	  a	  p-­‐value	  
of	  <0.0001.	  Multiple	  comparisons	  between	  the	  samples	  using	  SNK	  test	  shows	  a	  significant	  dif-­‐



































	  	  	  	  	  	  	  	   	  
Figure	  13D:	  MCP-­‐1	  expression	  during	  PBMC	  exposure	  of	  mock,	  HSV-­‐1,	  or	  B	  virus	  infected	  HFF	  
cells	  for	  18	  hrs.	  One-­‐way	  ANOVA	  of	  mock,	  HSV-­‐1,	  and	  B	  virus	  infected	  samples	  yields	  a	  p-­‐value	  


































	  	  	  	  	  	   	  
Figure	  13E:	  MIP-­‐1β 	  expression	  during	  PBMC	  exposure	  of	  mock,	  HSV-­‐1,	  or	  B	  virus	  infected	  HFF	  
cells	  for	  18	  hrs.	  One-­‐way	  ANOVA	  of	  mock,	  HSV-­‐1,	  and	  B	  virus	  infected	  samples	  yields	  a	  p-­‐value	  






































Table	  3:	  Summary	  of	  expression	  levels	  of	  cytokines	  and	  chemokines	  responsible	  for	  NK	  cell	  
migration	  and	  activity	  during	  B	  virus	  and	  HSV-­‐1	  infection	  upon	  exposure	  to	  PBMCs.	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	   	  
Mock	  Infected	  HFF	  
	  
HSV-­‐1	  infected	  HFF	  
cells	  
	  
B	  virus	  infected	  HFF	  
cells	  
IFN-­‐α 	   ✖ 	  	  	  (0.09	  pg/ml)	   ⇑ 	  (282.6	  pg/ml)	   ⇑ 	  ?	  (36.5	  pg/ml)	  
IL-­‐15	   ✖ 	  (<=	  10	  pg/ml)	   ✖ 	  (<10	  pg/ml)	   ✖ 	  (<10	  pg/ml)	  
IP-­‐10	   ✔ 	  	  (6191.5	  pg/ml)	   ⇑(12300	  pg/ml)	   No	  Difference	  
IL-­‐8	   ✔ 	  	  (5544	  pg/ml)	   ⇓ 	  (1780	  pg/ml)	   ⇓ 	  (478	  pg/ml)	  
MCP-­‐1	   No	  Difference	   No	  Difference	   No	  Difference	  
MIP-­‐1α 	   ✖ 	  (<=	  10	  pg/ml)	   ✖ 	  (<10	  pg/ml)	   ✖ 	  (Undetectable)	  






Th1	  and	  Th2	  cytokines	  induced	  by	  NK	  cells	  upon	  exposure	  to	  B	  virus	  or	  HSV-­‐1	  infected	  
HFF	  cells.	  So	  far	  we	  have	  determined	  a	  number	  of	  specific	  factors	  that	  can	  induce	  NK	  cell	  activ-­‐
ity	  or	  inhibition,	  however,	  not	  all	  aspects	  were	  tested.	  To	  determine	  if	  primary	  NK	  cells	  from	  
sero-­‐negative	  donors	  are	  activated	  upon	  exposure	  to	  B	  virus	  infected	  cells,	  supernatants	  were	  
tested	  for	  Th1	  and	  Th2	  cytokines	  that	  are	  induced	  by	  activated	  NK	  cells.	  Expression	  of	  Th1	  cyto-­‐
kines,	  TNF-­‐α,	  IFN-­‐γ,	  GM-­‐CSF,	  and	  IL-­‐2,	  was	  measured	  in	  the	  supernatants	  using	  Liquichip™ as-­‐
say	  (Figure	  14A	  to	  Figure	  14D,	  Table	  4,	  5).	  Supernatants	  were	  also	  tested	  for	  Th2	  cytokines,	  IL-­‐4,	  
IL-­‐5,	  IL-­‐10,	  IL-­‐12,	  and	  IL-­‐15	  (Table	  4,	  5).	  In	  this	  experiment,	  NK	  cells	  were	  also	  treated	  with	  IL-­‐2	  
to	  see	  if	  there	  is	  enhanced	  NK	  cell	  activity	  specific	  to	  infection.	  TNF-­‐α	  was	  found	  to	  be	  up-­‐
regulated	  when	  NK	  cells	  were	  exposed	  to	  B	  virus	  infection	  when	  compared	  to	  mock.	  A	  signifi-­‐
cant	  TNF-­‐α	  up-­‐regulation	  was	  also	  observed	  in	  case	  of	  HSV-­‐1	  infection.	  No	  other	  Th1	  or	  Th2	  cy-­‐
tokines	  were	  induced	  in	  either	  case	  of	  infection.	  NK	  cells	  treated	  with	  IL-­‐2	  did	  not	  behave	  any	  
differently,	  with	  up-­‐regulation	  of	  TNF-­‐α	  observed	  in	  case	  of	  NK	  cells	  exposed	  to	  infected	  cells	  
compared	  to	  mock	  infected	  cells.	  This	  up-­‐regulation	  was	  not	  IL-­‐2	  specific,	  thus,	  IL-­‐2	  treatment	  
alone	  is	  not	  important	  for	  activation	  of	  NK	  cells	  or	  for	  the	  expression	  of	  TNF-­‐α.	  Therefore,	  we	  
conclude	  that	  TNF-­‐α	  is	  induced	  by	  primary	  NK	  cell	  upon	  exposure	  to	  B	  virus	  infection.	  The	  
amount	  of	  TNF-­‐α	  production	  during	  B	  virus	  or	  HSV-­‐1	  infection	  is	  less	  than	  what	  is	  found	  in	  
physiological	  concentration,	  therefore,	  the	  expression	  of	  TNF-­‐α	  could	  be	  a	  result	  of	  non-­‐specific	  












	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  14A:	  GM-­‐CSF	  expression	  in	  NK	  cells	  exposed	  to	  mock,	  HSV-­‐1,	  or	  B	  virus	  infected	  HFF	  
cells.	  One-­‐way	  ANOVA	  of	  mock,	  HSV-­‐1,	  and	  B	  virus	  infected	  samples	  yields	  a	  p-­‐value	  of	  0.001.	  
Multiple	  comparisons	  between	  the	  samples	  using	  SNK	  test	  shows	  a	  significant	  difference	  be-­‐
tween	  mock	  and	  the	  infected	  cell	  supernatants.	  The	  error	  bars	  represent	  standard	  errors.	  
	  








































	  	  	  	  	  	  	  	  	  	   	  
	  
Figure	  14B:	  GM-­‐CSF	  expression	  in	  NK	  cells	  with	  IL-­‐2	  treatment	  exposed	  to	  mock,	  HSV-­‐1,	  or	  B	  
virus	  infected	  HFF	  cells.	  One-­‐way	  ANOVA	  of	  mock,	  HSV-­‐1,	  and	  B	  virus	  infected	  samples	  yields	  a	  
p-­‐value	  of	  0.00004.	  Multiple	  comparisons	  between	  the	  samples	  using	  SNK	  test	  shows	  a	  signifi-­‐
cant	  difference	  between	  mock	  and	  the	  infected	  cell	  supernatants.	  The	  error	  bars	  represent	  
standard	  errors.	  
	  































	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
	  	  	  	  	  	  	  	  	   	  	   	  
Figure	  14C:	  TNF-­‐α 	  expression	  in	  NK	  cells	  exposed	  to	  mock,	  HSV-­‐1,	  or	  B	  virus	  infected	  HFF	  
cells.	  Increased	  expression	  of	  TNF-­‐α	  is	  observed	  in	  case	  of	  B	  virus	  infection.	  One-­‐way	  ANOVA	  of	  
mock,	  HSV-­‐1,	  and	  B	  virus	  infected	  samples	  yields	  a	  p-­‐value	  of	  0.000134.	  Multiple	  comparisons	  
between	  the	  samples	  using	  SNK	  test	  shows	  a	  significant	  difference	  between	  B	  virus	  and	  mock	  































	  	  	  	  	   	  
Figure	  14D:	  TNF-­‐α 	  expression	  in	  NK	  cells	  with	  IL-­‐2	  treatment	  exposed	  to	  mock,	  HSV-­‐1,	  or	  B	  
virus	  infected	  HFF	  cells.	  One-­‐way	  ANOVA	  of	  mock,	  HSV-­‐1,	  and	  B	  virus	  infected	  samples	  yields	  a	  
p-­‐value	  of	  0.024.	  Multiple	  comparisons	  between	  the	  samples	  using	  SNK	  test	  shows	  a	  significant	  
difference	  between	  B	  virus	  and	  mock	  and	  also	  between	  HSV-­‐1	  and	  mock.	  The	  error	  bars	  repre-­‐
sent	  standard	  errors.	  
	  
	  




























Table	  4:	  Summary	  of	  cytokines	  released	  by	  NK	  cells	  upon	  exposure	  to	  mock,	  B	  virus	  or	  HSV-­‐1	  
infected	  HFF	  cells	  for	  18	  hrs.	  
	  
	   	  
Mock	  Infected	  HFF	  
	  
HSV-­‐1	  infected	  HFF	  
cells	  
	  
B	  virus	  infected	  HFF	  
cells	  
GM-­‐CSF	  (Th1)	   ✔ 	  (16.12	  pg/ml)	   ✖ 	  (<10	  pg/ml)	   ✖ 	  (<10	  pg/ml)	  
TNF-­‐α 	  (Th1)	   ✖ 	  	  (<10	  pg/ml)	   ⇑ 	  (13.29	  pg/ml)	   ⇑ 	  (18.03	  pg/ml)	  
IFN-­‐γ 	  	  (Th1)	   ✖ 	  (<10	  pg/ml)	   ✖ 	  (<10	  pg/ml)	   ✖ 	  (<10	  pg/ml)	  
IL-­‐2	   ✖ 	  (Undetectable)	   ✖ 	  (Undetectable)	   ✖ 	  (Undetectable)	  

























Table	  5:	  Summary	  of	  cytokines	  released	  by	  NK	  cells	  with	  IL-­‐2	  treatment	  upon	  exposure	  to	  
mock,	  B	  virus	  or	  HSV-­‐1	  infected	  HFF	  cells	  for	  18	  hrs.	  
	  
	   	  
Mock	  Infected	  HFF	  
	  
HSV-­‐1	  infected	  HFF	  
cells	  
	  
B	  virus	  infected	  HFF	  
cells	  
GM-­‐CSF	  (Th1)	   ✔ 	  (124.98	  pg/ml)	   ⇓ 	  (10.6	  pg/ml)	   ✖ 	  (<10	  pg/ml)	  
TNF-­‐α 	  (T12)	   ✔ 	  	  (17.73	  pg/ml)	   ✔(19.87	  pg/ml)	   ✔ 	  (22.69	  pg/ml)	  
IFN-­‐γ 	  	  (Th1)	   ✔ 	  	  (27.55	  pg/ml)	   ✖ 	  (<10	  pg/ml)	   ✖ 	  (<10	  pg/ml)	  
IL-­‐2	   NR	   NR	   NR	  
Th2	   ✖ 	  (<=	  10	  pg/ml)	   ✖ 	  (<10	  pg/ml)	   ✖ 	  (Undetectable)	  











Th1/Th2	  cytokines	  induced	  during	  PBMC	  exposure	  to	  infected	  HFF	  cells.	  In	  our	  previ-­‐
ous	  results	  we	  observed	  that	  NK	  cell	  activating	  IFN-­‐α	  and	  IL-­‐10	  were	  induced	  in	  the	  presence	  of	  
PBMCs.	  Because	  PBMCs	  also	  contain	  NK	  cells	  we	  wanted	  to	  test	  for	  Th1	  and	  Th2	  cytokine	  ex-­‐
pression	  in	  the	  supernatants	  of	  infected	  HFF	  cells	  sub-­‐cultured	  with	  PBMCs.	  Although	  Th1	  and	  
Th2	  cytokines	  are	  also	  induced	  by	  activated	  T-­‐cells,	  we	  can	  rule	  that	  possibility	  out	  because	  
these	  PBMCs	  were	  derived	  from	  sero-­‐negative	  individuals	  that	  do	  not	  have	  activated	  T-­‐cells.	  
Therefore,	  whatever	  Th1	  and	  Th2	  cytokine	  expression	  is	  observed	  it	  is	  presumably	  induced	  by	  
NK	  cells	  that	  do	  not	  need	  prior	  activation.	  Here,	  we	  observe	  that	  a	  significant	  up-­‐regulation	  in	  
TNF-­‐α	  was	  in	  case	  of	  PBMCs	  sub-­‐cultured	  with	  HSV-­‐1	  infected	  cells,	  but	  not	  in	  case	  of	  B	  virus	  
infection	  suggesting	  that	  TNF-­‐α	  could	  be	  induced	  by	  other	  cells	  during	  HSV-­‐1	  infection	  but	  only	  
by	  NK	  cells	  during	  B	  virus	  infection	  (Figure	  15C).	  Significant	  down-­‐regulation	  of	  GM-­‐CSF	  and	  IL-­‐2	  
(Figures	  15A	  and	  15B	  respectively)	  was	  observed	  in	  infected	  cells	  and	  no	  expression	  of	  IFN-­‐γ	  
was	  observed	  in	  any	  of	  the	  supernatants	  tested	  (Table	  6).	  No	  significant	  expression	  of	  Th2	  cyto-­‐
kines	  was	  observed	  (Table	  6).	  These	  results	  suggest	  that	  NK	  cells	  during	  HSV-­‐1	  or	  B	  virus	  infec-­‐
















	  	  	  	  	  	  	  	  	   	  
Figure	  15A:	  Expression	  of	  GM-­‐CSF	  by	  PBMCs	  exposed	  to	  mock,	  HSV-­‐1	  or	  BV	  infected	  HFF	  cells	  
for	  18	  hrs.	  One-­‐way	  ANOVA	  of	  mock,	  HSV-­‐1,	  and	  B	  virus	  infected	  samples	  yields	  a	  p-­‐value	  of	  
0.002.	  Multiple	  comparisons	  between	  the	  samples	  using	  SNK	  test	  shows	  a	  significant	  difference	  





































	  	  	  	  	  	  	  	  	  	  	  	   	   	  
Figure	  15B:	  Expression	  of	  IL-­‐2	  by	  PBMCs	  exposed	  to	  mock,	  HSV-­‐1	  or	  BV	  infected	  HFF	  cells	  for	  
18	  hrs.	  One-­‐way	  ANOVA	  of	  mock,	  HSV-­‐1,	  and	  B	  virus	  infected	  samples	  yields	  a	  p-­‐value	  of	  
<0.0001.	  Multiple	  comparisons	  between	  the	  samples	  using	  SNK	  test	  shows	  a	  significant	  differ-­‐
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Figure	  15C:	  TNF-­‐α 	  expression	  by	  PBMCs	  exposed	  to	  mock,	  HSV-­‐1,	  B	  virus	  infected	  HFF	  cells	  for	  
18	  hrs.	  One-­‐way	  ANOVA	  of	  mock,	  HSV-­‐1,	  and	  B	  virus	  infected	  samples	  yields	  a	  p-­‐value	  of	  0.009.	  
Multiple	  comparisons	  between	  the	  samples	  using	  SNK	  test	  shows	  a	  significant	  difference	  be-­‐
tween	  HSV-­‐1	  and	  mock	  treated	  cells	  and	  HSV-­‐1	  and	  B	  virus	  treated	  cells.	  The	  error	  bars	  repre-­‐






































Table	  6:	  Summary	  of	  cytokines	  released	  by	  NK	  cells	  under	  the	  influence	  of	  PBMCs.	  
	  
	   	  
Mock	  Infected	  HFF	  
	  
HSV-­‐1	  infected	  HFF	  
cells	  
	  
B	  virus	  infected	  HFF	  
cells	  
GM-­‐CSF	  (Th1)	   ✔ 	  	  (167.08	  pg/ml)	   ✖ 	  (<10	  pg/ml)	   ✖ 	  (<10	  pg/ml)	  
TNF-­‐α 	  (T12)	   ✔ 	  (20.52	  pg/ml)	   ⇑(62.37	  pg/ml)	   ✔ 	  (30.26	  pg/ml)	  
IFN-­‐γ 	  	  (Th1)	   ✖ 	  (<10	  pg/ml)	   ✖ 	  (<10	  pg/ml)	   ✖ 	  (<10	  pg/ml)	  
IL-­‐2	   ⇑ 	  (68	  pg/ml)	   ✖ 	  (<10	  pg/ml)	   ✖ 	  (<10	  pg/ml)	  














NK	  cell	  expression	  of	  cytotoxic	  granules,	  perforin	  and	  granzyme	  B,	  during	  B	  virus	  infec-­‐
tion.	  Upon	  activation	  NK	  cells	  can	  induce	  either	  cytokines	  and/or	  cause	  cytotoxicity.	  NK	  cells	  
exert	  cytotoxicity	  by	  the	  production	  of	  perforin	  and	  granzyme	  B.	  Therefore,	  in	  this	  experiment	  
we	  wanted	  to	  investigate	  whether	  NK	  cells	  engaged	  early	  cytolytic	  activity	  during	  B	  virus	  or	  
HSV-­‐1	  infection.	  Our	  results	  show	  that	  neither	  perforin	  nor	  granzyme	  B	  is	  induced	  during	  B	  virus	  
or	  HSV-­‐1	  infection	  by	  NK	  cells	  (Figure	  16A	  and	  Figure	  16B	  respectively)	  with	  or	  without	  IL-­‐2	  
treatment.	  IL-­‐2,	  among	  other	  factors,	  plays	  an	  important	  role	  in	  NK	  cell	  cytotoxicity,	  therefore,	  
we	  see	  an	  up-­‐regulation	  of	  perforin	  in	  mock	  cells	  with	  NK/IL-­‐2	  treatment.	  This	  up-­‐regulation	  
does	  not	  imply	  cytolysis,	  but	  simply	  the	  formation	  of	  cytotoxic	  granules	  naturally	  occurring	  in	  
NK	  cells.	  Interestingly, up-­‐regulation	  was	  not	  observed	  in	  case	  of	  HSV-­‐1	  or	  B	  virus	  infected	  cells.	  
From	  these	  results	  we	  concluded	  that	  primary	  NK	  cells	  with	  or	  without	  IL-­‐2	  treatment	  produced	  




















	  	  	  	  	  	   	  
Figure	  16A:	  Release	  of	  cytotoxic	  granule,	  perforin	  by	  NK	  cells	  with	  or	  without	  IL-­‐2	  treatment	  
during	  mock,	  HSV-­‐1,	  or	  B	  virus	  infection.	  One-­‐way	  ANOVA	  of	  mock,	  HSV-­‐1,	  and	  B	  virus	  infected	  
samples	  yields	  a	  p-­‐value	  of	  0.025	  and	  <0.001	  for	  cells	  exposed	  to	  NK	  or	  NK/IL-­‐2	  respectively.	  
Multiple	  comparisons	  between	  the	  samples	  using	  SNK	  test	  shows	  a	  significant	  difference	  be-­‐
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Figure	  16B:	  Release	  of	  cytotoxic	  granule,	  granzyme	  B	  by	  NK	  cells	  with	  or	  without	  IL-­‐2	  treat-­‐
ment	  during	  mock,	  HSV-­‐1,	  or	  B	  virus	  infection.	  One-­‐way	  ANOVA	  of	  mock,	  HSV-­‐1,	  and	  B	  virus	  
infected	  samples	  yields	  a	  p-­‐value	  of	  0.0003	  and	  0.008	  for	  cells	  exposed	  to	  NK	  or	  NK/IL-­‐2	  respec-­‐
tively.	  Multiple	  comparisons	  between	  the	  samples	  using	  SNK	  test	  shows	  a	  significant	  difference	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   Cytotoxic	  granules	  release	  during	  PBMC	  exposure	  to	  B	  virus	  infected	  HFF	  cells.	  Peforin	  
and	  Granzyme	  B	  are	  mostly	  released	  by	  activated	  NK	  cells	  or	  activated	  CTLs.	  Because	  in	  our	  ex-­‐
periment	  we	  used	  antibody	  negative	  donor	  PBMCs,	  we	  assume	  that	  CTLs	  are	  not	  active.	  There-­‐
fore,	  the	  perforin	  or	  granzyme	  B	  if	  released	  should	  most	  probably	  be	  because	  of	  NK	  cells	  that	  
have	  been	  activated	  either	  by	  contact	  with	  the	  infected	  target	  cells	  or	  under	  the	  influence	  of	  
other	  effector	  cells	  in	  the	  PBMCs.	  Our	  experimental	  results	  show	  that	  there	  is	  no	  significant	  in-­‐
crease	  in	  the	  release	  of	  granzyme	  B	  during	  B	  virus	  infection	  but	  similar	  expression	  to	  mock	  dur-­‐
ing	  HSV-­‐1	  infection	  (Figure	  17B).	  A	  significant	  up-­‐regulation	  is	  observed	  in	  perforin	  release	  in	  
HSV-­‐1	  infection	  as	  compared	  to	  mock	  and	  B	  virus	  infection	  (Figure	  17A).	  From	  these	  results	  we	  
can	  conclude	  that	  IFN-­‐α	  and	  IP-­‐10	  might	  play	  a	  role	  in	  inducing	  the	  release	  of	  perforin	  by	  NK	  
cells	  in	  HSV-­‐1	  infections,	  however,	  these	  cytokines	  might	  not	  be	  important	  for	  TNF-­‐α	  up-­‐
regulation.	  Thus,	  the	  absence	  of	  IFN-­‐α,	  among	  other	  things,	  during	  B	  virus	  infection	  could	  con-­‐






















Figure	  17A:	  Release	  of	  cytotoxic	  granule,	  perforin	  by	  PBMCs	  during	  mock,	  HSV-­‐1,	  or	  B	  virus	  
infection.	  One-­‐way	  ANOVA	  of	  mock,	  HSV-­‐1,	  and	  B	  virus	  infected	  samples	  yields	  a	  p-­‐value	  of	  
0.0006.	  Multiple	  comparisons	  between	  the	  samples	  using	  SNK	  test	  shows	  a	  significant	  differ-­‐
ence	  between	  PBMCs	  exposed	  to	  HSV-­‐1	  and	  PBMCs	  exposed	  to	  mock	  or	  B	  virus	  treated	  cells.	  




































Figure	  17B:	  Release	  of	  cytotoxic	  granule,	  granzyme	  B	  by	  PBMCs	  during	  mock,	  HSV-­‐1,	  or	  B	  vi-­‐
rus	  infection.	  One-­‐way	  ANOVA	  of	  mock,	  HSV-­‐1,	  and	  B	  virus	  infected	  samples	  yields	  a	  p-­‐value	  of	  
0.011.	  Multiple	  comparisons	  between	  the	  samples	  using	  SNK	  test	  shows	  a	  significant	  difference	  
between	  PBMCs	  exposed	  to	  B	  virus	  as	  compared	  to	  PBMCs	  exposed	  to	  mock	  or	  HSV-­‐1	  treated	  




























	   ITAM	  receptors	  are	  not	  activated	  in	  NK	  cells	  or	  PBMCs	  during	  B	  virus	  infection.	  NK	  cell	  
activation	  receptors	  are	  divided	  into	  three	  different	  family	  members:	  ITAM,	  Non-­‐ITAM,	  and	  in-­‐
tegrins.	  T-­‐cells,	  B-­‐cells	  and	  NK	  cells	  express	  ITAM	  activation	  receptors.	  In	  this	  experiment	  we	  
wanted	  to	  investigate	  if	  ITAM	  activation	  receptors	  are	  induced	  in	  NK	  cells	  and	  PBMCs	  during	  B	  
virus	  infection.	  When	  an	  ITAM	  receptor	  is	  engaged	  by	  the	  respective	  ligand,	  Syk	  protein	  (spleen	  
protein	  tyrosine	  kinase)	  is	  phosphorylated.	  ITAM	  receptors	  induced	  activation	  signal	  transduc-­‐
tion	  is	  Syk-­‐dependent.	  Therefore,	  in	  this	  experiment	  we	  measured	  Syk	  phosphorylation	  in	  NK	  
cells	  and	  PBMCs	  that	  are	  exposed	  to	  mock	  infected,	  B	  virus,	  or	  HSV-­‐1	  infected	  cells.	  Our	  west-­‐
ern	  blot	  results	  show	  that	  Syk	  is	  not	  phosphorylated	  in	  PBMCs	  or	  NK	  cells	  with	  or	  without	  IL-­‐2	  
treatment	  (Figure	  18).	  From	  these	  results	  we	  conclude	  that	  if	  there	  is	  any	  activation	  observed	  in	  
NK	  cells	  or	  PBMCs	  upon	  infection	  it	  is	  not	  due	  to	  the	  engagement	  of	  ITAM	  receptors	  or	  Syk-­‐
dependent	  activation.	  We	  did	  observe	  TNF-­‐α	  production	  during	  NK	  cell	  exposure	  to	  B	  virus,	  and	  
this	  production	  could	  be	  due	  to	  Syk-­‐independent	  activation	  of	  NK	  cells.	  Also,	  the	  expression	  of	  
cytotoxic	  granules,	  perforin,	  by	  PBMC	  upon	  exposure	  to	  HSV-­‐1	  infected	  cells	  could	  be	  the	  result	  

















Figure	  18:	  western	  blot	  analysis	  of	  syk	  protein	  phosphorylation	  in	  NK	  cells,	  NK	  cells	  +	  IL-­‐2,	  and	  
PBMCs.	  Syk	  is	  not	  phosphorylated	  in	  NK	  cells	  with	  or	  without	  IL-­‐2	  and	  PBMCs,	  thus	  indicating	  
that	  syk-­‐dependent	  activation	  is	  inhibited	  during	  B	  virus	  or	  HSV-­‐1	  infection.	  
	  











The	  close	  relationship	  between	  B	  virus	  and	  human	  simplex	  viruses	  of	  the	  same	  family	  
results	  in	  nearly	  conserved	  phenotypes	  and	  related	  function.	  In	  spite	  of	  this,	  earlier	  work	  in	  our	  
laboratory,	  coupled	  with	  the	  work	  performed	  during	  this	  dissertation	  research	  showed	  that	  B	  
virus	  lacks	  a	  functional	  domain	  of	  a	  major	  virus	  protein,	  ICP47.	  The	  missing	  domain	  lead	  to	  the	  
speculation	  that	  in	  B	  virus	  infected	  cells	  virus	  peptides	  would	  be	  presented	  via	  MHC	  class	  I	  
molecules	  on	  the	  surface	  of	  the	  infected	  cells.	  This	  speculation,	  if	  confirmed	  would	  essentially	  
change	  in	  a	  major	  way	  a	  mechanism	  by	  which	  infected	  cells	  could	  be	  cleared	  or	  destroyed	  by	  
the	  host	  immune	  system	  when	  compared	  to	  what	  is	  known	  about	  other	  simplex	  viruses.	  Our	  
hypothesis	  was	  that	  B	  virus	  regulated	  MHC	  class	  I	  antigen	  presentation	  differently	  in	  human	  
derived	  cell	  lines	  when	  compared	  to	  HSV-­‐1.	  Thus,	  at	  the	  onset	  of	  this	  project,	  we	  sought	  to	  ver-­‐
ify	  whether	  B	  virus	  infected	  cell	  peptides	  were	  presented	  on	  the	  cell	  surface	  via	  MHC	  class	  I	  
molecules.	  In	  fact,	  the	  results	  of	  these	  initial	  analyses	  showed	  that,	  MHC	  class	  I	  bound	  viral	  pep-­‐
tides	  were	  presented,	  albeit	  in	  somewhat	  reduced	  amounts	  though	  not	  significantly	  different	  
levels	  when	  compared	  to	  the	  levels	  of	  MHC	  class	  I	  peptide	  presentation	  in	  cells	  treated	  with	  
uninfected	  cell	  lysates.	  The	  significance	  of	  this	  reduction	  may	  be	  related	  to	  several	  observations	  
that	  will	  be	  subsequently	  discussed.	  
During	  virus	  infection,	  excess	  viral	  and	  infected	  cell	  proteins	  are	  degraded	  to	  8-­‐10	  amino	  
acid	  long	  peptides	  by	  the	  proteosome.	  The	  resultant	  small	  peptides	  bind	  to	  the	  TAP	  (TAP1	  and	  




associates	  with	  loaded	  TAP	  via	  tapasin.	  The	  peptide	  loaded	  MHC	  class	  I	  molecule	  in	  the	  endo-­‐
plasmic	  reticulum	  is	  transported	  to	  the	  cell	  surface	  following	  modification	  in	  the	  Golgi	  complex.	  
Virus-­‐specific	  CD8+	  T-­‐cells	  then	  recognize	  the	  peptide-­‐bound	  MHC	  class	  I	  on	  the	  cell	  surface	  of	  
the	  infected	  cell,	  bind	  to	  the	  peptide	  through	  TCR,	  and	  subsequently	  induce	  cell	  lysis.	  The	  re-­‐
sponse	  of	  the	  CD8+	  T	  cells,	  however,	  is	  delayed	  until	  these	  cells	  arrive	  at	  the	  site	  of	  infection.	  
During	  alphaherpesvirus	  infections	  in	  humans,	  the	  virus	  down-­‐regulates	  surface	  expression	  of	  
antigen	  presenting	  MHC	  class	  I	  molecules,	  which	  results	  in	  evasion	  of	  CD8+	  T-­‐cell	  recognition,	  
but	  susceptibility	  to	  NK	  cell	  killing.	  	  In	  the	  case	  of	  HSV	  infection,	  this	  mechanism	  of	  down-­‐
regulation	  of	  surface	  MHC	  class	  I	  antigen	  presentation	  is	  attributed	  to	  ICP47	  protein	  (57,	  68,	  
184).	  The	  N-­‐	  terminal	  region	  of	  HSV-­‐1	  ICP47	  consists	  of	  a	  TAP	  binding	  domain	  that	  is	  also	  pre-­‐
sent	  in	  HSV-­‐2	  ICP47.	  This	  TAP	  binding	  domain	  binds	  to	  the	  host	  TAP	  and	  prevents	  peptide	  
transport	  resulting	  in	  sequestering	  of	  unloaded	  MHC	  class	  I	  in	  the	  cytoplasm	  (68).	  
In	  our	  investigation,	  we	  report	  for	  the	  first	  time	  that	  B	  virus	  does	  not	  down-­‐regulate	  
HLA-­‐A,	  -­‐B,	  -­‐C	  cell	  surface	  expression	  as	  efficiently	  as	  HSV-­‐1.	  Data	  analysis	  suggested	  there	  is	  no	  
significant	  difference	  between	  uninfected	  and	  B	  virus	  infected	  macaque-­‐derived	  cells,	  MK2	  
cells,	  with	  respect	  to	  MHC	  class	  I	  presentation.	  There	  is	  approximately	  30%	  down-­‐regulation	  of	  
surface	  MHC	  class	  I	  antigen	  presentation	  in	  B	  virus	  infected	  human-­‐derived	  cells,	  HFF	  cells,	  
however,	  significantly	  less	  than	  that	  observed	  in	  HSV-­‐1	  infected	  HFF	  cells	  (64%).	  Together,	  
these	  data	  suggest	  that	  B	  virus	  does	  not	  down-­‐regulate	  HLA-­‐A,	  -­‐B,	  -­‐C	  cell	  surface	  expression	  re-­‐
gardless	  of	  the	  host	  cell	  line	  used.	  In	  HSV-­‐1	  and	  HSV-­‐2	  ICP47	  amino	  acids	  3	  to	  32	  make	  up	  for	  
the	  functional	  TAP	  binding	  domain	  (58),	  effectively	  preventing	  peptides	  from	  being	  loaded	  onto	  




ICP47	  (Figure	  19).	  This	  domain	  is	  not	  found	  in	  any	  other	  B	  virus	  encoded	  proteins.	  Although,	  B	  
virus	  ICP47	  is	  a	  relatively	  small	  protein	  similar	  to	  HSV	  ICP47	  and	  is	  oriented	  in	  a	  similar	  manner	  
to	  HSV	  ICP47	  (126,	  137),	  the	  lack	  of	  TAP	  binding	  domain	  can	  be	  predicted	  to	  allow	  for	  peptide	  
loading	  onto	  the	  cell’s	  TAP	  molecule	  for	  transport	  to	  the	  MHC	  class	  I	  molecule	  location.	  Com-­‐
parison	  of	  ICP47	  homolog	  sequences	  between	  human	  simplex	  viruses	  (HSV-­‐1,	  HSV-­‐2)	  and	  non-­‐
human	  primate	  simplex	  viruses	  (B	  virus,	  SA8,	  HVP	  2)	  shows	  that	  the	  latter	  herpes	  simplex	  virus	  
ICP47	  diverged	  from	  human	  herpes	  simplex	  viruses	  in	  that	  they	  lack	  TAP	  binding	  domain	  (Figure	  
19)	  (19).	  Each	  virus	  ICP47	  homolog’s	  amino	  acid	  sequence	  length,	  i.e.,	  HSV-­‐1,	  HSV-­‐2,	  BV,	  HVP-­‐2,	  
and	  SA8,	  are	  88,	  86,	  81,	  78,	  and	  78,	  respectively.	  Perhaps	  HSV	  diverged	  when	  it	  added	  the	  
ICP47	  TAP	  binding	  domain.	  The	  region	  that	  binds	  to	  host	  TAP	  in	  ICP47	  of	  HSV-­‐1	  and	  2	  is	  present	  
in	  the	  N-­‐terminal	  region.	  When	  ICP47	  sequence	  is	  compared	  between	  all	  5	  viruses	  (mentioned	  
above),	  greater	  sequence	  identity	  is	  observed	  in	  region	  down-­‐stream	  to	  TAP	  binding	  domain	  of	  
ICP47.	  This	  observation	  indicates	  a	  function	  other	  than	  MHC	  class	  I	  down-­‐regulation,	  may	  be	  
associated	  with	  the	  region	  that	  is	  highly	  homologous	  in	  all	  the	  above	  viruses.	  
Although	  down-­‐regulation	  of	  MHC-­‐I	  is	  characteristic	  of	  most	  human	  herpesviruses,	  B	  vi-­‐
rus	  fails	  to	  do	  so	  efficiently	  in	  cells	  derived	  from	  human	  or	  macaques.	  In	  contrast,	  certain	  hu-­‐
man	  herpesviruses,	  such	  as,	  CMV	  even	  encode	  for	  more	  than	  one	  protein	  to	  down-­‐regulate	  
MHC	  class	  I	  (18),	  suggesting	  that	  down-­‐regulation	  of	  MHC	  class	  I	  is	  an	  important	  aspect	  in	  evad-­‐
ing	  host	  adaptive	  immune	  responses	  elicited	  by	  CD8+	  T-­‐cells	  as	  discussed	  by	  Goldsmith	  et	  al	  
(61).	  By	  down-­‐regulating	  MHC	  class	  I	  during	  viral	  infection,	  viruses	  prevents	  CD8+	  T-­‐cells	  from	  




ence	  from	  activated	  CD8+	  T-­‐cells.	  However,	  the	  down-­‐regulation	  is	  recognized	  by	  NK	  cells	  sur-­‐







Figure	  19:	  ICP47	  sequence	  comparison	  between	  human	  herpes	  viruses	  (HSV-­‐1	  and	  HSV-­‐2)	  and	  
simian	  herpes	  viruses	  (B	  virus,	  HVP	  2,	  and	  SA8).	  Figure	  A	  shows	  the	  sequence	  homology	  be-­‐
tween	  HSV-­‐1,	  HSV-­‐2,	  B	  virus,	  and	  HVP-­‐2	  ICP47	  (1-­‐60	  amino	  acids).	  The	  N-­‐terminal	  region	  of	  HSV	  
ICP47	  is	  the	  TAP	  binding	  domain,	  which	  is	  not	  conserved	  in	  B	  virus	  ICP47	  or	  in	  HVP-­‐2	  ICP47.	  The	  
C-­‐terminal	  region	  of	  ICP47,	  however,	  is	  the	  most	  homologous	  region	  in	  all	  the	  4	  viruses.	  Figure	  
B	  shows	  the	  phylogenic	  tree	  indicating	  the	  ICP47	  divergence	  between	  human	  and	  non-­‐human	  





The	  next	  goal	  of	  the	  research	  was	  to	  determine	  whether	  the	  presentation	  of	  cell	  surface	  
MHC	  class	  I	  molecules	  loaded	  with	  B	  virus	  infected	  cell	  polypeptides	  abrogated	  a	  major	  defense	  
observed	  to	  exist	  against	  human	  simplex	  viruses,	  i.e.,	  destruction	  of	  infected	  cells	  by	  natural	  
killer	  cells.	  The	  important	  role(s)	  of	  NK	  cells	  in	  host	  defenses	  to	  reduce	  HSV-­‐1	  induced	  morbid-­‐
ities	  coupled	  with	  the	  failure	  of	  B	  virus	  infected	  cells	  to	  significantly	  down-­‐regulate	  MHC	  class	  I	  
led	  us	  to	  explore	  whether	  the	  escape	  of	  infected	  cells	  from	  primary	  innate	  defense	  strategies	  
could	  occur.	  
The	  down	  side	  of	  down-­‐regulation	  of	  MHC	  class	  I	  molecules	  is	  that	  human	  herpesvirus	  
infected	  cells	  are	  prone	  to	  NK	  cell	  cytotoxicity,	  since	  when	  present,	  surface	  MHC	  class	  I	  mole-­‐
cules	  act	  as	  inhibitory	  ligands	  to	  NK	  cells.	  NK	  cells	  recognize	  the	  MHC	  class	  I	  molecules	  pre-­‐
sented	  on	  normal	  cells	  and	  distinguish	  between	  “self”	  and	  “non-­‐self”	  or	  infected	  and	  unin-­‐
fected	  cells	  (105,	  106,	  175).	  Absence	  of	  MHC	  class	  I	  on	  the	  cell	  surface	  triggers	  NK	  cells	  to	  kill	  
target	  cells,	  and	  thus,	  HSV-­‐1	  infected	  cells	  are	  sensitive	  to	  NK	  cell	  lysis	  (119).	  At	  the	  same	  time,	  
NK	  cells	  require	  activation	  ligands	  on	  target	  cells	  to	  bind	  to	  the	  receptors	  necessary	  for	  activa-­‐
tion.	  A	  balance	  generally	  exists	  between	  activation	  and	  inhibitory	  ligands	  in	  order	  to	  modulate	  
NK	  cell	  activity.	  Because	  B	  virus	  does	  not	  block	  MHC	  class	  I	  expression	  on	  infected	  cell	  surfaces,	  
we	  hypothesized	  that	  B	  virus	  modulates	  the	  infected	  cell	  in	  a	  manner,	  which	  results	  in	  protec-­‐
tion	  against	  NK	  cell	  lysis,	  resulting	  in	  critical	  time	  for	  greater	  local	  virus	  replication.	  
	  To	  better	  understand	  how	  B	  virus	  may	  confer	  protection	  against	  NK	  lysis	  of	  the	  infected	  
cells,	  it	  is	  instructive	  to	  evaluate	  HLA-­‐E	  and	  HLA-­‐G,	  the	  two	  isoforms	  comprising	  MHC-­‐	  Ib	  mole-­‐
cules.	  MHC-­‐	  Ib	  proteins	  are	  less	  polymorphic	  than	  MHC-­‐Ia	  proteins.	  HLA-­‐E	  on	  the	  cell	  surface	  




pressed	  in	  almost	  all	  nucleated	  cells	  and	  present	  the	  leader	  peptide	  of	  classical	  MHC-­‐Ia	  mole-­‐
cules	  (HLA-­‐A,	  -­‐B,	  -­‐C).	  Reduction	  of	  HLA-­‐A,	  -­‐B,	  -­‐C	  cell	  surface	  expression	  also	  reduces	  surface	  
HLA-­‐E	  expression.	  Our	  results	  confirmed	  the	  direct	  correlation	  between	  HLA-­‐A,	  -­‐B,	  -­‐C	  and	  HLA-­‐E	  
expression	  in	  B	  virus	  infected	  HFF	  cells,	  suggesting	  for	  the	  first	  time	  that	  B	  virus	  has	  a	  mecha-­‐
nism	  for	  suppression	  of	  NK	  cell	  killing,	  preserving	  the	  infected	  cell	  to	  fuse	  with	  neighboring	  cells	  
to	  facilitate	  increased	  virus	  replication.	  Since	  MHC-­‐Ia	  molecules	  and	  HLA-­‐E	  are	  expressed	  on	  B	  
virus	  infected	  cells,	  infected	  cell	  surfaces	  display,	  inhibitory	  ligands	  to	  NK	  cell	  inhibitory	  recep-­‐
tors.	  Is	  the	  presence	  of	  this	  ligands	  sufficient	  to	  inhibit	  NK	  cell	  killing	  of	  infected	  target	  cells?	  
HLA-­‐G	  is	  also	  an	  MHC-­‐class	  Ib	  molecule,	  which	  binds	  to	  KIR	  inhibitory	  receptor	  of	  NK	  
cells.	  These	  molecules	  are	  mostly	  expressed	  on	  the	  placental	  cells	  (specifically	  cytotrophoblast	  
cells)	  to	  protect	  the	  fetus	  from	  maternal	  NK	  cell	  induced	  cytolysis.	  HLA-­‐G	  molecules	  are	  not	  ex-­‐
pressed	  on	  all	  cells,	  e.g.,	  fibroblast	  cells	  do	  not	  express	  HLA-­‐G	  under	  normal	  conditions.	  During	  
virus	  infection,	  however,	  HLA-­‐G	  expression	  can	  be	  induced	  and	  expressed	  on	  fibroblasts.	  HLA-­‐G	  
is	  expressed	  on	  the	  placenta	  to	  protect	  the	  fetus	  from	  maternal	  NK	  cell.	  HLA-­‐G	  is	  the	  least	  po-­‐
lymorphic	  of	  the	  MHC	  class	  I	  molecules,	  consisting	  of	  7	  isoforms	  resulting	  from	  alternative	  splic-­‐
ing	  (116).	  The	  membrane	  bound	  isoforms,	  HLA-­‐G1,	  HLA-­‐G2,	  HLA-­‐G3,	  and	  HLA-­‐G4	  are	  also	  in-­‐
volved	  in	  inhibiting	  CTL	  lysis,	  which	  is	  one	  possible	  reason	  for	  the	  expression	  of	  HLA-­‐G	  in	  HSV-­‐1	  
infected	  HFF	  cells.	  Previous	  research	  by	  Lafon	  et	  al.,	  has	  shown	  that	  HSV-­‐1	  induces	  HLA-­‐G	  ex-­‐
pression	  in	  neuronal	  cells,	  however,	  their	  research	  showed	  that	  this	  HSV	  induced	  HLA-­‐G	  was	  
not	  expressed	  on	  the	  neuronal	  cell	  surface	  (94).	  In	  our	  experiments,	  we	  observed	  only	  low-­‐level	  




that	  the	  presence	  of	  MHC	  class	  I	  molecules	  on	  the	  surface	  on	  B	  virus	  infected	  HFF	  cells	  are	  suf-­‐
ficient	  to	  successfully	  inhibit	  some,	  if	  not	  all,	  NK	  cell	  activities.	  	  
Huard	  et	  al.	  first	  suggested	  that	  lack	  of	  MHC	  class	  I	  protein	  on	  the	  cell	  surface	  leads	  to	  
NK	  cell	  lysis	  of	  HSV-­‐1	  infected	  cells	  (74).	  Thus,	  we	  suggest	  here	  that	  although	  NK	  inhibitory	  HLA-­‐
G	  molecules	  were	  expressed	  on	  the	  cell	  surface	  of	  HSV-­‐1	  infected	  HFF	  cells,	  it	  apparently	  in	  in-­‐
sufficient	  to	  protect	  the	  HSV-­‐1	  infected	  HFF	  cells	  from	  NK	  cell	  lysis,	  although	  this	  remains	  to	  be	  
tested.	  This	  study	  has	  revealed	  that	  B	  virus,	  unlike	  human	  herpes	  viruses,	  does	  not	  down-­‐
regulate	  MHC	  class	  I	  molecules	  on	  the	  cell	  surface	  efficiently	  if	  at	  all.	  This	  also	  appears	  to	  be	  the	  
case	  for	  HVP-­‐2,	  another	  closely-­‐related	  nonhuman	  primate	  simplex	  virus,	  leading	  us	  to	  believe	  
that	  B	  virus,	  HVP-­‐2,	  and	  SA8,	  and	  perhaps	  all	  non-­‐human	  primate	  simplex	  viruses	  use	  a	  differ-­‐
ent	  mechanism	  to	  evade	  infected	  cell	  lysis	  by	  host	  immune	  responses.	  None	  of	  these	  viruses	  
have	  TAP	  binding	  domains	  present	  in	  the	  ICP47.5	  protein.	  
Another	  function	  of	  MHC	  class	  I	  molecules	  is	  associated	  with	  regulation	  of	  NK	  cell	  activ-­‐
ity	  by	  binding	  to	  the	  inhibitory	  receptors	  (ITIMS),	  which	  subsequently	  result	  in	  the	  phosphoryla-­‐
tion	  of	  these	  ITIMS,	  which	  then	  recruit	  SHP-­‐1	  or	  SHP-­‐2	  tyrosine	  phosphatase,	  which	  in	  turn	  in-­‐
activates	  the	  signaling	  pathway	  for	  NK	  cell	  cytotoxicity	  and/	  or	  cytokine	  production	  (95,	  98,	  
175).	  Many	  viruses	  are	  known	  to	  down-­‐regulate	  NK	  cell	  activity	  by	  employing	  different	  mecha-­‐
nisms.	  As	  discussed	  previously,	  CMV	  can	  down-­‐regulate	  expression	  of	  ULBP	  activation	  ligand	  by	  
binding	  and	  preventing	  cell	  surface	  expression.	  The	  MCMV	  glycoprotein	  m157	  binds	  to	  Ly49	  
receptor	  of	  NK	  cells	  and	  inhibits	  NK	  cell	  activity	  through	  recruitment	  of	  SHP-­‐1	  or	  SHP-­‐2	  to	  phos-­‐
phorylated	  ITIM	  cytoplasmic	  domains	  of	  LY49	  (105).	  Another	  protein	  found	  in	  both	  MCMV	  and	  




of	  NK	  cells.	  Specific	  peptides	  from	  UL40	  glycoprotein	  of	  HCMV	  bind	  to	  HLA-­‐E,	  which	  in	  turn	  in-­‐
hibits	  NK	  cell	  activity.	  HIV	  nef	  protein	  down-­‐regulates	  HLA-­‐A	  and	  –B,	  but	  not	  HLA-­‐C	  and	  HLA-­‐E,	  
leading	  to	  down-­‐regulation	  of	  MHC	  class	  I	  on	  the	  cell	  surface,	  however,	  the	  presence	  of	  HLA-­‐E	  
and	  HLA-­‐C	  confer	  resistance	  to	  NK	  cell	  cytotoxicity	  (105).	  KSHV	  and	  HCV	  (glossary)	  viruses	  are	  
also	  known	  to	  down-­‐regulate	  NK	  cell	  activity	  (142).	  While	  some	  virus	  infected	  cells	  are	  resistant	  
to	  NK	  cell	  lysis,	  other	  virus	  infected	  cells	  are	  sensitive	  to	  NK	  cell	  cytolysis,	  which	  prevents	  sus-­‐
tained	  replication	  of	  the	  virus.	  HSV-­‐1	  infected	  cells	  are	  sensitive	  to	  NK	  cell	  cytolysis	  due	  to	  
down-­‐regulation	  of	  cell	  surface	  MHC	  class	  I	  molecules	  (74).	  Vaccinia	  virus	  infected	  cells	  were	  
also	  found	  to	  be	  sensitive	  to	  NK	  cell	  cytolysis,	  because	  of	  the	  up	  regulation	  of	  cell	  surface	  
ligands	  to	  NK	  receptors	  such	  as,	  NKp30,	  NKp44,	  Nkp46,	  and	  NCR	  (33),	  each	  serving	  as	  an	  acti-­‐
vating	  ligand.	  
Taking	  into	  consideration	  the	  differences	  in	  the	  modulation	  of	  cell	  surface	  MHC	  class	  I	  
molecules	  in	  HSV-­‐1	  and	  B	  virus	  infected	  cells,	  we	  hypothesized	  that	  B	  virus	  does	  not	  activate	  NK	  
cells	  during	  infection,	  escaping	  NK	  cell	  cytolysis	  and	  cytokine	  production,	  which	  ultimately	  leads	  
to	  increased	  virus	  replication	  at	  the	  site	  of	  the	  primary	  site	  of	  infection.	  In	  order	  to	  test	  the	  hy-­‐
pothesis	  that	  B	  virus	  down	  modulates	  NK	  cell	  activities,	  we	  considered	  all	  aspects	  that	  deter-­‐
mine	  NK	  cell	  activity.	  To	  this	  end,	  we	  designed	  an	  experimental	  plan	  that	  determines	  an	  exter-­‐
nal	  effect	  exerted	  on	  the	  infected	  cell	  by	  NK	  cells	  as	  regulated	  by	  infected	  cells	  directly	  or	  by	  
circulating	  effector	  cells	  (PBMCs),	  indirectly.	  
We	  first	  quantified	  MICA	  and	  MICB	  expression	  in	  human	  derived	  HFF	  cells	  infected	  B	  vi-­‐
rus	  or	  HSV-­‐1.	  The	  stress	  proteins	  MICA	  and	  MICB	  bind	  to	  NKG2D	  activation	  receptors	  on	  the	  




role	  especially	  in	  overcoming	  the	  inhibitory	  effect	  of	  MHC	  class	  I	  cell	  surface	  molecules	  on	  NK	  
cells.	  In	  humans,	  NKG2D	  molecules	  are	  also	  present	  on	  all	  CD8+	  and	  γδ	  TCR+	  cells.	  	  B	  virus	  effi-­‐
ciently	  blocks	  cell	  surface	  expression	  of	  MHC	  class	  I	  molecules	  as	  does	  HSV-­‐1	  as	  shown	  in	  the	  
experimental	  data	  presented.	  Additionally,	  these	  experiments	  on	  MICA	  and	  MICB	  expression	  
demonstrated	  that	  surface	  MICB	  expression	  was	  up	  regulated	  at	  12	  and	  24	  hpi.	  	  When	  we	  used	  
a	  combination	  antibody	  anti-­‐MICA/MICB,	  which	  recognized	  both	  MICA	  and	  MICB,	  to	  detect	  cell	  
surface	  expression,	  there	  was	  increase	  expression	  of	  MICA/MICB	  on	  B	  virus	  and	  HSV-­‐1	  infected	  
cells.	  	  However,	  when	  antibodies	  to	  only	  MICA	  were	  used	  in	  cell	  sorting	  experiments,	  we	  noted	  
an	  absence	  of	  MICA	  present	  on	  the	  cell	  surface	  of	  infected	  cells.	  	  From	  this	  we	  concluded	  that	  
the	  increase	  was	  likely	  due	  to	  the	  presence	  of	  MICB	  in	  the	  absence	  of	  availability	  of	  anti-­‐MICB	  
specific	  antibodies.	  Additionally,	  ULBP	  stress	  proteins	  are	  not	  expressed	  in	  uninfected	  HFF	  cells,	  
however,	  they	  are	  also	  not	  expressed	  in	  either	  B	  virus	  or	  HSV-­‐1	  infected	  cells.	  Studies	  on	  
NKG2D	  ligands	  on	  HSV-­‐1	  infected	  HeLa	  and	  U373	  cells	  by	  Schepis	  et	  al.,	  previously	  revealed	  
down-­‐regulation	  of	  surface	  MICA	  on	  HSV-­‐1	  infected	  cells,	  however,	  MICB	  was	  not	  expressed	  
i(156).	  There	  are	  discrepancies	  in	  the	  results	  between	  our	  study	  and	  Schepis	  et	  al.,	  study	  per-­‐
haps	  due	  to	  the	  cell	  lines	  used.	  The	  cells	  used	  in	  the	  study	  presented	  here	  are	  derived	  from	  
primary	  fibroblasts,	  whereas,	  Schepis	  group	  used	  HeLa	  cells	  (transformed	  cells)	  and	  U373	  (hu-­‐
man	  glioblastoma-­‐	  astrocytoma	  cell	  line).	  The	  fact	  that	  different	  cells	  express	  MICA,	  MICB,	  
ULBP1-­‐4	  proteins	  at	  different	  levels	  (190)	  has	  been	  observed	  before,	  therefore	  there	  appears	  to	  





Our	  data	  suggests	  regulation	  of	  MICA/	  MICB	  cell	  surface	  expression	  on	  B	  virus	  or	  HSV-­‐1	  
infected	  cells,	  thus,	  we	  next	  sought	  to	  quantify	  NK	  cell	  activity	  upon	  their	  exposure	  to	  the	  
MICA/	  MICB	  expressing	  infected	  cells.	  For	  these	  experiments	  we	  chose	  naïve	  NK	  cells	  from	  B	  
virus/HSV-­‐1/HSV-­‐2	  antibody-­‐negative	  individuals,	  because	  of	  the	  lack	  of	  ready	  availability	  of	  
fresh	  blood	  for	  same	  day	  use	  from	  B	  virus	  positive	  donors.	  	  Further,	  we	  used	  freshly	  isolated	  
PBMCs	  to	  quantify	  the	  specific	  factors	  that	  have	  the	  potential	  to	  influence	  NK	  cell	  activity.	  For	  
NK	  cells	  to	  be	  activated	  either	  via	  cytokines	  and	  /or	  by	  binding	  to	  respective	  ligands,	  infected	  
cells	  should	  release	  specific	  cytokines	  or	  chemokines	  that	  are	  requisite	  for	  activation	  and	  migra-­‐
tion	  of	  NK	  cells.	  NK	  cell	  activator,	  IFN-­‐α,	  is	  produced	  by	  leukocytes	  and	  it	  helps	  in	  activation	  of	  
NK	  cells.	  NK	  cells	  are	  recruited	  to	  the	  site	  of	  infection	  as	  a	  result	  of	  infected	  cell	  release	  of	  
chemokines,	  e.g.,	  IP-­‐10,	  MIP-­‐1a,	  MIP-­‐1b,	  MCP-­‐1,	  and	  IL-­‐8	  (21,	  162).	  Studies	  on	  the	  influence	  of	  
IFN-­‐α	  on	  the	  NK	  cell	  activity	  during	  HSV-­‐1	  infection	  have	  shown	  that	  increased	  IFN-­‐α	  expression	  
correlated	  with	  increased	  NK	  cell	  induced	  cytotoxicity	  (119).	  Experiments	  on	  VZV	  and	  NK	  cell	  
activity	  also	  showed	  that	  NK	  cell	  activity	  is	  enhanced	  by	  IFN-­‐α	  treatment	  (114).	  In	  our	  experi-­‐
ments	  we	  did	  not	  see	  any	  expression	  of	  migration	  or	  activation	  cytokines	  (mentioned	  above)	  
produced	  by	  B	  virus	  or	  HSV-­‐1	  infected	  cell	  at	  6	  or	  24	  hpi.	  Previously,	  other	  investigators	  have	  
shown	  that	  during	  HSV-­‐1	  infection	  there	  is	  rapid	  production	  of	  IFN-­‐α	  by	  recruited	  leukocytes	  
and	  this	  IFN-­‐α	  is	  important	  for	  NK	  cell	  killing	  of	  HSV-­‐1	  infected	  cells	  (53).	  In	  the	  current	  studies,	  
treatment	  of	  cells	  with	  uninfected	  cell	  lysates	  alone	  induced	  secretion	  of	  specific	  cytokines,	  
however,	  B	  virus	  effectively	  blocked	  the	  production	  of	  these	  cytokines	  and	  chemokines	  respon-­‐




To	  quantify	  cytokines	  induced	  by	  leukocytes	  during	  HSV-­‐1	  or	  B	  virus	  infection,	  we	  ex-­‐
posed	  B	  virus	  or	  HSV-­‐1	  infected	  HFF	  cells	  to	  PBMCs	  to	  create	  a	  cell	  based	  in	  vivo	  model.	  Effec-­‐
tor:	  target	  ratios	  of	  50	  :	  1	  were	  used	  in	  order	  to	  ensure	  the	  presence	  of	  all	  leukocytes	  in	  sub-­‐
stantial	  numbers.	  There	  was	  greater	  production	  of	  IFN-­‐α	  and	  IP-­‐10,	  which	  are	  important	  for	  NK	  
cell	  activity	  in	  supernatants	  from	  cultures	  containing	  PBMCs	  exposed	  to	  HSV-­‐1	  infected	  HFF	  
cells,	  but	  not	  from	  PBMCs	  exposed	  to	  B	  virus	  infected	  cell.	  	  Other	  groups	  have	  reported	  the	  in-­‐
duction	  of	  IFN-­‐α	  in	  pDCs	  during	  HSV-­‐1	  infection	  (71,	  144,	  159).	  Thus,	  it	  is	  clear	  that	  PBMCs	  to	  
produce	  cytokines	  necessary	  for	  NK	  cell	  activity	  when	  exposed	  to	  HSV-­‐1	  infected	  HFF	  cells,	  
whereas,	  B	  virus	  appears	  to	  have	  a	  mechanism	  to	  block	  the	  production	  of	  cytokines	  even	  in	  
PBMCs.	  These	  results	  support	  our	  hypothesis	  that	  B	  virus	  down-­‐regulates	  specific	  innate	  im-­‐
mune	  responses,	  unlike	  HSV-­‐1,	  which	  has	  not	  selected	  for	  these	  blockades.	  	  Whether	  these	  dif-­‐
ferent	  pathogenesis	  patterns	  account	  for	  the	  fact	  that	  B	  virus	  causes	  severe	  morbidity	  and	  of-­‐
ten	  fatal	  infections	  in	  human	  hosts	  remains	  to	  be	  studied,	  however,	  humans	  lacking	  innate	  im-­‐
mune	  responses	  reportedly	  experience	  significant	  morbidities	  and	  frequent	  mortality	  as	  a	  result	  
of	  HSV-­‐1	  infection	  (118).	  	  
To	  examine	  to	  what	  extent	  direct	  activation	  of	  NK	  cells	  by	  B	  virus	  and	  HSV-­‐1	  infected	  
HFF	  cells	  occurred,	  an	  effector:	  target	  cells	  ratio	  of	  5:1	  was	  used	  in	  similarly	  designed	  experi-­‐
ments.	  For	  cytotoxicity	  assays,	  the	  effector:	  target	  ratio	  of	  5:1	  does	  not	  yield	  significant	  differ-­‐
ences	  in	  cytotoxicity	  between	  mock	  infected	  and	  virus	  infected	  cells.	  We	  preferred	  to	  use	  this	  
ratio	  because	  we	  did	  not	  want	  to	  force	  killing	  by	  adding	  higher	  numbers	  of	  NK	  cells.	  Therefore,	  
to	  quantify	  NK	  cell	  killing	  of	  infected	  cells,	  we	  quantified	  perforin	  and	  granzyme	  B	  release	  into	  




exposed	  infected	  cells	  to	  NK	  cells	  treated	  with	  IL-­‐2	  treatment	  during	  the	  course	  of	  18	  hrs.	  We	  
used	  a	  final	  IL-­‐2	  concentration	  of	  70	  U/ml	  of	  culture	  media	  during	  NK	  cell	  exposure	  to	  infected	  
cells	  and	  an	  initial	  concentration	  of	  100	  U/ml	  for	  1	  hr	  before	  infection.	  Prolonged	  treatment	  of	  
NK	  cells	  with	  IL-­‐2	  drives	  the	  NK	  cells	  toward	  synapse	  formation,	  subsequent	  exocytosis	  of	  per-­‐
forin-­‐	  granzyme	  lysosome,	  and	  target	  cell	  cytotoxicity	  at	  as	  low	  as	  10	  U/ml	  (46,	  73,	  109).	  We	  
observed	  no	  significant	  release	  of	  perforin	  or	  granzyme	  B	  by	  NK	  cells	  upon	  exposure	  to	  B	  virus	  
or	  HSV-­‐1	  infected	  HFF	  cells,	  suggesting	  that	  neither	  virus	  induces	  direct	  killing	  by	  naïve	  NK	  cells	  
even	  with	  IL-­‐2	  treatment.	  Virus	  selection	  of	  traits	  that	  promote	  NK	  cell	  induced	  cytolysis	  of	  in-­‐
fected	  cells	  would	  not	  be	  beneficial	  for	  virus	  survival	  within	  a	  host.	  	  On	  the	  other	  hand,	  selec-­‐
tions	  of	  traits	  that	  reduce	  virus	  replication	  and	  ensure	  host	  survival	  are	  beneficial	  to	  the	  virus	  
long-­‐term	  survival.	  	  Unlike	  B	  virus,	  HSV-­‐1	  infections	  in	  humans	  result	  in	  minimum	  morbidity	  and	  
the	  virus	  can	  utilize	  an	  individual	  host	  for	  the	  entire	  lifetime	  of	  that	  individual.	  
As	  a	  result	  of	  the	  experiments	  designed	  for	  this	  study,	  we	  observed	  that	  TNF-­‐α	  was	  pro-­‐
duced	  during	  B	  virus	  infection	  upon	  exposure	  of	  infected	  cells	  to	  NK	  cells,	  suggesting	  the	  pres-­‐
ence	  of	  cell	  surface	  ligands	  that	  bind	  to	  NK	  cell	  that	  result	  in	  the	  production	  of	  TNF-­‐α.	  Further,	  
IL-­‐2	  treatment	  of	  NK	  cells	  induces	  an	  increase	  in	  TNF-­‐α	  production	  over	  and	  above	  that	  result-­‐
ing	  from	  NK	  cell	  receptor:	  ligand	  binding	  to	  infected	  cells.	  Another	  possibility	  is	  that	  the	  TNF-­‐α	  
produced	  during	  B	  virus	  infection	  might	  be	  produced	  by	  undifferentiated	  NK	  cells	  as	  the	  
amount	  of	  TNF-­‐α	  produced	  was	  below	  the	  functional	  TNF-­‐α	  concentrations	  (139).	  
Because	  there	  was	  no	  observed	  activation	  of	  NK	  cell	  cytotoxicity	  resulting	  from	  direct	  in-­‐
teraction	  of	  infected	  cells	  with	  NK	  cells,	  and	  since	  we	  observed	  the	  production	  of	  IFN-­‐α	  and	  IP-­‐




accomplish	  this,	  we	  exposed	  infected	  cells	  to	  PBMC	  at	  50:1	  effector:	  target	  ratio	  and	  deter-­‐
mined	  NK	  cell	  cytotoxicity	  by	  measuring	  perforin	  and	  granzyme	  B	  release.	  Generally,	  NK	  cell	  
(during	  primary	  infection)	  and	  CTL	  populations	  (during	  secondary	  infection)	  contained	  in	  PBMCs	  
primarily	  release	  perforin	  and	  granzyme	  B.	  Because	  we	  used	  virus	  antibody	  negative	  donors,	  
CTL	  cell	  populations	  would	  not	  be	  activated	  upon	  exposure	  to	  B	  virus	  or	  HSV-­‐1	  infected	  cells,	  
and	  thus	  perforin	  and	  granzyme	  B	  released	  can	  be	  attributed	  to	  NK	  cells	  only.	  In	  the	  experi-­‐
ments	  presented	  here,	  we	  observed	  increased	  perforin	  in	  supernatants	  collected	  from	  cultures	  
containing	  PBMCs	  exposed	  to	  HSV-­‐1	  infected	  HFF	  cells	  compared	  to	  mock	  infected	  cells,	  how-­‐
ever,	  there	  was	  no	  observed	  increase	  in	  perforin	  and	  granzyme	  B	  in	  the	  supernatants	  obtained	  
from	  B	  virus	  infected	  HFF	  cells	  exposed	  to	  PBMCs.	  These	  results	  suggest	  that	  NK	  cells	  within	  the	  
PBMCs	  were	  not	  exposed	  to	  IFN-­‐α	  and	  IP-­‐10	  during	  B	  virus	  infection,	  while	  naïve	  NK	  cells	  with-­‐
out	  previous	  exposure	  to	  infection	  remained	  inactive	  even	  when	  stimulated	  with	  IL-­‐2.	  Thus,	  B	  
virus	  infected	  cells	  do	  not	  stimulate	  NK	  cell	  responses	  probably	  as	  a	  result	  of	  the	  B	  virus	  specific	  
blockade	  of	  cytokine	  and	  chemokine	  production	  necessary	  for	  NK	  cell	  activation	  as	  well	  as	  the	  
preservation	  of	  MHC	  class	  I	  surface	  antigen	  presentation.	  B	  virus	  infected	  cells	  do,	  however,	  
have	  a	  positive	  effect	  on	  TNF-­‐α	  production	  indirectly.	  	  
The	  production	  of	  TNF-­‐α	  by	  NK	  cells	  during	  B	  virus	  was	  not	  observed	  to	  be	  regulated	  by	  
Syk-­‐dependent	  pathway	  and	  therefore	  a	  non-­‐ITAM	  receptor-­‐ligand	  induced	  pathway	  is	  most	  
probably	  responsible	  e.g.,	  DAP10:NKG2D.	  Similarly	  in	  case	  perforin	  and	  granzyme	  B	  release	  by	  
PBMC	  activated	  NK	  cells	  exposed	  to	  HSV-­‐1	  infected	  cells,	  the	  NK	  cell	  activity	  is	  not	  through	  




	  Figure	  20	  and	  21	  illustrate	  NK	  cell	  activity	  during	  B	  virus	  infection	  and	  the	  parallel	  ef-­‐








Figure	  20:	  NK	  cell	  activity	  during	  HSV-­‐1	  infection.	  HSV-­‐1	  infected	  HFF	  cells	  down	  regulate	  or	  do	  not	  
induce	  cytokines	  and	  chemokines	  needed	  for	  NK	  cell	  activity.	  PBMCs	  exposed	  to	  HSV-­‐1	  infected	  cells	  














Figure	  21:	  NK	  cell	  activity	  during	  B	  virus	  infection.	  B	  virus	  infected	  HFF	  cells	  or	  these	  cells	  exposed	  
to	  PBMCs	  down	  regulate	  or	  do	  not	  induce	  cytokines	  and	  chemokines	  needed	  for	  NK	  cell	  activity.	  




In	  ICP47	  deletion	  mutants,	  HSV	  is	  less	  neurovirulent	  as	  a	  result	  of	  infected	  cell	  destruc-­‐
tion	  by	  CTLs.	  Thus,	  HSV-­‐specific	  CD8+	  T-­‐cells	  do	  play	  an	  important	  role	  in	  eliminating	  HSV	  in-­‐
fected	  cells,	  and	  thus,	  reducing	  neurovirulence,	  however,	  they	  are	  not	  a	  primary	  defense	  
mechanism	  early	  in	  infection.	  Virus-­‐specific	  CTLs	  also	  play	  a	  similar	  role	  during	  secondary	  infec-­‐
tion	  (61,	  103,	  171).	  Due	  to	  stress	  or	  other	  factors	  resulting	  in	  suppression	  of	  immune	  response,	  
HSV	  specific	  CD8+	  T-­‐cell	  responses	  can	  be	  impaired	  and	  virus	  can	  reactivate	  (11,	  14,	  55,	  120).	  In	  
the	  case	  of	  B	  virus,	  infected	  cells	  can	  activate	  CTLs,	  yet	  neurovirulence	  is	  striking	  in	  zoonotically	  
infected	  humans.	  How	  then	  does	  B	  virus	  control	  CTL	  destruction	  at	  the	  primary	  site	  of	  infec-­‐
tion?	  	  Does	  suppression	  of	  NK	  responses	  allow	  sufficient	  time	  for	  virus	  to	  replicate,	  such	  that	  
the	  effect	  of	  CTLs	  at	  a	  later	  time	  point	  does	  not	  significantly	  reduce	  virus	  load.	  
Natural	  killer	  cell	  lysis	  of	  infected	  cells	  leads	  to	  controlled	  virus	  replication	  thereby	  pre-­‐
venting	  the	  rapid	  spread	  of	  virus.	  For	  this	  reason	  NK	  cells	  were	  implicated	  in	  HSV-­‐1	  infection	  
since	  their	  absence	  correlated	  to	  increased	  morbidity	  e.g.,	  encephalitis.	  Mouse	  studies	  by	  Alder	  
et	  al	  have	  suggested	  that	  NK	  cells	  provide	  protective	  immunity	  from	  mortality	  due	  to	  HSV-­‐1	  en-­‐
cephalitis	  in	  mice	  lacking	  T-­‐cells	  (5).	  This	  is	  particularly	  important	  because	  in	  human	  HSV-­‐1	  in-­‐
fection,	  CD8+	  T-­‐cells	  are	  rendered	  inactive	  due	  to	  lack	  of	  surface	  MHC	  class	  I	  antigen	  presenta-­‐
tion.	  	  
Activated	  natural	  killer	  cells	  are	  also	  capable	  of	  interacting	  with	  dendritic	  cells,	  ulti-­‐
mately	  enhancing	  the	  efficiency	  of	  adaptive	  immune	  response.	  Therefore,	  the	  presence	  of	  acti-­‐
vated	  NK	  cells	  is	  not	  only	  important	  for	  controlling	  virus	  replication,	  but	  also	  important	  for	  elic-­‐
iting	  robust	  adaptive	  immune	  responses.	  Because	  of	  the	  observations	  that	  B	  virus	  infection	  of-­‐




cumb	  to	  infection,	  we	  find	  it	  interesting	  to	  speculate	  that	  natural	  killer	  cell	  activity	  is	  important	  
for	  minimizing	  B	  virus	  pathogenesis.	  	  Whether	  natural	  killer	  cell	  populations	  are	  compromised	  
in	  individuals	  who	  succumb	  to	  zoonotic	  infection	  remains	  to	  be	  investigated.	  
Observations	  from	  our	  studies	  provide	  the	  basis	  for	  further	  examination	  of	  NK	  cell	  activ-­‐
ity	  using	  cell	  cytotoxicity	  assays	  that	  will	  help	  elucidate	  the	  role	  of	  NK	  cells.	  Factors	  that	  induce	  
cell	  death	  by	  NK	  cells	  other	  than	  the	  release	  of	  perforin	  and	  granzyme	  B	  include	  TNF-­‐α	  and	  Fas-­‐
FasL	  induced	  apoptosis.	  Future	  studies	  will	  focus	  on	  identification	  of	  CD8+	  T-­‐cell	  specificity	  di-­‐
rected	  toward	  B	  virus	  infected	  cells	  and	  whether	  CTL	  activity	  against	  B	  virus	  infected	  cells	  effec-­‐
tively	  limits	  virus	  replication.	  	  Future	  studies	  will	  allow	  us	  to	  explore	  different	  immune	  evasive	  
strategies	  employed	  by	  B	  virus	  that	  influence	  rapid	  spread	  of	  virus	  to	  the	  central	  nervous	  sys-­‐

















	   Previous	  results	  from	  our	  lab	  suggested	  that	  B	  virus	  infected	  cells	  do	  no	  mount	  robust	  
innate	  immune	  responses	  (Zao,	  et	  al.,	  submitted,	  2009).	  B	  virus	  infection	  in	  HFF	  cells	  does	  not	  
interfere	  with	  host	  MHC	  class	  I	  antigen	  loading	  and	  cell	  surface	  expression,	  unlike	  HSV-­‐1	  in-­‐
fected	  HFF	  cells.	  Our	  data	  suggest	  that	  CD8+	  T-­‐cell	  recognition	  of	  MHC	  class	  I	  presenting	  B	  virus	  
antigen	  on	  the	  infected	  cell	  surface	  has	  the	  potential	  to	  cytolyse	  infected	  cells	  later	  in	  infection,	  
since	  these	  cells	  are	  not	  present	  early	  in	  infection	  pathogenesis.	  This	  exploration	  was	  based	  on	  
the	  rationale	  that	  B	  virus	  lacked	  the	  ability	  to	  block	  peptide	  loading	  onto	  MHC	  class	  1	  mole-­‐
cules.	  	  In	  contrast,	  by	  blocking	  MHC	  class	  1	  peptide	  loading	  via	  ICP47,	  HSV	  can	  escape	  cytolysis	  
by	  CD8+	  CTLs.	  	  In	  doing	  so,	  however,	  infected	  cells	  can	  be	  quickly	  killed	  by	  NK	  cells	  on	  patrol	  for	  
cells	  not	  expressing	  these	  critical	  MHC	  class	  1	  molecules.	  These	  events	  do	  occur	  very	  early	  in	  
infection,	  within	  days	  of	  the	  onset	  of	  infection.	  MHC	  class	  I	  antigen	  expression	  on	  the	  B	  virus	  
infected	  cell	  surface	  indicates	  clearly	  that	  B	  virus	  employs	  a	  different	  strategy	  from	  HSV-­‐1	  in	  
evading	  host	  innate	  and	  adaptive	  immune	  responses.	  MHC	  class	  I	  antigen	  expression	  on	  the	  cell	  
surface	  negatively	  regulates	  NK	  cell	  activity,	  therefore,	  we	  suggest	  from	  our	  studies	  that	  B	  virus	  
is	  insensitive	  to	  host	  natural	  killer	  cell	  defenses.	  Naïve	  NK	  cells	  upon	  exposure	  to	  B	  virus	  in-­‐
fected	  cells	  did	  not	  release	  any	  cytotoxic	  granules	  (perforin	  and	  granzyme	  B),	  while	  these	  cells	  
did	  produce	  TNF-­‐α,	  they	  did	  not	  produce	  any	  other	  cytokines	  such	  as,	  IFN-­‐γ	  and	  GM-­‐CSF.	  Fur-­‐
ther,	  our	  results	  suggest	  that	  B	  virus	  infection	  does	  not	  result	  in	  the	  release	  of	  cytokines	  or	  




infected	  HFF	  cells	  exposed	  to	  PBMCs	  induce	  IFN-­‐α	  and	  IP-­‐10	  that	  can	  further	  enhance	  NK	  cell	  
activation,	  already	  in	  motion	  due	  to	  the	  lack	  of	  MHC	  Class	  1	  antigen	  expression,	  which	  is	  
blocked	  by	  ICP47	  TAP-­‐binding	  domain.	  These	  results	  suggest	  that	  NK	  cells	  during	  B	  virus	  infec-­‐
tion	  are	  not	  functional.	  Thus,	  B	  virus	  down	  regulates	  NK	  cell	  cytotoxicity	  and	  cytokine	  activity	  in	  
order	  for	  the	  virus	  to	  replicate	  and	  spread	  rapidly	  to	  other	  cells.	  Non-­‐functional	  NK	  cells	  were	  
found	  to	  be	  one	  of	  the	  causes	  for	  HSV	  encephalitis	  and	  also	  other	  encephalitis	  causing	  viruses.	  
Therefore,	  from	  our	  results	  we	  speculate	  that	  CNS	  disease	  severity	  in	  fatal	  B	  virus	  infection	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